Contents

1	\mathbf{Exp}	erimental	4
	1.1	Methyl 3-oxodecanoate 21	4
	1.2	$\label{lem:methyl} \mbox{Methyl (E)-3-((4-((tert\mbox{-}butoxycarbonyl)amino)phenyl)amino)dec-2-enoate $\bf 24$$	5
	1.3	6-Amino-2-heptylquinolin-4-ol ${\bf 25}$	5
	1.4	Heptyl magnesium bromide 28	6
	1.5	2-Chloro- N -methoxy- N -methylacetamide ${\bf 30}$	6
	1.6	1-Chlorononan-2-one 31	7
	1.7	2-Oxononyl 2-amino-5-nitrobenzoate ${\bf 33}$	7
	1.8	6-Nitro-2-heptyl-3-hydroxyquinolin-4(1 H)-one 34	8
	1.9	6-Amino-2-heptyl-3-hydroxyquinolin-4(1 H)-one ${\bf 35}$	9
	1.10	6-Azido-2-heptyl-3-hydroxyquinolin-4(1 H)-one ${\bf 36}$	9
	1.11	(3S)-2-Oxotetra hydrofuran-3-aminium bromide ${\bf 38}$	10
	1.12	(S)-2-Bromo-N-(2-oxotetra hydrofuran-3-yl)acetamide ${\bf 40}$	11
	1.13	(S)-2-Azido- N -(2-oxotetra hydrofuran-3-yl) acetamide ${\bf 41}$	11
	1.14	$(S)\text{-}4\text{-}Bromo-N-(2-oxotetrahydrofuran-3-yl) butanamide \ 44 \ . \ . \ . \ . \ . \ . \ . \ . \ . \ $	12
	1.15	$(S)\mbox{-6-Bromo-}N\mbox{-}(2\mbox{-oxotetrahydrofuran-3-yl})\mbox{hexanamide } {\bf 45} \qquad . \qquad $	13
	1.16	(S)-6-Azido- N -(2-oxotetra hydrofuran-3-yl) hexanamide ${\bf 47}$	13
	1.17	Hex-5-ynal 49	14
	1.18	$\textit{tert}\text{-Butyl 4-(hex-5-yn-1-yl)piperazine-1-carboxylate } \textbf{51} \dots \dots \dots \dots \dots \dots \dots \dots \dots $	15
	1.19	1-(Hex-5-yn-1-yl)piperazine 52	15
	1.20	1- Cyclopropyl-6-fluoro-7- (4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1, 4-dihydroquinoline-3-carboxylic	
		acid 54	16
	1.21	(S) - 1 - Cyclopropyl - 6 - fluoro - 4 - oxo - 7 - (4 - (4 - (1 - (2 - oxo - 2 - ((2 - oxo tetra hydrofuran - 3 - yl)amino) ethyl) - 1 H - (2 - oxo - 2 - ((2 - oxo - 2 - ((
		1,2,3-triazol-4-yl) butyl) piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid ${\bf 124}$	18
	1.22	(S) - 1 - cyclopropyl - 6 - fluoro - 4 - oxo - 7 - (4 - (4 - (4 - (4 - (4 - oxo - 4 - ((2 - oxotetrahydrofuran - 3 - yl)amino)butyl) - 1 H - (2 - oxotetrahydrofuran - 3 - yl)amino)butyl) - 1 H - (2 - oxotetrahydrofuran - 3 - yl)amino)butyl) - 1 H - (3 - oxotetrahydrofuran - 3 - yl)amino)butyl) - 1 H - (4 - oxotetrahydrofuran - 3 - yl)amino)butyl) - 1 H - (4 - oxotetrahydrofuran - 3 - yl)amino)butyl) - 1 H - (4 - oxotetrahydrofuran - 3 - yl)amino)butyl) - 1 H - (4 - oxotetrahydrofuran - 3 - yl)amino)butyl) - 1 H - (4 - oxotetrahydrofuran - 3 - yl)amino)butyl) - 1 H - (4 - oxotetrahydrofuran - 3 - yl)amino)butyl) - 1 H - (4 - oxotetrahydrofuran - 3 - yl)amino)butyl) - 1 H - (4 - oxotetrahydrofuran - 3 - yl)amino)butyl) - 1 H - (4 - oxotetrahydrofuran - 3 - yl)amino)butyl) - 1 H - (4 - oxotetrahydrofuran - 3 - yl)amino)butyl) - (4 - ox	
		1,2,3-triazol-4-yl) butyl) piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid ${\bf 125}$	19
	1.23	(S) - 1 - cyclopropyl - 6 - fluoro - 4 - oxo - 7 - (4 - (4 - (1 - (6 - oxo - 6 - ((2 - oxotetra hydrofuran - 3 - yl)amino) hexyl) - 1 H- (1 - (1 - (1 - (1 - (1 - (1 - (1	
		1,2,3-triazol-4-yl) butyl) piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid ${\bf 126}$	20
	1.24	1-cyclopropyl-6-fluoro-7- (4-(4-(4-(4-(2-heptyl-4-oxo-1,4-dihydroquinolin-6-yl)-1H-1,2,3-triazol-4-yl) butyl-4-oxo-1,4-dihydroquinolin-6-yl) but	d)piperazin-
		1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ${\bf 127}$	21
	1.25	6-(4-(4-(4-(4-(4-(4-(4-(4-(4-(4-(4-(4-(4-	
		2-heptylquinolin-4(1H)-one 128	22
	1.26	2-(6-(4-(4-(4-(4-(4-(4-(4-(4-(4-(4-(4-(4-(4-	
		1-yl)hexyl)-3-hydroxyquinolin-4(1H)-one ${\bf 129}$	23
	1.27	(S)-6-(4-(4-(4-(4-(4-(4-(4-(4-(4-(4-(4-(4-(4-	
		1-yl)-N-(2-oxotetrahydrofuran-3-yl)hexanamide ${\bf 130}$	24
	1.28	$\label{lem:methyl-1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate~ {\bf 131}~.~.$	26
	1.29	4-Bromo- N -(2-oxotetrahydrothiophen-3-yl) butanamide ${\bf 132}$	26
	1.30	4-Azido- N -(2-oxotetrahydrothiophen-3-yl) butanamide ${\bf 133}$	27
	1.31	$Methyl\ 1-cyclopropyl-6-fluoro-4-oxo-7- \big(4-\big(4-oxo-4-\big((2-oxotetrahydrothiophen-3-yl\big)amino\big)butyl\big)piperson of the property of the propert$	razin-
		1-yl)-1,4-dihydroquinoline-3-carboxylate 134	28

1.32	1- Cyclopropyl-6-fluoro-4-oxo-7- (4-(4-(1-(4-oxo-4-((2-oxotetrahydrothiophen-3-yl)amino)butyl)-1 H-1-(2-oxotetrahydrothiophen-3-yl)amino)butyl)-1 H-1-(2-oxotetrahydrothiophen-3-yl)am		
	1,2,3-triazol-4-yl) butyl) piperazin-1-yl)-1,4-dihydroquinol-ine-3-carboxylic acid ${\bf 135}$	29	
1.33	$1- Cyclopropyl-6-fluoro-4-oxo-7- \big(4-\big(\big(\big((4-\big(1-\big(4-oxo-4-\big(\big(2-oxotetrahydrothiophen-3-yl\big)amino\big)butyl\big)-(2-oxotetrahydrothiophen-3-yl)amino\big)butyl\big)-(2-oxotetrahydrothiophen-3-yl)amino\big)butyl)-(2-oxotetrahydrothiophen-3-yl)amino\big)$		
	1H-1,2,3-triazol-4-yl) butanoyl) oxy) methoxy) carbonyl) piper-azin-1-yl)-1,4-dihydroquinoline-3-carbonyl) piper-azin-1-yl-1-yl-1-yl-1-yl-1-yl-1-yl-1-yl-1-y		
	boxylic acid 136	29	
1.34	4-Bromo- N -(2-methoxyphenyl) butanamide ${\bf 137}$	30	
1.35	4-Bromo- N -(3-methoxyphenyl) butanamide 138	31	
1.36	4-Azido- N -(2-methoxyphenyl) butanamide 139	32	
1.37	4-Azido- N -(3-methoxyphenyl)butanamide 140	32	
1.38	Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-((2-methoxyphenyl)amino)-4-oxobutyl)-piperazin-1-yl)-4-oxo-		
	1,4-dihydroquinoline-3-carboxylate 141	33	
1.39	$Methyl\ 1-cyclopropyl-6-fluoro-7-(4-(4-((3-methoxyphenyl)amino)-4-oxobutyl)-piperazin-1-yl)-4-oxobutyl)$		
	1,4-dihydroquinoline-3-carboxylate 142	34	
1.40	1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-((2-methoxyphenyl)amino)-4-oxobutyl)-1H-1,2,3-triazol-4-yl)bu		piperazin-
		- /-	. 1
1.41	1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-((3-methoxyphenyl)amino)-4-oxobutyl)-1H-1,2,3-triazol-4-yl)bu		piperazin-
	1-yl)-4-oxo-1,4-dihydroquinoline-3-carb-oxylic acid 144	. , .	. 1
1.42	Methyl 7-(4-(4-(tert-butoxy)-4-oxobutyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-		
	quinoline-3-carboxylate 145	37	
1.43	4-(4-(1-Cyclopropyl-6-fluoro-3-(methoxycarbonyl)-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-yl)but		ic
1.10			
1.44	(1S,2S)-2- $(((S)$ -1-Phenylethyl)amino)cyclopentan-1-ol 147 and $(1R,2R)$ -2- $(((S)$ -1-phenylethyl)amin		clopentan-
	1-ol 148		orop orroarr
1.45	(1S,2S)-2-Aminocyclopentan-1-ol 149		
	(1R,2R)-2-Aminocyclopentan-1-ol 150		
	(1R,2R)-2- $((tert$ -butyldimethylsilyl)oxy)cyclopentan-1-amine 151		
	4-Chloro- N -(($(1S,2S)$ -2-hydroxycyclopentyl)butanamide 152		
	4-Chloro- N -(($1R$, $2R$)-2-hydroxycyclopentyl)butanamide 153		
	4 -Azido- N -(($1R,2R$)-2-(($tert$ -butyldimethylsilyl)oxy)cyclopentyl)butanamide ${\bf 154}(RR)$		check
	4-Azido- N -((18,2 S)-2-hydroxycyclopentyl)butanamide 155		brack-
	4-Azido- N -((1 R ,2 R)-2-hydroxycyclopentyl)butanamide 156		ets out-
	Methyl 1-cyclopropyl-6-fluoro-7- $(4-(4-(((1S,2S)-2-hydroxycyclopentyl)amino)-4-oxobutyl)$ piperazin-		side for
1.00	1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 157		all
1 54	Methyl 1-cyclopropyl-6-fluoro-7- $(4-(4-(((1R,2R)-2-hydroxycyclopentyl)amino)-4-oxobutyl)$ piperazin-		COLL
1.01	1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 158		
1 55	Methyl (R)-1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxocyclopentyl)am-ino)butyl)piperazin-	10	
1.00	1-yl)-1,4-dihydroquinoline-3-carboxylate 159	47	
1 56	7-(4-(4-(4-(4-(4-(4-(4-(4-(4-(4-(4-(4-(4-	.,	
1.00	triazol-4-yl)butyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid	1	
		47	
1 57	1-Cyclopropyl-6-fluoro-7- $(4-(4-(4-(((1S,2S)-2-hydroxycyclopentyl)amino)-4-oxobutyl)-1H-1,2,3-$	11	
1.01	triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 161	48	
1 52	1-Cyclopropyl-6-fluoro-7- $(4-(4-(1-(4-(((1R,2R)-2-hydroxycyclopentyl)amino)-4-oxobutyl)-1H-1,2,3-$	40	
1.00	triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 162	50	
1 50	(S)-1-cyclopropyl-6-fluoro-4-oxo-7- $(4$ - $(4$ - $(4$ - $(4$ - $(4$ - $(4$ - $(4$ - $(4$	90	
1.03	azol-4-vl)butvl)piperazin-1-vl)-1.4-dihvdroquinoline-3-carboxvlic acid 163	50	
	ONZOLI YIDAUYIDDIDOLOZDELI YILIG MINYULUUUDUUUUTU. TOFUALDOAYIU AUU IUO	SU	

2	Refe	erences	57
		4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 171	56
	1.67	1- Cyclopropyl-6-fluoro-4-oxo-7- (4-(4-(4-(4-oxo-4-((2-oxocyclohexyl)amino)butyl)-1H-1,2,3-triazol-1-(2-oxocyclohexyl)amino)butyl)-1H-1,2,3-triazol-1-(2-oxocyclohexyl)amino)butyl)-1H-1,2,3-triazol-1-(2-oxocyclohexyl)amino)butyl)-1H-1,2,3-triazol-1-(2-oxocyclohexyl)amino)butyl)-1H-1,2,3-triazol-1-(2-oxocyclohexyl)amino)butyl)-1H-1,2,3-triazol-1-(2-oxocyclohexyl)amino)butyl)-1H-1,2,3-triazol-1-(2-oxocyclohexyl)amino)butyl)-1H-1,2,3-triazol-1-(2-oxocyclohexyl)amino)butyl)-1H-1,2,3-triazol-1-(2-oxocyclohexyl)amino)butyl)-1-(2-oxocyclohexy	
		azol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ${\bf 170}$	55
	1.66	1- Cyclopropyl-6-fluoro-7- (4-(4-(4-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-oxobutyl)-1 H-1, 2, 3-trickly amino)-4-oxobutyl)-1 H-1, 3-trickly amino)-1 H	
		1,4-dihydroquinoline-3-carboxylate 169	
	1.65	$Methyl\ 1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxocyclohexyl)amino)-butyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxocyclohexyl)amino)-butyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxocyclohexyl)amino)-butyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxocyclohexyl)amino)-butyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxocyclohexyl)amino)-butyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxocyclohexyl)amino)-butyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxocyclohexyl)amino)-butyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxocyclohexyl)amino)-butyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxocyclohexyl)amino)-butyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-7-((2-oxocyclohexyl)amino)-butyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-7-((2-oxocyclohexyl)amino)-butyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-7-((2-oxocyclohexyl)amino)-butyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-7-((2-oxocyclohexyl)amino)-butyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-7-((2-oxocyclohexyl)amino)-butyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-7-((2-oxocyclohexyl)amino)-butyl)-1-cyclopropyl-6-fluoro-4-oxo-7-((2-oxocyclohexyl)amino)-butyl)-1-cyclopropyl-6-fluoro-6-f$	
		1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 168	53
	1.64	$Methyl\ 1-cyclopropyl-6-fluoro-7-(4-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-oxobutyl) piperazin-1-cyclopropyl-6-fluoro-7-(4-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-oxobutyl) piperazin-1-cyclopropyl-6-fluoro-7-(4-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-oxobutyl) piperazin-1-cyclopropyl-6-fluoro-7-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-oxobutyl) piperazin-1-cyclopropyl-6-fluoro-7-(4-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-oxobutyl) piperazin-1-cyclopropyl-6-fluoro-7-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-oxobutyl) piperazin-1-cyclopropyl-6-fluoro-7-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-oxobutyl) piperazin-1-cyclopropyl-6-fluoro-7-(4-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-oxobutyl) piperazin-1-cyclopropyl-6-fluoro-7-(4-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-oxobutyl) piperazin-1-cyclopropyl-6-fluoro-7-(4-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-oxobutyl) piperazin-1-cyclopropyl-6-fluoro-7-(4-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-oxobutyl-6-fluoro-7-(((trans)-4-hydroxycyclohexyl) piperazin-1-cyclopropyl-6-fluoro-7-(((trans)-4-hydroxycyclohexyl)amino)-4-oxobutyl-6-fluoro-7-(((trans)-4-hydroxycyclohexyl)$	
		4-Azido- N -((trans)-2-hydroxycyclohexyl)butanamide ${\bf 167}$	52
		4-Chloro- N -((trans)-2-hydroxycyclohexyl) butanamide ${\bf 166}$	
		(Trans)-2-aminocyclohexan-1-ol 165	
		azol-4-yl) butyl) piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid	
	1.60	(R) - 1 - cyclopropyl - 6 - fluoro - 4 - oxo - 7 - (4 - (4 - (4 - (4 - oxo - 4 - ((2 - oxocyclopentyl)amino) - butyl) - 1H - 1, 2, 3 - tri- (1 - (4 - oxo - 4 - ((2 - oxocyclopentyl)amino) - butyl) - 1H - 1, 2, 3 - tri- (1 - (4 - oxo - 4 - ((2 - oxocyclopentyl)amino) - butyl) - 1H - 1, 2, 3 - tri- (1 - (4 - oxo - 4 - ((2 - oxocyclopentyl)amino) - butyl) - 1H - 1, 2, 3 - tri- ((2 - oxocyclopentyl)amino) - ((2 - o	

1 Experimental

1.1 Methyl 3-oxodecanoate 21

fix eps

Meldrum's acid (9.0 g, 63 mmol, 1 eq.) was dissolved in anhydrous CH_2Cl_2 (150 mL) and cooled to 0 °C. Pyridine (10.2 mL, 126 mmol, 2 eq.) was added dropwise over 20 min. Octanoyl chloride (11.7 mL, 69 mmol, 1.1 eq.) was then added and the mixture was stirred at 0 °C for a further 4 h. The mixture was allowed to warm to r.t., diluted with CH_2Cl_2 (20 mL) and poured into a mixture of ice (~ 30 g) and HCl (2 N, 90 mL). The solution was washed with NaCl (sat., aq., 150 mL) and dried over Mg_2SO_4 . The solvent was removed under vacuum to give an orange-brown oil. The oil was refluxed in anhydrous MeOH (150 mL) for 5 h and the solvent was removed under vacuum. The resulting residue was purified by column chromatography (SiO₂, 5 % $Et_2O/40$ -60 P.E.) to give a tautomeric mixture of **21** and **22** as a colourless oil (8.34 g, 41.6 mmol, 66 %, 92 % **21** as determined by NMR).

Keto form 21

IR (neat) ν_{max} / cm⁻¹ = 2927.84 (C-H), 2856.26 (C-H), 1746.86 (ester C=O), 1716.70 (ketone C=O)

¹H NMR (400 MHz, CDCl₃) δ / ppm = 3.74 (s, 3 H, OC<u>H</u>₃), 3.45 (s, 2 H, C(=O)C<u>H</u>₂C(=O)), 2.53 (t, J = 7.4 Hz, 2 H, C<u>H</u>₂CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 1.60 (quin, J = 7.1 Hz, 2 H, CH₂C<u>H</u>₂CH₂CH₂CH₂CH₂CH₂CH₃), 1.39 - 1.19 (m, 8 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 0.88 (t, J = 6.8 Hz, 3 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₂CH₃)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 202.3 (CH₃OC(=O)CH₂C(=O)), 167.3 (CH₃OC(=O)CH₂C(=O)), 51.7 (O<u>C</u>H₃), 48.5 (CH₃OC(=O)<u>C</u>H₂C(=O)), 42.5 (<u>C</u>H₂), 31.3 (<u>C</u>H₂), 28.7 (<u>C</u>H₂), 28.6 (<u>C</u>H₂), 23.1 (<u>C</u>H₂), 22.2 (CH₂), 13.6 (CH₃)

Enol form 22

IR (neat) ν_{max} / cm⁻¹ = 2927.84 (C-H), 2856.26 (C-H), 1653.80 (C=C), 1629.21 (α, β unsaturated C=O)

¹**H NMR** (400 MHz, CDCl₃) δ / ppm = 12.02 (s, 1 H, CO<u>H</u>), 4.99 (s, 1 H, C(=O)C<u>H</u>=COH), 3.73 (s, 3 H, OC<u>H</u>₃), 2.20 (t, J = 7.4 Hz, 2 H, C<u>H</u>₂CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 1.76 - 1.72 (m, 2 H, CH₂C<u>H</u>₂CH₂CH₂CH₂CH₂CH₃), 1.39 - 1.19 (m, 8 H, CH₂CH₂C<u>H</u>₂C<u>H</u>₂C<u>H</u>₂C<u>H</u>₂C<u>H</u>₂CH₂CH₃), 0.88 (t, J = 6.8 Hz, 3 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₂CH₃)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 178.7 (CH₃OC(=O)CH= \underline{C} OH), 172.7 (CH₃O<u>C</u>(=O)CH=COH), 88.2 (CH₃OC(=O) \underline{C} H=COH), 50.5 (O \underline{C} H₃), 37.9 (\underline{C} H₂), 34.6 (\underline{C} H₂), 31.2 (\underline{C} H₂), 29.0 (\underline{C} H₂), 25.9 (\underline{C} H₂), 22.3 (\underline{C} H₂), 13.6 (\underline{C} H₃)

1.2 Methyl (E)-3-((4-((tert-butoxycarbonyl)amino)phenyl)amino)dec-2-enoate 24

Methyl 3-oxodecanoate **21** (500 mg, 2.50 mmol, 1.00 eq.) and *tert*-butyl (4-aminophenyl)carbamate **172** (520 mg, 2.50 mmol, 1.00 eq.) were dissolved in MeOH (10 mL) and refluxed for 18 h. The solvent was removed under vacuum and the resulting residue was purified by column chromatography (SiO₂, gradient of 0 to 20 % $\rm Et_2O/40$ -60 P.E.) to give a white powder (0.169 mg, 0.480 mmol, 19 %).

TLC $R_f = ?? (5 \% \text{ Et}_2\text{O}/40\text{-}60 \text{ P.E.})$

pending

mp $T / {}^{\circ}\text{C} = 78.8 \text{ (Et}_2\text{O}/40\text{-}60 \text{ P.E.)}$

IR (neat) ν_{max} / cm⁻¹ = 3336.97 (N-H), 2927.71 (C-H), 2857.14 (C-H), 1723.71 (carbamate C=O), 1634.49 (α,β unsaturated C=O), 1610.73 (C=C), 1580.85 (N-H bend)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 171.1 (\underline{C} (=O)CH=C), 164.3 (C(=O)CH= \underline{C}), 152.7 (O \underline{C} (=O)NH), 136.0 (para to NHBoc), 134.1 (\underline{C} NHBoc), 126.3 (meta to NHBoc), 119.1 (ortho to NHBoc), 83.8 (C(=O) \underline{C} H=C), 80.7 (\underline{C} (CH₃)₃), 50.2 (O \underline{C} H₃), 32.2 (\underline{C} H₂), 31.6 (\underline{C} H₂), 29.1 (\underline{C} H₂), 28.8 (\underline{C} H₂), 28.3 (C(\underline{C} H₃)₃), 28.0 (\underline{C} H₂), 22.6 (\underline{C} H₂), 14.0 (\underline{C} H₃)

HRMS (ESI⁺) m/z / Da = 391.2589, [M+H]⁺, [C₂₂H₃₅N₂O₄]⁺ requires 391.2591

1.3 6-Amino-2-heptylquinolin-4-ol 25

$$H_2N$$

Methyl (E)-3-((4-((tert-butoxycarbonyl)amino)phenyl)amino)dec-2-enoate **24** (168 mg, 0.649 mmol, 1 eq.) and polyphosphoric acid (5 g) were heated to 90 °C for 1 h. The reaction mixture was then poured into NaHCO₃

(sat., aq., 50 mL) cooled with ice. The precipitate was collected by vacuum filtration, washed with water (50 mL) and dried under high vacuum to give a pale yellow powder (121 mg, 0.468 mmol, 72 %).

$$mp (H_2O) T / {}^{\circ}C = 249$$

IR (neat) ν_{max} / cm⁻¹ = 3336.52 (N-H), 2926.47 (C-H), 2856.89 (C-H), 1723.88 (aromatic), 1634.48 (aromatic), 1610.84 (aromatic), 1583.26 (aromatic), 1519.06 (aromatic)

¹H NMR (400 MHz, DMSO-d₆) δ / ppm = 7.26 (d, J = 8.7 Hz, 1 H, meta to NH₂), 7.15 (d, J = 2.6 Hz, 1 H, para to COH), 6.95 (dd, J = 2.7, 8.8 Hz, 1 H, ortho to COH), 5.74 (s, 1 H, ortho to OH), 5.16 (s, 2 H, NH₂), 2.52 (t, J = 7.4 Hz, 2 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 1.64 (quin, J = 7.6 Hz, 2 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 1.36 - 1.19 (m, 8 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 0.86 (t, J = 7.0 Hz, 3 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₂CH₃)

¹³C NMR (101 MHz, DMSO-d₆) δ / ppm = 176.7 ($\underline{\text{COH}}$), 151.7 ($\underline{\text{CCH}}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 145.1 ($\underline{\text{CNH}}_2$), 132.4 (para to NH₂), 126.6 (para to CH₂CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 121.1 (ortho to NH₂ and para to COH), 119.0 (meta to NH₂ and meta to COH), 106.2 (ortho to NH₂ and ortho to COH), 105.9 (ortho to CH₂CH₂CH₂CH₂CH₂CH₂CH₂CH₃ and ortho to OH), 33.6 ($\underline{\text{CH}}_2$), 31.6 ($\underline{\text{CH}}_2$), 29.0 ($\underline{\text{CH}}_2$), 29.0 ($\underline{\text{CH}}_2$), 28.9 ($\underline{\text{CH}}_2$), 22.5 ($\underline{\text{CH}}_2$), 14.4 ($\underline{\text{CH}}_3$)

HRMS (ESI⁺) m/z / Da = 259.1810, [M+H]⁺, [C₁₆H₂₃N₂O]⁺ requires 259.1803

1.4 Heptyl magnesium bromide 28

Magnesium turnings (352 mg, 14.5 mmol, 1 eq.) were added to a dry flask under argon. THF (15 mL) was added, followed by bromoheptane (2.40 mL, 14.5 mmol, 1 eq.) dropwise. The mixture was stirred at r.t. for 2 h followed by heating to reflux for 2 h to give the Grignard reagent as a pale grey suspension (15 mL, \sim 1 M) which was used without further purification.

1.5 2-Chloro-N-methoxy-N-methylacetamide 30

$$CI \longrightarrow N$$

N,O-Dimethylhydroxyl amine hydrochloride (6.00 g, 61.5 mmol, 1 eq.) and toluene (75 mL) were added successively to a solution of potassium carbonate (22.4 g, 162 mmol, 2.63 eq.) in water (75 mL) at 0 °C under argon. The mixture was cooled to -5 °C and chloroacetyl chloride (5.88 mL, 73.8 mmol, 1.20 eq.) was added dropwise over 5 min. The mixture was allowed to warm to r.t. over 30 min, then the organic layer was separated and the aqueous layer was extracted with toluene (3 × 20 mL). The four combined organic extracts were dried with MgSO₄ and the solvent was removed by rotary evaporation followed by high vacuum to give white, prism-like crystals (7.24 g, 52.6 mmol, 71 %).

mp (toluene) $T / {}^{\circ}C = 38.8$

IR (neat) ν_{max} / cm⁻¹ = 3016.69 (C-H), 2966.38 (C-H), 2946.75 (C-H), 2827.73 (C-H), 1666.20 (C=O)

¹**H NMR** (400 MHz, CDCl₃) δ / ppm = 4.20 (s, 2 H, ClCH₂C=O), 3.71 (m, 3 H, OCH₃), 3.18 (s, 3 H, NCH₃)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 167.4 (C=O), 61.6 (OCH₃), 40.9 (ClCH₂C=O), 32.6 (NCH₃)

Spectroscopic data are consistent with the literature.³

1.6 1-Chlorononan-2-one 31

2-Chloro-N-methoxy-N-methylacetamide (1.00 g, 7.26 mmol, 1 eq.) was added to a dry flask under argon. THF (20 mL) was added and the flask cooled to 0 °C. Heptyl magnesium bromide (~ 1 M, 15.0 mL, 15.0 mmol, 2.07 eq.) was added dropwise over 5 min, then the mixture was allowed to warm to r.t. and stirred for 15 h. The reaction mixture was then poured into HCl (aq., 2 N, 60 mL) at 0 °C and stirred for 10 min. The mixture was extracted with toluene (30 mL) and the aqueous layer discarded. The organic layer was washed with brine and dried with MgSO₄. The solvent was removed by rotary evaporation to give a colourless oil (1.23 g, 6.96 mmol, 96 %).

IR (neat) ν_{max} / cm⁻¹ = 2951.65 (C-H), 2924.99 (C-H), 2855.46 (C-H), 1720.39 (C=O)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 202.6 (<u>C</u>=O, 48.1 (<u>C</u>H₂Cl), 39.6 (C(=O)<u>C</u>H₂), 31.5 (<u>C</u>H₂CH₂CH₃)), 28.9 (<u>C</u>H₂), 28.9 (<u>C</u>H₂), 23.5 (C(=O)CH₂<u>C</u>H₂), 22.5 (<u>C</u>H₂CH₃), 13.9 (<u>C</u>H₃)

Spectroscopic data are consistent with the literature.³

1.7 2-Oxononyl 2-amino-5-nitrobenzoate 33

5-Nitroanthranilic acid (500 mg, 2.75 mmol, 1.38 eq.) and potassium carbonate (270 mg, 2.00 mmol, 1 eq.) were dissolved in DMF (5 ml). The mixture was heated under argon to 90 $^{\circ}$ C and stirred for 1 h then cooled to r.t.. 1-chlorononan-2-one **31** (353 mg, 2.00 mmol, 1 eq.) was added and the mixture was stirred for 15 h. The

solution was poured into Na_2HCO_3 (aq., 10 %, 50 ml) and ice (~ 20 g). The precipitate was collected by vacuum filtration, washed with water and dried under high vacuum to give a yellow powder (0.674 g, 2.00 mmol, 100 %).

$$mp (H_2O) T / {}^{\circ}C = 135$$

IR (neat) ν_{max} / cm⁻¹ = 3453.32 (N-H), 3350.52 (N-H), 2924.93 (C-H), 2853.87 (C-H), 1720.10 (ester C=O) 1703.91 (ketone C=O) 1626.14 (N-H bend) 1602.74 (aromatic) 1572.48 (N-O) 1506.58 (N-O)

¹³C NMR (101 MHz, DMSO-d₆) δ / ppm = 204.4 (OCH₂C(=O)), 165.6 (C(=O)O), 156.3 (CNH₂), 135.7 (CNO₂), 129.6 (para to C=O), 128.9 (ortho to C=O), 117.4 (meta to C=O), 107.5 (CC(=O)O), 68.8 (OCH₂C(=O)), 38.3 (CH₂), 31.6 (CH₂), 28.9 (CH₂), 28.9 (CH₂), 23.2 (CH₂), 22.5 (CH₂), 14.4 (CH₃)

HRMS (ESI⁺) m/z / Da = 323.1610, [M+H]⁺, [C₁₆H₂₃N₂O₅]⁺ requires 323.1607

1.8 6-Nitro-2-heptyl-3-hydroxyquinolin-4(1H)-one 34

2-Oxononyl 2-amino-5-nitrobenzoate (100 mg, 0.340 mmol, 1 eq.) and polyphosphoric acid (300 mg) were stirred for 5.5 h at 90 °C under argon. The mixture was then poured into NaHCO $_3$ (sat., aq., 50 mL) cooled on ice. The precipitate was collected by vacuum filtration, washed with water (50 mL) and dried under high vacuum to give a yellow-brown powder (44 mg, 0.145 mmol, 43 %) which could be recrystallised from EtOAc to give yellow-brown plate-like crystals.

$$\mathbf{mp}\;(\mathrm{H_2O})\;T\;/\;^{\circ}\mathrm{C}=223$$

IR (neat) ν_{max} / cm⁻¹ = 3436.01 (N-H), 3000.00 (O-H, br), 2955.37 (C-H), 2925.76 (C-H), 2850.93 (C-H), 1648.18 (aromatic), 1606.05 (aromatic), 1570.67 (N-O), 1536.35 (N-O)

¹H NMR (400 MHz, DMSO-d₆) δ / ppm = 12.00 (s, 1 H, N<u>H</u>), 8.91 (d, J = 2.8 Hz, 1 H, ortho to C=O), 8.29 (dd, J = 2.7, 9.2 Hz, 1 H, para to C=O), 7.70 (d, J = 9.3 Hz, 1 H, meta to C=O), 2.75 (t, J = 7.7 Hz, 2 H, C<u>H</u>₂CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 1.67 (quin, J = 7.3 Hz, 2 H, CH₂C<u>H</u>₂CH₂CH₂CH₂CH₂CH₂CH₃), 1.36 - 1.23 (m, 8 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 0.85 (t, J = 7.0 Hz, 3 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₂CH₃)

¹³**C NMR** (101 MHz, DMSO-d₆) δ / ppm = 169.7 (<u>C</u>=O), 141.9 (<u>C</u>OH), 140.7 (para to NO₂), 139.6 (<u>C</u>NO₂),

137.3 (CHCC=O), 124.3 (ortho to NO₂ and ortho to C=O), 122.3 (ortho to NO₂ and para to C=O), 121.5 ($\underline{C}CH_2CH_2CH_2CH_2CH_2CH_2CH_3$), 120.0 (meta to NO₂ and meta to C=O), 31.6 ($\underline{C}H_2$), 29.2 ($\underline{C}H_2$), 28.9 ($\underline{C}H_2$), 28.5 ($\underline{C}H_2$), 28.1 ($\underline{C}H_2$), 22.5 ($\underline{C}H_2$), 14.4 ($\underline{C}H_3$)

HRMS (ESI⁺) m/z / Da = 305.1501, [M+H]⁺, [C₁₆H₂₁N₂O₄]⁺ requires 305.1500

1.9 6-Amino-2-heptyl-3-hydroxyquinolin-4(1H)-one 35

6-Nitro-2-heptyl-3-hydroxyquinolin-4(1H)-one **34** (20 mg, 0.0658 mmol, 1 eq.) and PtO₂ (2 mg, 10 weight %) were stirred in MeOH (1 mL) under a H₂ atmosphere for 45 min at room temperature and pressure. The reaction mixture was then filtered through celite and the solvent was removed under vacuum to give a yellow-brown powder (14.5 mg, 0.0529 mmol, 80 %).

 $mp \text{ (MeOH) } T / ^{\circ}C = 176$

IR (neat) ν_{max} / cm⁻¹ = 3000.00 (O-H, br) 2925.41 (C-H), 2854.09 (C-H), 1613.43 (aromatic) 1555.29 (aromatic) 1504.47 (aromatic)

¹³C NMR (101 MHz, DMSO-d₆) δ / ppm = pending

HRMS (ESI⁺) m/z / Da = 275.1760, [M+H]⁺, [C₁₆H₂₃N₂O₂]⁺ requires 275.1762

1.10 6-Azido-2-heptyl-3-hydroxyquinolin-4(1H)-one 36

6-Amino-2-heptyl-3-hydroxyquinolin-4(1H)-one **35** (18.2 mg, 0.0664 mmol, 1 eq.) was dissolved in HCl (conc., aq., 0.8 mL) and MeOH (0.5 mL) at 0 °C. NaNO₂ (5.0 mg, 0.0725 mmol, 1.09 eq.) in H₂O (0.2 mL) was added dropwise over 2 min and the mixture was stirred at 0 °C for 50 min, during which time the solution turned from yellow to orange. NaN₃ (4.9 mg, 0.0754 mmol, 1.14 eq.) in H₂O (0.2 mL) was then added and the mixture

was allowed to warm to r.t. and stirred for 4 h. The reaction mixture was then filtered to give a brown powder (5.5 mg, 0.0183 mmol, 28 %).

 $mp (H_2O/MeOH) T / °C = pending$

IR (neat) ν_{max} / cm⁻¹ = pending

¹³C NMR (101 MHz, DMSO-d₆) δ / ppm = pending

HRMS (ESI⁺) m/z / Da = pending, [M+H]⁺, [C₁₆H₂₁N₄O₂]⁺ requires 301.1659

1.11 (3S)-2-Oxotetrahydrofuran-3-aminium bromide 38

$$O$$
 NH_3Br

L-Methionine (3.04 g, 20.4 mmol, 1 eq.) and bromoacetic acid (3.08 g, 22.2 mmol, 1.09 eq.) were dissolved in i-PrOH (12.5 mL), H₂O (12.5 mL) and AcOH (5 mL). The reaction was refluxed for 15 h then concentrated under vacuum. The resulting brown oil was added to a mixture of i-PrOH (16 mL) and HBr (33 % in AcOH, 4 mL), causing the precipitation of a pale pink powder. The precipitate was collected by filtration and washed with i-PrOH (20 mL). The filtrate was concentrated under vacuum and precipitated again using the same procedure. The two crops of precipitate were combined to give a pale pink powder (1.73 g, 9.50 mmol, 41 % yield).

mp (*i*-PrOH/AcOH) T / °C = 242 (gas evolved)

IR (neat) ν_{max} / cm⁻¹ = 2972.09 (N-H), 2877.54 (N-H), 1771.77 (C=O), 1585.05 (N-H bend), 1572.24 (N-H bend)

¹**H NMR** (400 MHz, DMSO-d₆) δ / ppm = 8.59 (br s, 3 H, N $\underline{\text{H}}_{3}^{+}$), 4.46 (dt, J = 1.3, 8.9 Hz, 1 H, OC $\underline{\text{H}}_{2}$), 4.37 (dd, J = 8.8, 11.4 Hz, 1 H, C $\underline{\text{H}}$ NH $_{3}^{+}$), 4.29 (ddd, J = 6.1, 8.8, 10.9 Hz, 1 H, OC $\underline{\text{H}}_{2}$), 2.57 (dddd, J = 1.2, 6.1, 8.9, 12.3 Hz, 1 H, OCH₂C $\underline{\text{H}}_{2}$), 2.26 (dtd, J = 9.0, 11.2, 12.2 Hz, 1 H, OCH₂C $\underline{\text{H}}_{2}$)

¹³C NMR (101 MHz, DMSO-d₆) δ / ppm = 173.3 (C=O), 66.2 (OCH₂), 47.8 (CHNH₃⁺), 27.0 (OCH₂CH₂)

$$[\alpha]_D^{26.6} \ / \ ^{\circ}10^{-1} \mathrm{cm}^2 \mathrm{g}^{-1} = - \ 21 \ (c \ / \ \mathrm{g}(100 \ \mathrm{mL})^{-1} = 0.09833 \ , \ \mathrm{MeOH})$$

Spectroscopic data and m.p. are consistent with the literature.⁴

1.12 (S)-2-Bromo-N-(2-oxotetrahydrofuran-3-yl)acetamide 40

$$O \longrightarrow H$$

$$O \longrightarrow Br$$

$$O \longrightarrow Br$$

(3S)-2-Oxotetrahydrofuran-3-aminium bromide **38** (100 mg, 0.549 mmol, 1.08 eq.) and NaHCO₃ (84.9 mg, 1.01 mmol, 2.00 eq.) were dissolved in CH₂Cl₂ (2 mL) and H₂O (2 mL). Bromoacetyl bromide (44.0 μ L, 102 mg, 0.505 mmol, 1.00 eq.) was then added dropwise. The reaction mixture was stirred for 24 h, after which the CH₂Cl₂ was removed under vacuum. The aqueous phase was extracted with EtOAc (4 × 10 mL) and the combined organic layers were dried with MgSO₄. The solvent was removed under vacuum to give white, needle-like crystals (88.0 mg, 0.396 mmol, 74 %).

mp (EtOAc) $T / ^{\circ}C = 132$

IR (neat) ν_{max} / cm⁻¹ = 3255.69 (N-H), 3066.58 (C-H), 1763.02 (lactone C=O), 1657.99 (amide C=O), 1552.67 (N-H bend)

 $^{1}\mathbf{H} \ \mathbf{NMR} \ (400 \ \mathrm{MHz}, \mathrm{CDCl_{3}}) \ \delta \ / \ \mathrm{ppm} = 6.95 \ (\mathrm{br} \ \mathrm{d}, 1 \ \mathrm{H}, \mathrm{N}\underline{\mathrm{H}}), 4.58 \ (\mathrm{ddd}, J = 5.9, 8.6, 11.7 \ \mathrm{Hz}, 1 \ \mathrm{H}, \mathrm{C}\underline{\mathrm{H}}\mathrm{NHC} = \mathrm{O}), \\ 4.53 \ (\mathrm{dt}, J = 1.0, 9.2 \ \mathrm{Hz}, 1 \ \mathrm{H}, \mathrm{OC}\underline{\mathrm{H}_{2}}), 4.33 \ (\mathrm{ddd}, J = 5.9, 9.4, 11.3 \ \mathrm{Hz}, 1 \ \mathrm{H}, \mathrm{OC}\underline{\mathrm{H}_{2}}), 3.95 \ (\mathrm{d}, J = 1.3 \ \mathrm{Hz}, 2 \ \mathrm{H}, \\ \mathrm{C}(=\mathrm{O})\mathrm{C}\underline{\mathrm{H}_{2}}\mathrm{Br}), 2.88 \ (\mathrm{dddd}, J = 1.3, 5.9, 8.6, 12.6 \ \mathrm{Hz}, 1 \ \mathrm{H}, \mathrm{OC}\mathrm{H_{2}}\mathrm{C}\underline{\mathrm{H}_{2}}), 2.24 \ (\mathrm{dtd}, J = 8.9, 11.5, 12.6 \ \mathrm{Hz}, 1 \ \mathrm{H}, \\ \mathrm{OC}\mathrm{H_{2}}\mathrm{C}\underline{\mathrm{H}_{2}})$

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 174.6 (O<u>C</u>=O), 166.4 (<u>C</u>(=O)NH), 66.1 (O<u>C</u>H₂), 49.8 (<u>C</u>HNHC=O), 29.9 (OCH₂<u>C</u>H₂), 28.2 (O=C<u>C</u>H₂Br)

$$[\alpha]_D^{26.6} / {}^{\circ}10^{-1} \mathrm{cm}^2 \mathrm{g}^{-1} = -11 \ (c / \mathrm{g}(100 \ \mathrm{mL})^{-1} = 0.10000 \ , \mathrm{MeOH})$$

Spectroscopic data are consistent with the literature.⁴

1.13 (S)-2-Azido-N-(2-oxotetrahydrofuran-3-yl)acetamide 41

(3S)-2-Oxotetrahydrofuran-3-aminium bromide **38** (100 mg, 0.552 mmol, 1.08 eq.), NaN₃ (85.7 mg, 1.32 mmol, 2.61 eq.) and NaHCO₃ (84.9 mg, 1.01 mmol, 2.00 eq.) were dissolved in CH₂Cl₂ (2 mL) and H₂O (2 mL). Bromoacetyl bromide (44.0 μ L, 102 mg, 0.505 mmol, 1.00 eq.) was then added dropwise. The reaction mixture was stirred for 48 h, after which the CH₂Cl₂ was removed under vacuum. The aqueous phase was extracted with EtOAc (4 × 10 mL) and the combined organic layers were dried with MgSO₄. The solvent was removed under vacuum to give white, needle-like crystals (38.4 mg, 0.209 mmol, 41 %).

mp (EtOAc) $T / ^{\circ}C = 87$

IR (neat) ν_{max} / cm⁻¹ = 3283.47 (N-H), 2923.28 (C-H), 2852.99 (C-H), 2129.69 (N₃), 1782.86 (lactone C=O), 1661.40 (amide C=O), 1536.81 (N-H bend)

¹**H NMR** (400 MHz, CDCl₃) δ / ppm = 7.07 (br d, J = 5.1 Hz, 1 H, N $\underline{\text{H}}$), 4.65 (ddd, J = 6.8, 8.7, 11.6 Hz, 1 H, C $\underline{\text{H}}$ NHC=O), 4.49 (dt, J = 1.3, 9.1 Hz, 1 H, OC $\underline{\text{H}}$ 2), 4.31 (ddd, J = 6.0, 9.2, 11.2 Hz, 1 H, OC $\underline{\text{H}}$ 2), 4.05 (s, 2 H, C(=O)C $\underline{\text{H}}$ 2N₃), 2.77 (dddd, J = 1.4, 6.0, 8.8, 12.5 Hz, 1 H, OCH₂C $\underline{\text{H}}$ 2), 2.26 (dq, J = 8.9, 11.8 Hz, 1 H, OCH₂C $\underline{\text{H}}$ 2)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 174.9 (OC=O), 167.5 (C=ONH), 66.0 (OCH₂), 52.2 (O=CCH₂N₃), 48.9 (CHNHC=O), 29.7 (OCH₂CH₂)

$$[\alpha]_D^{26.6} / {}^{\circ}10^{-1} \text{cm}^2 \text{g}^{-1} = -23 (c / \text{g}(100 \text{ mL})^{-1} = 0.17500, \text{MeOH})$$

Spectroscopic data and m.p. are consistent with the literature.⁴

1.14 (S)-4-Bromo-N-(2-oxotetrahydrofuran-3-yl)butanamide 44

$$O \longrightarrow H$$

$$O \longrightarrow N$$

$$O \longrightarrow Br$$

(3S)-2-Oxotetrahydrofuran-3-aminium bromide **38** (200 mg, 1.10 mmol, 1.00 eq.) and NaHCO₃ (170 mg, 2.02 mmol, 1.84 eq.) were dissolved in CH₂Cl₂ (2 mL) and H₂O (2 mL). Bromobutyryl chloride (140 μ L, 224 mg, 1.21 mmol, 1.10 eq.) was then added dropwise. The reaction mixture was stirred for 1 h, after which the CH₂Cl₂ was removed under vacuum. The aqueous phase was extracted with EtOAc (7 × 5 mL) and the combined organic layers were dried with MgSO₄. The solvent was removed under vacuum to give white crystals which were recrystallised from EtOAc to give white, needle-like crystals (219 mg, 0.878 mmol, 80 %).

mp (EtOAc)
$$T / ^{\circ}C = 105$$

IR (neat) ν_{max} / cm⁻¹ = 3307.92 (N-H), 3073.85 (C-H), 2948.93 (C-H), 1773.66 (lactone C=O), 1643.46 (amide C=O), 1541.39 (N-H bend)

¹**H NMR** (400 MHz, CDCl₃) δ / ppm = 6.31 (br d, J = 5.5 Hz, 1 H, N<u>H</u>), 4.59 (ddd, J = 6.2, 8.7, 11.5 Hz, 1 H, C<u>H</u>NHC=O), 4.48 (dt, J = 1.2, 8.9 Hz, 1 H, OC<u>H</u>₂), 4.30 (ddd, J = 5.8, 9.3, 11.3 Hz, 1 H, OC<u>H</u>₂), 3.49 (t, J = 6.3 Hz, 2 H, C<u>H</u>₂Br), 2.82 (dddd, J = 1.3, 5.9, 8.7, 12.5 Hz, 1 H, OCH₂C<u>H</u>₂), 2.47 (t, J = 7.3 Hz, 2 H, C(=O)CH₂), 2.26 - 2.15 (m, 3 H, OCH₂CH₂ and C(=O)CH₂CH₂CH₂Br)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 175.4 (O<u>C</u>=O), 172.3 (<u>C</u>(=O)NH), 66.1 (O<u>C</u>H₂), 49.3 (<u>C</u>HNHC=O), 33.9 (C(=O)CH₂), 33.1 (CH₂Br), 30.3 (OCH₂CH₂), 27.9 (C(=O)CH₂CH₂CH₂Br)

$$[\alpha]_D^{26.6} / ^{\circ}10^{-1} \text{cm}^2 \text{g}^{-1} = -78 (c / \text{g}(100 \text{ mL})^{-1} = 0.08333, \text{MeOH})$$

1.15 (S)-6-Bromo-N-(2-oxotetrahydrofuran-3-yl)hexanamide 45

$$O \longrightarrow H$$

$$O \longrightarrow Br$$

(3S)-2-Oxotetrahydrofuran-3-aminium bromide 38 (100 mg, 0.549 mmol, 1.00 eq.) and NaHCO₃ (84.9 mg, 1.01 mmol, 1.84 eq.) were dissolved in CH₂Cl₂ (2 mL) and H₂O (2 mL). Bromohexanoyl chloride (93.0 μ L, 130 mg, 0.608 mmol, 1.11 eq.) was then added dropwise. The reaction mixture was stirred for 4 h, after which the CH₂Cl₂ was removed under vacuum. The mixture was then filtered, washed with H₂O (10 mL) and dried under high vacuum to give white, needle-like crystals (101 mg, 0.362 mmol, 66 %).

$$\mathbf{mp} \; (\mathrm{CH_2Cl_2/H_2O}) \; T \; / \; ^{\circ}\mathrm{C} = 106$$

IR (neat) ν_{max} / cm⁻¹ = 3300.30 (N-H), 3067.62 (C-H), 2937.37 (C-H), 2856.67 (C-H), 1784.83 (lactone C=O), 1639.33 (amide C=O), 1539.87 (N-H bend)

HRMS (ESI⁺) m/z / Da = 278.0381, [M+H]⁺, [C₁₀H₁₇BrNO₃]⁺ requires 278.0386

$$[\alpha]_D^{26.6} / ^{\circ}10^{-1} \text{cm}^2 \text{g}^{-1} = -16 (c / \text{g}(100 \text{ mL})^{-1} = 0.20833, \text{MeOH})$$

1.16 (S)-6-Azido-N-(2-oxotetrahydrofuran-3-yl)hexanamide 47

$$0 \longrightarrow H \longrightarrow N_{2}$$

(S)-6-Bromo-N-(2-oxotetra hydrofuran-3-yl)hexanamide (80 mg, 0.320 mmol, 1.00 eq.) and $\rm NaN_3$ (26.3 mg, 0.405 mmol, 1.27 eq.) were heated in DMF (0.5 mL) for 5 h at 100 °C. The reaction mixture was then partitioned between CH₂Cl₂ (5 mL) and $\rm H_2O$ (5 mL). The aqueous phase was extracted twice more with $\rm CH_2Cl_2$ $(2 \times 5 \text{ mL})$ and the organic layers were combined and dried over MgSO₄. The solvent was removed by rotary evaporation followed by high vacuum to give white, needle-like crystals (42.7 mg, 0.178 mmol, 56 %).

$$mp (CH_2Cl_2) T / °C = 90.0$$

IR (neat) ν_{max} / cm⁻¹ = 3314.00 (N-H), 2931.56 (C-H), 2862.89 (C-H), 2095.06 (N₃), 1775.38 (lactone C=O), 1643.14 (amide C=O), 1547.90 (N-H bend)


¹H NMR (400 MHz, CDCl₃) δ / ppm = 5.97 (br d, J = 4.2 Hz, 1 H, N<u>H</u>), 4.56 (ddd, J = 5.7, 8.6, 11.7 Hz, 1 H, C<u>H</u>NHC=O), 4.50 (dt, J = 1.0, 9.1 Hz, 1 H, OC<u>H</u>₂), 4.31 (ddd, J = 5.8, 9.4, 11.3 Hz, 1 H, OC<u>H</u>₂), 3.31 (t, J = 6.9 Hz, 2 H, C<u>H</u>₂N₃), 2.90 (dddd, J = 1.1, 5.8, 8.6, 12.5 Hz, 1 H, OCH₂C<u>H</u>₂), 2.30 (dt, J = 1.8, 7.4 Hz, 2 H, O=CC<u>H</u>₂), 2.15 (dtd, J = 8.8, 11.5, 12.3 Hz, 1 H, OCH₂C<u>H</u>₂), 1.72 (quin, J = 7.6 Hz, 2 H, O=CCH₂CH₂CH₂CH₂CH₂CH₂N₃), 1.65 (quin, J = 7.2 Hz, 2 H, O=CCH₂CH₂CH₂CH₂CH₂CH₂N₃) 1.46 (m, 2 H, O=CCH₂CH₂CH₂CH₂CH₂N₃)

 $^{13}\textbf{C NMR} \ (101 \ \text{MHz}, \text{CDCl}_3) \ \delta \ / \ \text{ppm} = 175.4 \ (\text{O\underline{C}} = \text{O}), 172.2 \ (\underline{\text{C}} (= \text{O}) \text{NH}), 66.1 \ (\text{O\underline{C}} \text{H}_2), 51.2 \ (\text{C} (= \text{O}) \text{CH}_2 \text{CH}_2 \text{CH}_2 \text{CH}_2 \text{CH}_2 \text{CH}_2 \text{CH}_2 \text{N}_3), 30.7 \ (\text{OCH}_2 \underline{\text{C}} \text{H}_2), 28.6 \ (\text{C} (= \text{O}) \text{CH}_2 \text$

HRMS (ESI⁺) m/z / Da = 241.1289, [M+H]⁺, [C₁₀H₁₇N₄O₃]⁺ requires 241.1295

$$[\alpha]_D^{26.6} \ / \ ^{\circ}10^{-1} {\rm cm^2 g^{-1}} = \text{-} \ 16 \ (c \ / \ {\rm g}(100 \ {\rm mL})^{-1} = 0.20833 \ , \ {\rm MeOH})$$

1.17 Hex-5-ynal 49



Pyridinium chlorochromate (14.6 g, 68.1 mmol, 1.50 eq) and DCM (500 mL) were stirred at r.t. under argon. 5-hexyn-1-ol (5.00 mL, 45.4 mmol, 1 eq.) was added and the reaction mixture was stirred for 5 h followed by addition of $\rm Et_2O$ (125 mL) and silica gel (62.5 g). The suspension was stirred for 1 h then filtered through a pad of silica (100 g) and washed with $\rm Et_2O$. The solvent was removed by rotary evaporation to give a pale yellow-green oil (4.72 g, 49.1 mmol, 72 %).

IR (neat) ν_{max} / cm⁻¹ = 3292.68 (alkyne C-H), 2943.26 (alkane C-H), 2830.88 (aldehyde C-H), 2728.56 (aldehyde C-H), 1720.29 (C=O)

¹**H NMR** (400 MHz, CDCl₃) δ / ppm = 9.80 (s, 1 H, C(=O)<u>H</u>), 2.60 (t, J = 7.1 Hz, 2 H, C<u>H</u>₂C(=O)H), 2.26 (dt, J = 2.6, 6.8 Hz, 2 H, HC≡CC<u>H</u>₂), 1.98 (t, J = 2.7 Hz, 1 H, <u>H</u>C≡C), 1.85 (quin, J = 7.0 Hz, 2 H, HC≡CCH₂C<u>H</u>₂)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 201.6 (<u>C</u>=O), 83.1 (HC≡<u>C</u>), 69.3 (H<u>C</u>≡C), 42.4 (<u>C</u>H₂C=O), 20.7 (HC≡CCH₂CH₂CH₂C=O), 17.6 (HC≡C<u>C</u>H₂CH₂CH₂C=O)

Spectroscopic data are consistent with the literature.⁵

1.18 tert-Butyl 4-(hex-5-yn-1-yl)piperazine-1-carboxylate 51

Hex-5-ynal 49 (0.407 g, 4.24 mmol, 1.00 eq.) and tert-butyl piperazine-1-carboxylate (0.791 g, 4.24 mmol, 1.00 eq.) were stirred under a N_2 atmosphere in 1,2-dichloroethane (20 mL) for 2.5 h followed by addition of sodium triacetoxyborohydride (6.25 g, 29.5 mmol, 6.96 eq.) in four portions over 4 d. The mixture was stirred for a further day then NaHCO₃ (sat., aq., 120 mL) was added and the product extracted with EtOAc (2 × 100 mL). The solvent was dried over MgSO₄, and removed by rotary evaporation to give a colourless liquid (1.12 g, 4.21 mmol, 99 %).

TLC R_f (10 % MeOH/CH₂Cl₂) = 0.55

IR (neat) ν_{max} / cm⁻¹ = 3303.59 (alkyne C-H), 2939.96 (alkane C-H), 2865.23 (C-H), 2810.42 (C-H), 1691.29 (C=O)

¹H NMR (400 MHz, CDCl₃) δ / ppm = 3.44 (t, J = 5.2 Hz, 4 H, BocN(C $\underline{\text{H}}_2$)C $\underline{\text{H}}_2$), 2.39 (t, J = 5.1 Hz, 4 H, HC \equiv CCH₂CH₂CH₂CH₂N(C $\underline{\text{H}}_2$), 2.37 (t, J = 7.3 Hz, 2 H, HC \equiv CCH₂CH₂CH₂CH₂CH₂N), 2.23 (dt, J = 2.7, 6.8 Hz, 2 H, HC \equiv CCH₂CH₂CH₂CH₂CH₂CH₂CH₂N), 1.96 (t, J = 2.7 Hz, 1 H, $\underline{\text{H}}$ C \equiv CCH₂CH₂CH₂CH₂N), 1.65 - 1.53 (m, 4 H, HC \equiv CCH₂CH₂CH₂CH₂N), 1.47 (s, 9 H, C $\underline{\text{H}}_3$)

HRMS (ESI⁺) m/z / Da = 267.2073, [M+H]⁺, [C₁₅H₂₇N₂O₂]⁺ requires 267.2064

1.19 1-(Hex-5-yn-1-yl)piperazine 52

tert-Butyl 4-(hex-5-yn-1-yl)piperazine-1-carboxylate 51 (763 mg, 2.86 mmol) was stirred in TFA (10 mL) at r.t. for 2 h. The TFA was removed under vacuum followed by co-evaporation with $\mathrm{CH_2Cl_2}$ (2 × 20 mL). The oil was diluted with $\mathrm{H_2O}$ (10 mL) and the pH adjusted to 14 with NaOH (10 % aq.). This mixture was extracted with $\mathrm{CH_2Cl_2}$ (2 × 20 mL) and the combined organic layers were dried over MgSO₄. The solvent was removed under vacuum and purified by column chromatography (SiO₂ MeOH/CH₂Cl₂ 3:7) to give a colourless liquid (476 mg, 2.86 mmol, 100 %).

TLC R_f (30 % MeOH/CH₂Cl₂) = 0.20

IR (neat) ν_{max} / cm⁻¹ = 3295.87 (alkyne C-H), 2941.07 (alkane C-H), 2810.64 (aldehyde C-H), 1637.22 (N-H bend)

¹**H NMR** (400 MHz, CDCl₃) δ / ppm = 2.88 (t, J = 4.9 Hz, 4 H, HN(C $\underline{\text{H}}_2$)C $\underline{\text{H}}_2$), 2.39 (m, 4 H, HC \equiv CCH₂CH₂-CH₂CH₂N(C $\underline{\text{H}}_2$)C $\underline{\text{H}}_2$), 2.31 (t, J = 7.1 Hz, 2 H, HC \equiv CCH₂CH₂CH₂CH₂CH₂N), 2.20 (dt, J = 2.7, 6.8 Hz, 2 H, HC \equiv CC $\underline{\text{H}}_2$), 2.05 (br s, 1 H, N $\underline{\text{H}}$), 1.93 (t, J = 2.7 Hz, 1 H, $\underline{\text{H}}$ C \equiv C), 1.65 - 1.48 (m, 4 H, HC \equiv CCH₂C $\underline{\text{H}}_2$ C $\underline{\text{H}}_2$ CH₂-CH₂N)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 84.3 (HC≡C), 68.4 (HC≡C), 58.6 (HC≡CCH₂CH₂CH₂CH₂CH₂N), 54.5 (HC≡CCH₂CH₂CH₂CH₂N(CH₂)CH₂), 46.0 (HN(CH₂)CH₂), 26.4 (HC≡CCH₂CH₂CH₂CH₂CH₂N), 25.7 (HC≡CCH₂CH₂CH₂CH₂N), 18.3 (HC≡CCH₂CH₂CH₂CH₂N)

HRMS (ESI⁺) m/z / Da = 167.1548, [M+H]⁺, [C₁₀H₁₉N₂]⁺ requires 167.1548

1.20 1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid 54

1-(Hex-5-yn-1-yl) piperazine **52** (200 mg, 1.20 mmol) and 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquino-line-3-carboxylic acid **53** (100 mg, 0.355 mmol) were stirred in TEA (5 mL). The reaction mixture was heated at reflux for 18 h then cooled to r.t.. The solvent was removed under vacuum and the resulting solid was triturated with MeOH to give a white powder.

mp (MeOH) $T / {}^{\circ}C = 228$

IR (neat) ν_{max} / cm⁻¹ = 3211.99 (alkyne C-H), 2459.32 (O-H), 1722.63 (carboxylic acid C=O), 1626.76 (quino-line C=O)

¹³C NMR (101 MHz, DMSO-d₆) δ / ppm = 166.3 (\underline{C} (=O)OH), 148.2 (\underline{C} =CC(=O)OH), 139.4 (para to F), 111.2 (ortho to C=O and ortho to F), 111.0 (para to piperazine), 106.8 (meta to C=O and meta to F), 106.4 (\underline{C} C(=O)OH), 84.8 (HC= \underline{C}), 71.4 (H \underline{C} =C), 57.1 (HC=CCH₂CH₂CH₂CH₂N), 52.5 (HC=CCH₂CH₂CH₂CH₂N-(\underline{C} H₂) \underline{C} H₂), 49.6 (HN(\underline{C} H₂)CH₂), 49.5 (HN(CH₂) \underline{C} H₂), 36.1 (N \underline{C} H(CH₂)₂), 26.0 (HC=CCH₂CH₂CH₂CH₂N),

 $25.3~(HC \equiv CCH_2CH_2CH_2CH_2N),~17.8~(HC \equiv C\underline{C}H_2CH_2CH_2CH_2N),~7.7~(NCH(\underline{C}H_2)_2)$

HRMS (ESI⁺) m/z / Da = 412.2036, [M+H]⁺, [C₂₃H₂₇N₃O₃F]⁺ requires 412.2030

1.21 (S)-1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(2-oxo-2-((2-oxotetrahydrofuran-3-yl)amino)ethyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 124

50 % water/t-BuOH (2 ml) was degassed by bubbling N₂ through it. This was then added to a mixture of 1-cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 173 (20.6 mg, 50.0 μ mol, 1 eq.) and (S)-2-azido-N-(2-oxotetrahydrofuran-3-yl)acetamide 41 (9.2 mg, 50.0 μ mol, 1 eq.). A similarly degassed solution of CuSO₄ · 5 H₂O (624 μ g, 2.5 μ mol, 0.05 eq. 50 mM), THPTA (1.09 mg, 2.5 μ mol, 0.05 eq. 50 mM) and sodium ascorbate (991 μ g, 5 μ mol, 0.1 eq., 100 mM) in 50 % water/t-BuOH (50 μ l) was then added. The mixture was stirred at r.t. under argon for 3h. On observation that the reaction had stalled, the reaction was degassed again, and a further portion of cataylst solution (50 μ l) was added. After a further 3h the reaction mixture was evaporated under reduced pressure. The residue was purified by preparatory HPLC(% acetonitrile/water over 15 min). The combined pure fractions were evaporated under reduced pressure and then partitioned between NaHCO₃ (aq., sat., 10 ml) and 10 % i-PrOH/CHCl₃ (10 ml). The organic layer was dried with MgSO₄ and evaporated under reduced pressure. 124 was obtained as a ?? (??).

TLC $R_f = ?? (??)$

mp $T / {}^{\circ}C = ?? (??)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹H NMR (400 MHz, DMSO d₆) δ / ppm = 15.23 (s, 1 H, C(=O)O<u>H</u>), 8.84 (d, J = 7.9 Hz, 1 H, N<u>H</u>), 8.66 (s, 1 H, ortho to C(=O)OH), 7.90 (d, J = 13.3 Hz, 1 H, ortho to F), 7.82 (s, 1 H, C<u>H</u>=CCH₂), 7.57 (d, J = 7.6 Hz, 1 H, meta to F), 5.13 (s, 1 H, C(=O)C<u>H</u>HN), 5.12 (s, 1 H, C(=O)CH<u>H</u>N), 4.64 (ddd, J = 10.9, 9.0, 7.8 Hz, 1 H, C<u>H</u>NH), 4.36 (td, J = 8.9, 1.7 Hz, 1 H, OC<u>H</u>H), 4.23 (ddd, J = 10.6, 8.8, 6.4 Hz, 1 H, OCH<u>H</u>), 3.83 (tt, J = 7.0, 4.0 Hz, 1 H, NC<u>H</u>(CH₂)₂), 3.32 (br s, 4 H, CH₂CH₂CH₂N(CH₂C<u>H</u>₂)CH₂C<u>H</u>₂), 2.67 (t, J = 7.4 Hz, 2 H, CH=CC<u>H</u>₂), 2.58 (br t, J = 5.0 Hz, 4 H, CH₂CH₂CH₂N(C<u>H</u>₂)C<u>H</u>₂), 2.42 - 2.49 (m, 1 H, OCH₂C<u>H</u>H), 2.40 (t, J = 7.1 Hz, 1 H, CH=CCH₂CH₂CH₂CH₂), 2.17 (dtd, J = 11.7, 10.8, 10.8, 9.0 Hz, 1 H, OCH₂CH<u>H</u>), 1.66 (quin, J = 7.2 Hz, 1 H, CH=CCH₂CH₂CH₂), 1.53 (quin, J = 7.2 Hz, 1 H, CH=CCH₂CH₂C, 1.28 - 1.35 (m, 1 H, NCH(C<u>H</u>H)₂)), 1.16 - 1.21 (m, 1 H, NCH(CH<u>H</u>)₂)

¹³C NMR (101 MHz, DMSO d₆) δ / ppm = 176.4 (\underline{C} (=O)CC(=O)OH), 174.9 (O \underline{C} (=O)), 166.0 (\underline{C} (=O)OH), 165.9 (NH \underline{C} (=O)), 153.1 (d, J = 250.8 Hz, ipso to F), 148.0 (\underline{C} H=CC(=O)OH), 146.6 (CH= \underline{C} CH₂), 145.3 (d, J = 9.6 Hz, ipso to piperazine), 139.2 (para to F), 123.4 (\underline{C} H=CCH₂), 118.5 (d, J = 7.5 Hz, para to piperazine), 110.9 (d, J = 23.5 Hz, ortho to C=O and ortho to F), 106.7 (\underline{C} C(=O)OH), 106.4 (d, J = 3.2 Hz, meta to C=O and meta to F), 65.4 (O \underline{C} H₂), 57.3 (CH=CCH₂CH₂CH₂CH₂CH₂N), 52.4 (CH₂CH₂CH₂CH₂N(\underline{C} H₂), 51.2

IDK what happened after this, check, weigh etc.

column?
equipment?

 $(C(=O)\underline{C}H_2N)$, 49.5 (d, J=4.3 Hz, $CH_2CH_2CH_2N(CH_2\underline{C}H_2)CH_2\underline{C}H_2$), 48.2 ($\underline{C}HNH$), 35.9 ($N\underline{C}H(CH_2)_2$), 28.2 ($\underline{C}H_2CHNH$), 26.8 ($CH=CCH_2\underline{C}H_2$), 25.7 ($CH=CCH_2CH_2\underline{C}H_2$), 24.9 ($CH=C\underline{C}H_2$), 7.6 ($NCH(\underline{C}H_2)_2$)

¹⁹**F NMR** (376.45 MHz, DMSO d₆) δ / ppm = ??

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

1.22 (S)-1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(4-oxo-4-((2-oxotetrahydrofuran-3-yl)amino)butyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 125

50 % water/t-BuOH (2 ml) was degassed by bubbling N₂ through it. This was then added to a mixture of 1-cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **173** (20.6 mg, 50.0 μ mol, 1 eq.) and (S)-4-azido-N-(2-oxotetrahydrofuran-3-yl)butanamide **46** (10.6 mg, 50.0 μ mol, 1 eq.). A similarly degassed solution of CuSO₄ · 5 H₂O (624 μ g, 2.5 μ mol, 0.05 eq. 50 mM), THPTA (1.09 mg, 2.5 μ mol, 0.05 eq. 50 mM) and sodium ascorbate (991 μ g, 5 μ mol, 0.1 eq., 100 mM) in 50 % water/t-BuOH (50 μ l) was then added. The mixture was stirred at r.t. under argon for 3h, then the reaction mixture was evaporated under reduced pressure. The residue was purified by preparatory HPLC(% acetonitrile/water over 15 min). The combined pure fractions were evaporated under reduced pressure and then partitioned between NaHCO₃ (aq., sat., 10 ml) and 10 % i-PrOH/CHCl₃ (10 ml). The organic layer was dried with MgSO₄ and evaporated under reduced pressure. **125** was obtained as a ?? (??).

TLC $R_f = ?? (??)$

mp T / °C = ?? (??)

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹H NMR (500 MHz, DMSO d₆) δ / ppm = 15.22 (br s, 1 H, C(=O)O<u>H</u>), 8.65 (s, 1 H, ortho to C(=O)OH), 8.40 (d, J = 8.0 Hz, 1 H, N<u>H</u>), 7.88 (d, J = 13.4 Hz, 1 H, ortho to F), 7.85 (s, 1 H, C<u>H</u>=CCH₂), 7.55 (d, J = 7.5 Hz, 1 H, meta to F), 4.53 (ddd, J = 10.9, 9.0, 8.1 Hz, 1 H, C<u>H</u>NH), 4.33 (td, J = 8.9, 1.8 Hz, 1 H, OC<u>H</u>H), 4.31 (t, J = 7.0 Hz, 2 H, C<u>H</u>2NCH=C), 4.20 (ddd, J = 10.5, 8.8, 6.5 Hz, 1 H, OCH<u>H</u>), 3.82 (tt, J = 6.9, 4.0 Hz, 1 H, NC<u>H</u>(CH₂)₂), 3.32 (br. t, J = 4.2, 4.2 Hz, 4 H, CH₂CH₂CH₂N(CH₂C<u>H</u>₂)CH₂C<u>H</u>₂), 2.64 (t, J = 7.4 Hz, 2 H, CH=CC<u>H</u>₂), 2.57 (br. t, J = 5.0, 5.0 Hz, 2 H, CH₂CH₂CH₂N(C<u>H</u>₂)C<u>H</u>₂), 2.34 - 2.42 (m, 3 H, OCH₂C<u>H</u>H and CH=CCH₂CH₂CH₂CH₂), 2.09 - 2.19 (m, 3 H, OCH₂CH<u>H</u> and C(=O)C<u>H</u>₂), 2.02 (quin, J = 7.2 Hz, 2 H, C(=O)CH₂C<u>H</u>₂), 1.64 (quin, J = 7.6 Hz, 2 H, CH=CCH₂CH₂C), 1.52 (quin, J = 7.2 Hz, 2 H, CH=CCH₂CH₂C), 1.29 - 1.34 (m, 2 H, NCH(C<u>H</u>H)₂), 1.15 - 1.21 (m, 2 H, NCH(CH<u>H</u>)₂)

IDK
what
happened
after
this,
was it
prep or
combiflash?,
check,
weigh
etc.

column

equip-

ment?

¹³C NMR (126 MHz, DMSO d₆) δ / ppm = 176.3 ($\underline{\mathbf{C}}$ (=O)CC(=O)OH), 175.4 (O $\underline{\mathbf{C}}$ (=O)), 171.2 (NH $\underline{\mathbf{C}}$ (=O)), 166.0 ($\underline{\mathbf{C}}$ (=O)OH), 153.0 (d, J = 248.6 Hz, ortho to F), 148.0 ($\underline{\mathbf{C}}$ H=CC(=O)OH), 146.8 (CH= $\underline{\mathbf{C}}$ CH₂), 145.2 (d, J = 9.6 Hz, ipso to piperazine), 139.2 (para to F), 121.7 ($\underline{\mathbf{C}}$ H=CCH₂), 118.5 (d, J = 7.5 Hz, para to piperazine), 110.9 (d, J = 22.4 Hz, ortho to C=O and ortho to F), 106.7 ($\underline{\mathbf{C}}$ CC(=O)OH), 106.3 (d, J = 3.2 Hz, meta to C=O and meta to F), 65.3 (O $\underline{\mathbf{C}}$ H₂), 57.3 (CH=CCH₂CH₂CH₂CH₂N), 52.4 (CH₂CH₂CH₂N($\underline{\mathbf{C}}$ H₂)CH₂), 49.5 (CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 49.4 (CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 48.6 ($\underline{\mathbf{C}}$ H₂NCH=C), 47.9 (NHC(=O)CH₂CH₂), 35.9 (N $\underline{\mathbf{C}}$ H(CH₂)), 31.7 (NHC(=O) $\underline{\mathbf{C}}$ H₂), 28.2 ($\underline{\mathbf{C}}$ H₂CHNH), 26.9 (CH=CCH₂CH₂), 25.8 (NHC(=O)CH₂CH₂ and CH=CCH₂CH₂CH₂), 24.9 (CH=C $\underline{\mathbf{C}}$ H₂), 7.6 (NCH($\underline{\mathbf{C}}$ H₂)₂)

¹⁹**F NMR** (376.45 MHz, MeOD) δ / ppm = ??

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

1.23 (S)-1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(6-oxo-6-((2-oxotetrahydrofuran-3-yl)amino)hexyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 126

50 % water/t-BuOH (2 ml) was degassed by bubbling N₂ through it. This was then added to a mixture of 1-cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **173** (20.6 mg, 50.0 μ mol, 1 eq.) and (S)-6-azido-N-(2-oxotetrahydrofuran-3-yl)hexanamide **47** (12.0 mg, 50.0 μ mol, 1 eq.). A similarly degassed solution of CuSO₄ · 5 H₂O (624 μ g, 2.5 μ mol, 0.05 eq. 50 mM), THPTA (1.09 mg, 2.5 μ mol, 0.05 eq. 50 mM) and sodium ascorbate (991 μ g, 5 μ mol, 0.1 eq., 100 mM) in 50 % water/t-BuOH (50 μ l) was then added. The mixture was stirred at r.t. under argon for 3h, then the reaction mixture was dry-loaded onto SiO₂ and purified by column chromatography using a Combiflash (SiO₂, 0-20 % MeOH/CH₂Cl₂). The combined pure fractions were dried with MgSO₄ and evaporated under reduced pressure. **124** was obtained as a ?? (??).

TLC $R_f = ?? (??)$

 $mp T / {}^{\circ}C = ?? (??)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹**H NMR** (500 MHz, DMSO d₆) δ / ppm = 15.22 (br s, 1 H, C(=O)O<u>H</u>), 8.65 (s, 1 H, ortho to C(=O)OH), 8.32 (d, J = 8.0 Hz, 1 H, N<u>H</u>), 7.89 (d, J = 13.3 Hz, 1 H, ortho to F), 7.84 (s, 1 H, C<u>H</u>=CCH₂), 7.55 (d, J = 7.6 Hz, 1 H, meta to F), 4.51 (ddd, J = 10.9, 9.1, 7.9 Hz, 1 H, C<u>H</u>NH), 4.33 (td, J = 8.8, 1.8 Hz, 1 H, OC<u>H</u>H), 4.28 (t, J = 7.1 Hz, 2 H, C<u>H</u>₂NCH=C), 4.19 (ddd, J = 10.5, 8.7, 6.6 Hz, 1 H, OCH<u>H</u>), 3.82 (tt, J = 7.0, 4.0 Hz, 1 H, NC<u>H</u>(CH₂)₂), 3.32 (br t, J = 4.5, 4 H, CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 2.63 (t, J = 7.5 Hz, 2

how to report?

IDK what happened after this, check, weigh

etc.

H, CH=CC $\underline{\text{H}}_2$), 2.57 (br t, J=4.2, 4.2 Hz, 4 H, CH₂CH₂CH₂N(C $\underline{\text{H}}_2$)C $\underline{\text{H}}_2$), 2.33 - 2.41 (m, 3 H, OCH₂C $\underline{\text{H}}_{\text{H}}$ and CH=CCH₂CH₂CH₂CH₂C $\underline{\text{H}}_2$), 2.06 - 2.16 (m, 3 H, OCH₂CH $\underline{\text{H}}$ and C(=O)C $\underline{\text{H}}_2$), 1.79 (quin, J=7.4 Hz, 2 H, C(=O)CH₂CH₂CH₂CH₂CH₂), 1.63 (quin, J=7.5 Hz, 2 H, CH=CCH₂C $\underline{\text{H}}_2$), 1.45 - 1.56 (m, 4 H, C(=O)CH₂C $\underline{\text{H}}_2$) and CH=CCH₂CH₂CH₂), 1.29 - 1.34 (m, 2 H, NCH(C $\underline{\text{H}}$ H)₂), 1.19 - 1.25 (m, 2 H, C(=O)CH₂CH₂C $\underline{\text{H}}_2$), 1.15 - 1.19 (m, 2 H, NCH(CH $\underline{\text{H}}$)₂)

¹³C NMR (126 MHz, DMSO d₆) δ / ppm = 176.4 ($\underline{\mathbf{C}}$ (=O)CC(=O)OH), 175.4 ($\underline{\mathbf{O}}$ C(=O)), 172.1 (NH $\underline{\mathbf{C}}$ (=O)), 166.0 ($\underline{\mathbf{C}}$ (=O)OH), 153.0 (d, J = 250.2 Hz, ipso to F), 148.0 ($\underline{\mathbf{C}}$ H=CC(=O)OH), 146.8 (CH= $\underline{\mathbf{C}}$ CH₂), 145.2 (d, J = 9.6 Hz, ipso to piperazine), 139.2 (para to F), 121.6 ($\underline{\mathbf{C}}$ H=CCH₂), 118.5 (d, J = 8.0 Hz, para to piperazine), 110.9 (d, J = 23.5 Hz, ortho to C=O and ortho to F), 106.7 ($\underline{\mathbf{C}}$ C(=O)OH), 106.3 (d, J = 2.1 Hz, meta to C=O and meta to F), 65.3 ($\underline{\mathbf{O}}$ CH₂), 57.4 (CH=CCH₂CH₂CH₂CH₂N), 52.4 (CH₂CH₂CH₂N($\underline{\mathbf{C}}$ H₂)CH₂), 49.5 (d, J = 3.2 Hz, CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 49.0 ($\underline{\mathbf{C}}$ H₂NCH=C), 47.8 ($\underline{\mathbf{C}}$ HNH), 35.9 ($\underline{\mathbf{N}}$ CH(CH₂)₂), 34.8 (NHC(=O)CH₂), 29.5 ($\underline{\mathbf{C}}$ H₂CH₂NCH=C), 28.3 ($\underline{\mathbf{C}}$ H₂CHNH), 26.9 (CH=CCH₂CH₂), 25.7 (CH=CCH₂CH₂CH₂), 25.4 (NHC(=O)CH₂CH₂), 24.9 (CH=CCH₂), 24.5 (NHC(=O)CH₂CH₂), 7.6 (NCH($\underline{\mathbf{C}}$ H₂)₂)

¹⁹**F NMR** (376.45 MHz, MeOD) δ / ppm = ??

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

1.24 1-cyclopropyl-6-fluoro-7-(4-(4-(1-(2-heptyl-4-oxo-1,4-dihydroquinolin-6-yl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 127

50 % water/t-BuOH (1 ml) was degassed by bubbling N₂ through it. This was then added to a mixture of 1-cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 173 (4.1 mg, 10.0 μ mol, 1 eq.) and 6-azido-2-heptylquinolin-4(1H)-one 26 (2.8 mg, 10.0 μ mol, 1 eq.). A similarly degassed solution of CuSO₄ · 5 H₂O (125 μ g, 0.5 μ mol, 0.05 eq. 50 mM), THPTA (218 μ g, 0.5 μ mol, 0.05 eq. 50 mM) and sodium ascorbate (198 μ g, 1 μ mol, 0.1 eq., 100 mM) in 50 % water/t-BuOH (10 μ l) was then added. The mixture was stirred at r.t. under argon for 1.5 h, then the reaction mixture was evaporated under reduced pressure. The residue was purified by preparatory HPLC (50-100 % acetonitrile/water over ??min). The combined pure fractions were evaporated under reduced pressure and then partitioned between NaHCO₃ (aq., sat., 10 ml) and 10 % i-PrOH/CHCl₃ (10 ml). The organic layer was dried with MgSO₄ and evaporated under reduced pressure. 125 was obtained as a ?? (??).

TLC $R_f = ?? (??)$

mp $T / {}^{\circ}C = ?? (??)$

check
column?
equipment?
needs
desalt-

ing

IR (neat)
$$\nu_{max} / \text{cm}^{-1} = ??$$

¹**H NMR** (400 MHz, MeOD) δ / ppm = ??

¹³**C NMR** (101 MHz, MeOD) δ / ppm = ??

¹⁹**F NMR** (376.45 MHz, MeOD) δ / ppm = ??

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

50 % water/t-BuOH (1 ml) was degassed by bubbling N₂ through it. This was then added to a mixture of 5-(4-(hex-5-yn-1-yloxy)-3,5-dimethoxybenzyl)pyrimidine-2,4-diamine 174 (3.6 mg, 10.0 μ mol, 1 eq.) and 6-azido-2-heptylquinolin-4(1H)-one 26 (2.8 mg, 10.0 μ mol, 1 eq.). A similarly degassed solution of CuSO₄ · 5 H₂O (125 μ g, 0.5 μ mol, 0.05 eq. 50 mM), THPTA (218 μ g, 0.5 μ mol, 0.05 eq. 50 mM) and sodium ascorbate (198 μ g, 1 μ mol, 0.1 eq., 100 mM) in water (10 μ l) was then added. The mixture was stirred at r.t. under argon for 1.5 h, then the reaction mixture was evaporated under reduced pressure. The residue was purified by preparatory HPLC (5-100 % acetonitrile/water over 20 min). The combined pure fractions were evaporated under reduced pressure. 128 was obtained as a ?? (??).

column' equipment?

check

all fre-

quen-

cies

TLC $R_f = 0.17 (20 \% \text{ MeOH/CH}_2\text{Cl}_2)$

 $mp T / {}^{\circ}C = ?? (??)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹H NMR (500 MHz, DMSO d₆) δ / ppm = 11.80 (s, 1 H, N<u>H</u>), 8.69 (s, 1 H, NC<u>H</u>=CCH₂), 8.41 (d, J = 2.7 Hz, 1 H, ortho to C=O), 8.17 (dd, J = 9.0, 2.6 Hz, 1 H, para to C=O), 7.73 (d, J = 9.0 Hz, 1 H, ortho to NH), 7.51 (br s, 4 H, NH₂), 7.41 (s, 1 H, C<u>H</u>N=CNH₂), 6.61 (s, 2 H, meta to CH₂), 6.02 (d, J = 1.8 Hz, 1 H, C(=O)C<u>H</u>), 3.86 (t, J = 6.3 Hz, 2 H, C<u>H</u>₂O), 3.73 (s, 6 H, OC<u>H</u>₃), 3.57 - 3.62 (m, 2 H, CC<u>H</u>₂C), 2.78 (t, J = 7.5 Hz, 2 H, CH=CC<u>H</u>₂), 2.63 (t, J = 7.3 Hz, 2 H, HNCC<u>H</u>₂), 1.85 (quin, J = 7.5 Hz, 2 H, CH=CCH₂C<u>H</u>₂C), 1.61 - 1.78 (m, 4 H, HNCCH₂C<u>H</u>₂ and CH=CCH₂CH₂C<u>H</u>₂), 1.31 - 1.40 (m, 4 H, HNCCH₂CH₂C<u>H</u>₂C<u>H</u>₂), 1.25 - 1.31 (m, 4 H, CH₃C<u>H</u>₂C<u>H</u>₂), 0.86 (t, J = 7.2 Hz, 3 H, C<u>H</u>₃CH₂)

¹³C NMR (125 MHz, DMSO d₆) δ / ppm = 176.4 (<u>C</u>=O), 164.1 (<u>CC(NH₂)N</u>), 154.3 (<u>HNC</u>), 154.2 (<u>NC(NH₂)N</u>), 153.1 (*ipso* to OCH₃), 148.3 (<u>CH=CCH₂CH₂</u>), 140.2 (<u>CHNC(NH₂)N</u>), 139.6 (*ipso* to NH), 135.4 (*ipso* to CH₂O),

 $132.8 \ (para \ to \ CH_2O), \ 132.1 \ (para \ to \ NH), \ 124.9 \ (ipso \ to \ C=O), \ 123.7 \ (para \ to \ C=O), \ 120.3 \ (\underline{CH}=CCH_2CH_2), \ 120.0 \ (meta \ to \ C=O \ and \ ortho \ to \ NH), \ 115.1 \ (ortho \ to \ C=O \ and \ meta \ to \ NH), \ 109.0 \ (CH_2\underline{CC}(NH_2)=N), \ 108.0 \ (C(=O)\underline{CH}), \ 106.3 \ (meta \ to \ CH_2O), \ 72.0 \ (CH_2CH_2\underline{CH}_2O), \ 56.0 \ (O\underline{CH}_3), \ 33.3 \ (HNC\underline{CH}_2), \ 32.1 \ (C\underline{CH}_2C), \ 31.2 \ (CH_3CH_2\underline{CH}_2), \ 29.1 \ (\underline{CH}_2CH_2O), \ 28.3 \ - \ 28.6 \ (CH_3CH_2\underline{CH}_2\underline{CH}_2\underline{CH}_2\underline{CH}_2), \ 25.3 \ (\underline{CH}_2CH_2CH_2O), \ 24.7 \ (CH=C\underline{CH}_2), \ 22.1 \ (CH_3\underline{CH}_2), \ 14.0 \ (\underline{CH}_3CH_2)$

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

$$\begin{array}{c} O \\ \\ N \\ \\ N \end{array}$$

50 % water/t-BuOH (1 ml) was degassed by bubbling N₂ through it. This was then added to a mixture of 5-(4-(hex-5-yn-1-yloxy)-3,5-dimethoxybenzyl) pyrimidine-2,4-diamine 174 (14.2 mg, 39.8 μ mol, 1 eq.) and 2-(6-azidohexyl)-3-hydroxyquinolin-4(1H)-one 70 (11.4 mg, 39.8 μ mol, 1 eq.). A similarly degassed solution of CuSO₄ · 5 H₂O (1.25 mg, 5 μ mol, 0.125 eq. 50 mM), THPTA (2.18 mg, 5 μ mol, 0.125 eq. 50 mM) and sodium ascorbate (1.98 mg, 10 μ mol, 0.25 eq., 100 mM) in water (100 μ l) was then added. The mixture was stirred at r.t. under argon for 3 h, then MeOH (1 ml) was added and the reaction mixture was dry-loaded onto SiO₂ and purified by column chromatography (SiO₂, 0-20 % MeOH/CH₂Cl₂). The combined pure fractions were dried with MgSO₄ and evaporated under reduced pressure. 129 was obtained as a ?? (??).

TLC $R_f = 0.21 \ (20 \% \ \text{MeOH/CH}_2\text{Cl}_2)$

 $mp T / {}^{\circ}C = ?? (??)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹H NMR (500 MHz, DMSO d₆) δ / ppm = 11.53 (br s, 1 H, N<u>H</u>), 8.09 (d, J = 8.0 Hz, 1 H, ortho to C=O), 7.83 (s, 1 H, NC<u>H</u>=CCH₂), 7.48 - 7.57 (m, 3 H, para to C=O, ortho to NH and C<u>H</u>N=CNH₂), 7.21 (ddd, J = 8.0, 6.3, 1.5 Hz, 1 H, para to NH), 6.55 (s, 2 H, meta to CH₂), 4.28 (t, J = 7.1 Hz, 2 H, C<u>H</u>₂N), 3.80 (t, J = 6.2 Hz, 2 H, C<u>H</u>₂O), 3.70 (s, 6 H, C<u>H</u>₃), 3.53 (d, J = 0.3 Hz, 2 H, CC<u>H</u>₂C), 2.73 (t, J = 7.5 Hz, 2 H, HNCC<u>H</u>₂), 2.64 (t, J = 7.4 Hz, 2 H, CH=CC<u>H</u>₂), 1.80 (quin, J = 7.4 Hz, 2 H, C<u>H</u>₂CH₂N), 1.73 (quin, J = 7.5 Hz, 2 H, CH=CCH₂C<u>H</u>₂), 1.66 (quin, J = 7.2 Hz, 2 H, HNCCH₂C<u>H</u>₂), 1.62 (quin, J = 6.8 Hz, 2 H, C<u>H</u>₂CH₂O), 1.33 - 1.40 (m, 2 H, HNCCH₂C<u>H</u>₂), 1.27 - 1.32 (m, 2 H, HNCCH₂CH₂CH₂C<u>H</u>₂)

¹³C NMR (125 MHz, DMSO d₆) δ / ppm = 168.9 (<u>C</u>=O), 162.5 (<u>C</u>C(NH₂)N), 162.5 (<u>N</u>C(NH₂)N), 152.9 (<u>C</u>HNC(NH₂)N), 152.8 (*ipso* to OCH₃), 146.8 (CH=<u>C</u>CH₂CH₂), 137.7 (<u>C</u>OH), 137.3 (*para* to OH), 135.4 (HNC), 135.1 (*para* to CH₂O), 134.8 (*ipso* to CH₂O), 129.9 (*para* to C=O), 124.4 (*ortho* to C=O and *meta*

to NH), 122.1 (*ipso* to C=O), 121.5 (*para* to NH), 121.4 ($\underline{\text{CH}}$ =CCH₂CH₂), 117.7 (*meta* to C=O and *ortho* to NH), 106.2 (CH₂CC(NH₂)=N), 105.8 (*meta* to CH₂O), 71.9 (CH₂CH₂CH₂O), 55.8 (OCH₃), 49.0 (CH₂N), 32.8 (CCH₂C), 29.5 (CH₂CH₂N), 29.0 (CH₂CH₂O), 28.1 (HNCCH₂CH₂CH₂), 27.9 (HNCCH₂), 27.6 (HNCCH₂CH₂), 25.6 (CH₂CH₂CH₂N), 25.4 (CH₂CH₂CH₂O), 24.6 (CH=CCH₂CH₂)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

$$0 \\ N \\ N = N$$

$$0 \\ N \\ NH_2$$

50 % water/t-BuOH (2 ml) was degassed by bubbling N₂ through it. This was then added to a mixture of 5-(4-(hex-5-yn-1-yloxy)-3,5-dimethoxybenzyl) pyrimidine-2,4-diamine 174 (20.6 mg, 50.0 μ mol, 1 eq.) and (S)-6-azido-N-(2-oxotetrahydrofuran-3-yl) hexanamide 47 (18.0 mg, 75.0 μ mol, 1.5 eq.). Similarly degassed solutions of CuSO₄ · 5 H₂O (624 μ g, 2.5 μ mol, 0.05 eq. 50 mM), THPTA (1.09 mg, 2.5 μ mol, 0.05 eq. 50 mM) and sodium ascorbate (991 μ g, 5 μ mol, 0.1 eq., 100 mM) in water (50 μ l) were then added. An extra portion of 47 (12.0 mg, 50.0 μ mol, 1 eq.) was added after 1 d. .

TLC $R_f = ?? (??)$

 $mp T / {}^{\circ}C = ?? (??)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹H NMR (500 MHz, DMSO d₆) δ / ppm = 8.34 (d, J = 8.0 Hz, 1 H, N $\underline{\text{H}}$), 7.83 (s, 1 H, NC $\underline{\text{H}}$ =CCH₂), 7.50 (s, 1 H, C $\underline{\text{H}}$ N=CNH₂), 6.54 (s, 2 H, meta to CH₂), 6.17 (br s, 2 H, CH₂CCN $\underline{\text{H}}$ ₂), 5.77 (br s, 2 H, CHN=CN $\underline{\text{H}}$ ₂), 4.51 (ddd, J = 11.0, 9.0, 8.1 Hz, 1 H, C $\underline{\text{H}}$ NH), 4.33 (td, J = 8.8, 1.9 Hz, 1 H, C $\underline{\text{H}}$ HOC(=O)), 4.27 (t, J = 7.1 Hz, 2 H, C $\underline{\text{H}}$ ₂N), 4.19 (ddd, J = 10.5, 8.7, 6.5 Hz, 1 H, CH $\underline{\text{H}}$ OC(=O)), 3.80 (t, J = 6.3 Hz, 2 H, C $\underline{\text{H}}$ ₂O), 3.70 (s, 6 H, C $\underline{\text{H}}$ ₃), 3.52 (s, 2 H, CC $\underline{\text{H}}$ ₂C), 2.64 (t, J = 7.5 Hz, 2 H, CH=CC $\underline{\text{H}}$ ₂), 2.36 (dddd, J = 12.1, 8.9, 6.7, 1.8 Hz, 1 H, C $\underline{\text{H}}$ HCHNH), 2.06 - 2.16 (m, 3 H, CH $\underline{\text{H}}$ CHNH and C(=O)C $\underline{\text{H}}$ ₂), 1.78 (quin, J = 7.4 Hz, 2 H, C $\underline{\text{H}}$ ₂CH₂N), 1.73 (quin, J = 7.7 Hz, 2 H, CH=CCH₂C $\underline{\text{H}}$ ₂), 1.63 (quin, J = 6.8 Hz, 2 H, C $\underline{\text{H}}$ ₂CH₂O), 1.52 (quin, J = 7.5 Hz, 2 H, C(=O)CH₂C $\underline{\text{H}}$ ₂), 1.17 - 1.27 (m, 2 H, C(=O)CH₂CH₂C $\underline{\text{H}}$ ₂)

IDK what happened after this, check, weigh etc.

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

1.28 Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate 131

Ciprofloxacin 97 (10.0 g, 30 mmol, 1 eq.) and p-toluenesulfonic acid (8.60 mg, 44.5 mmol, 1.5 eq.) were refluxed in methanol (500 ml) for 72 h. The mixture was cooled to room temperature and NaHCO₃ (sat., aq., 100 ml) and water (300 ml) were added. The product was extracted with $\mathrm{CH_2Cl_2}$ (2 \times 400 ml), which was dried over MgSO₄ and evaporated under reduced pressure. **131** was obtained as a white amorphous solid (9.16 g, 26.5 mmol, 83.3 %).

TLC $R_f = 0.13 \ (5 \% \text{ MeOH/CH}_2\text{Cl}_2)$

$$mp T / {}^{\circ}C = ?? (??)$$

IR (neat)
$$\nu_{max} / \text{cm}^{-1} = ??$$

¹**H NMR** (400 MHz, MeOD) δ / ppm = 8.55 (s, 1 H, ortho to C(=O)OCH₃), 7.71 (d, J = 13.5 Hz, 1 H, ortho to F), 7.41 (d, J = 7.2 Hz, 1 H, meta to F), 3.83 (s, 3 H, C $\underline{\text{H}}_3$), 3.62 (tt, J = 7.4, 3.5 Hz, 1 H, NC $\underline{\text{H}}_4$ (CH₂)₂), 3.24 - 3.29 (m, 4 H, HN(CH₂C $\underline{\text{H}}_2$)CH₂C $\underline{\text{H}}_2$), 3.02 - 3.10 (m, 4 H, HN(C $\underline{\text{H}}_2$)C $\underline{\text{H}}_2$), 1.31 - 1.38 (m, 2 H, NCH(C $\underline{\text{H}}$ H)₂), 1.12 - 1.20 (m, 2 H, NCH(CH $\underline{\text{H}}$)₂)

¹³C NMR (101 MHz, MeOD) δ / ppm = 175.2 ($\underline{C}(=O)CC(=O)OCH_3$), 166.8 ($\underline{C}(=O)OCH_3$), 154.9 (d, J = 248.0 Hz, ipso to F), 150.1 ($\underline{C}=CC(=O)OCH_3$), 146.6 (d, J = 10.4 Hz, ipso to piperazine), 139.9 (para to F), 123.3 (d, J = 6.9 Hz, para to piperazine), 113.0 (d, J = 23.4 Hz, ortho to C=O and ortho to F), 110.1 ($\underline{C}C(=O)OCH_3$), 107.1 (d, J = 3.5 Hz, meta to C=O and meta to F), 52.3 ($\underline{C}H_3$), 51.7 ($HN(CH_2\underline{C}H_2)CH_2CH_2$), 51.6 ($HN(CH_2CH_2)CH_2CH_2$), 46.5 ($HN(\underline{C}H_2)\underline{C}H_2$), 36.4 ($N\underline{C}H(CH_2)_2$), 8.7 ($NCH(\underline{C}H_2)_2$)

HRMS (ESI⁺)
$$m/z$$
 / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

The data are consistent with the literature.⁶

1.29 4-Bromo-N-(2-oxotetrahydrothiophen-3-yl)butanamide 132

$$S \xrightarrow{O} H \\ N \\ O$$
 Br

3-Aminodihydrothiophen-2(3H)-one hydrochloride 175 (15.0 g, 97.6 mmol, 1 eq.) and NaHCO₃ (16.4 g, 195 mmol, 2 eq.) were added to $\mathrm{CH_2Cl_2}$ (150 ml) and water (150 ml). 4-Bromobutyryl chloride 42 (11.3 ml, 107 mmol, 1.1 eq.) was added dropwise over 45 min at 0 °C and the mixture was stirred for a further 1 h. The organic layer was separated and the aqueous layer was extracted with a second portion of $\mathrm{CH_2Cl_2}$ (150 ml). The combined organic layers were dried over MgSO₄ and evaporated under reduced pressure. 132 was obtained as a white, amorphous solid (22.7 g, 85.8 mmol, 87.9 %)

TLC $R_f = 0.19 \ (50 \% \ EtOAc/PE)$

 $mp T / {}^{\circ}C = ?? (??)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹H NMR (400 MHz, CDCl₃) δ / ppm = 6.08 (d, J = 6.1 Hz, 1 H, N<u>H</u>), 4.54 (dt, J = 12.9, 6.5 Hz, 1 H, C<u>H</u>NH), 3.49 (t, J = 6.4 Hz, 2 H, C<u>H</u>₂Br), 3.37 (ddd, J = 12.2, 11.5, 5.3 Hz, 1 H, SC<u>H</u>H), 3.26 (ddd, J = 11.5, 6.9, 1.3 Hz, 1 H, SCH<u>H</u>), 2.91 (dddd, J = 12.5, 6.7, 5.3, 1.3 Hz, 1 H, SCH₂C<u>H</u>H), 2.45 (t, J = 7.4 Hz, 1 H, C(=O)C<u>H</u>H), 2.45 (t, J = 6.8 Hz, 1 H, C(=O)CH<u>H</u>), 2.20 (quin, J = 6.7 Hz, 1 H, C(=O)CH₂C<u>H</u>₂), 1.96 (dddd, J = 12.7, 12.5, 12.2, 7.0 Hz, 1 H, SCH₂CH<u>H</u>)

Orientat are not unambiguous without noesy.

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 205.4 (SC(=O)), 172.1 (NHC(=O)), 59.4 (CHNH), 34.1 (C(=O)CH₂), 33.1 (CH₂Br), 31.8 (SCH₂CH₂), 28.0 (C(=O)CH₂CH₂), 27.5 (SCH₂)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

The compound has been synthesised previously^{7,8} but characterisation was not published.

1.30 4-Azido-N-(2-oxotetrahydrothiophen-3-yl)butanamide 133

$$S \xrightarrow{O} H N_3$$

4-Bromo-N-(2-oxotetrahydrothiophen-3-yl)butanamide **132** (6.00 g, 27.0 mmol, 1 eq.) and NaN₃ (3.51 g, 54.1 mmol, 2 eq.) were refluxed in acetonitrile (120 ml) for 1.5 h. The solvent was evaporated under reduced pressure and the residue was partitioned between water (150 ml) and $\mathrm{CH_2Cl_2}$ (150 ml). The aqueous layer was extracted twice more with $\mathrm{CH_2Cl_2}$ (2 × 150 ml) and the combined organic fractions were dried with MgSO₄ and evaporated under reduced pressure. **133** was obtained as a white, low melting point solid (4.60 g, 20.1 mmol, 89.3 %).

check??

TLC $R_f = 0.19 (50 \% \text{ EtOAc/PE})$

mp $T / {}^{\circ}C = ?? (??)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹**H NMR** (400 MHz, CDCl₃) δ / ppm = 6.71 (d, J = 7.3 Hz, 1 H, N<u>H</u>), 4.54 (dt, J = 13.0, 7.0 Hz, 1 H,

 $\begin{array}{l} \text{C}\underline{\textbf{H}}\text{NH}),\ 3.30\ (\text{t},\ J=6.7\ \text{Hz},\ 2\ \text{H},\ \text{C}\underline{\textbf{H}}_2\text{N}_3),\ 3.31\ (\text{td},\ J=11.7,\ 5.3\ \text{Hz},\ 1\ \text{H},\ 1\ \text{H},\ \text{SC}\underline{\textbf{H}}\underline{\textbf{H}}),\ 3.19\ (\text{ddd},\ J=11.3,\ 7.0,\ 1.2\ \text{Hz},\ 1\ \text{H},\ \text{SC}\underline{\textbf{H}}\underline{\textbf{H}}),\ 2.29\ (\text{t},\ J=7.5\ \text{Hz},\ 1\ \text{H},\ \text{C}(=O)\underline{\textbf{C}}\underline{\textbf{H}}\underline{\textbf{H}}),\ 2.29\ (\text{t},\ J=7.5\ \text{Hz},\ 1\ \text{H},\ \text{C}(=O)\underline{\textbf{C}}\underline{\textbf{H}}\underline{\textbf{H}}),\ 2.28\ (\text{t},\ J=7.1\ \text{Hz},\ 1\ \text{H},\ \text{C}(=O)\underline{\textbf{C}}\underline{\textbf{H}}\underline{\textbf{H}}),\ 1.97\ (\text{qd},\ J=12.4,\ 7.0\ \text{Hz},\ 1\ \text{H},\ \text{SC}\underline{\textbf{H}}_2\underline{\textbf{C}}\underline{\textbf{H}}\underline{\textbf{H}}),\ 1.85\ (\text{quin},\ J=6.9\ \text{Hz},\ 2\ \text{H},\ \text{C}(=O)\underline{\textbf{C}}\underline{\textbf{H}}\underline{\textbf{2}}) \end{array}$

¹³**C NMR** (101 MHz, MeOD)
$$\delta$$
 / ppm = ??

missing

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

The compound has not been reported previously.

1.31 Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxotetrahydrothiophen-3-yl)amino)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate 134

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ &$$

Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate **131** (50 mg, 0.145 mmol, 1 eq.), 4-bromo-N-(2-oxotetrahydrothiophen-3-yl)butanamide **132** (34.5 mg, 0.145 mmol, 1 eq.) and K_2CO_3 (20 mg, 0.145 mmol, 1 eq.) were stirred in acetonitrile (2 ml) at 50 °C under argon. After 24 h a further portion of **132** (34.5 mg, 0.145 mmol, 1 eq.) was added. After another 24 h a further portion was added (69.0 mg, 0.290 mmol, 2 eq.). After another 24 h the temperature was raised so the mixture was at reflux. After a final 24 h the precipitate was filtered off and the filtrate was purified by column chromatography (SiO₂, 5-10 % MeOH/CH₂Cl₂). **134** was obtained as a pale brown viscous liquid (9.4 mg, 0.018 mmol, 12.2 %).

TLC $R_f = 0.47 (10 \% \text{ MeOH/CH}_2\text{Cl}_2)$

 $mp \ T \ / \ ^{\circ}C = ?? \ (??)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹**H NMR** (400 MHz, MeOD) δ / ppm = ??_

decide which is cor-

rect

¹³**C NMR** (101 MHz, MeOD) δ / ppm = ??

¹⁹**F NMR** (376.45 MHz, MeOD) δ / ppm = ??

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

The compound has been synthesised previously.^{7,8} Only HRMS characterisation was published, and this agrees

1.32 1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(4-oxo-4-((2-oxotetrahydrothiophen-3-yl)amino)butyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinol-ine-3-carboxylic acid 135

1.33 1-Cyclopropyl-6-fluoro-4-oxo-7-(4-((((4-(1-(4-oxo-4-((2-oxotetrahydrothiophen-pure, 3-yl)amino)butyl)-1H-1,2,3-triazol-4-yl)butanoyl)oxy)methoxy)carbonyl)piper-very azin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 136

1-Cyclopropyl-6-fluoro-7-(4-(((hex-5-ynoyloxy)methoxy)carbonyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-c-arboxylic acid $\bf 176$ (0.203 mg, 0.407 mmol, 1 eq.), 4-azido-N-(2-oxotetrahydrothiophen-3-yl)butanamide $\bf 133$ (92.8 mg, 0.407 mmol, 1 eq.), CuI (40 mg, 0.190 mmol, 0.5 eq.) and DIPEA (0.356 ml, 0.264 mg, 2.04 mmol, 5 eq.) were stirred in CH₂Cl₂ (18.6 ml) at room temperature under Ar for 3 h. The mixture was fitered and the filtrate was dry-loaded onto SiO₂ and purified by column chromatography (SiO₂, 5-10 % MeOH/CH₂Cl₂). $\bf 136$ was obtained as a ??(??).

TLC $R_f = 0.40 (5 \% \text{ CH}_2\text{Cl}_2/\text{MeOH})$

$$mp T / {}^{\circ}C = ?? (??)$$

IR (neat)
$$\nu_{max} / \text{cm}^{-1} = ??$$

¹**H NMR** (400 MHz, DMSO d₆) δ / ppm = 15.16 (br. s., 1 H, C(=O)O<u>H</u>), 8.65 (s, 1 H, ortho to C(=O)OH), 8.21 (d, J = 8.5 Hz, 1 H, N<u>H</u>), 7.89 (d, J = 13.1 Hz, 1 H, ortho to F), 7.85 (s, 1 H, C<u>H</u>=CCH₂), 7.57 (d, J = 13.1 Hz, 1 H, ortho to F), 7.85 (s, 1 H, C<u>H</u>=CCH₂), 7.57 (d, J = 13.1 Hz, 1 H, ortho to F), 7.85 (s, 1 H, C<u>H</u>=CCH₂), 7.57 (d, J = 13.1 Hz, 1 H, ortho to F), 7.85 (s, 1 H, C<u>H</u>=CCH₂), 7.57 (d, J = 13.1 Hz, 1 H, ortho to F), 7.85 (s, 1 H, C<u>H</u>=CCH₂), 7.57 (d, J = 13.1 Hz, 1 H, ortho to F), 7.85 (s, 1 H, C<u>H</u>=CCH₂), 7.57 (d, J = 13.1 Hz, 1 H, ortho to F), 7.85 (s, 1 H, C<u>H</u>=CCH₂), 7.57 (d, J = 13.1 Hz, 1 H, ortho to F), 7.85 (s, 1 H, C<u>H</u>=CCH₂), 7.57 (d, J = 13.1 Hz, 1 H, ortho to F), 7.85 (s, 1 H, C<u>H</u>=CCH₂), 7.57 (d, J = 13.1 Hz, 1 H, ortho to F), 7.85 (s, 1 H, C<u>H</u>=CCH₂), 7.57 (d, J = 13.1 Hz, 1 H, ortho to F), 7.85 (s, 1 H, C<u>H</u>=CCH₂), 7.57 (d, J = 13.1 Hz, 1 H, ortho to F), 7.85 (s, 1 H, C<u>H</u>=CCH₂), 7.57 (d, J = 13.1 Hz, 1 H, ortho to F), 7.85 (s, 1 H, C<u>H</u>=CCH₂), 7.57 (d, J = 13.1 Hz, 1 H, ortho to F), 7.85 (s, 1 H, C<u>H</u>=CCH₂), 7.57 (d, J = 13.1 Hz, 1 H, ortho to F), 7.85 (s, 1 H, C<u>H</u>=CCH₂), 7.57 (d, J = 13.1 Hz, 1 H, ortho to F), 7.85 (s, 1 H, C<u>H</u>=CCH₂), 7.57 (d, J = 13.1 Hz, 1 H, ortho to F), 7.85 (s, 1 H, C<u>H</u>=CCH₂), 7.57 (d, J = 13.1 Hz, 1 H, ortho to F), 7.85 (s, 1 H, C<u>H</u>=CCH₂), 7.57 (d, J = 13.1 Hz, 1 H, ortho to F), 7.85 (s, 1 H, J = 13.1 Hz, J = 13.1 Hz,

Not hugely

dilute, no C or 2D!!

Write up if redoing.

7.4 Hz, 1 H, meta to F), 5.74 (s, 1 H, $OC\underline{H}_2O$), 4.58 (ddd, J = 12.6, 8.1, 7.2 Hz, 1 H, $C\underline{H}NH$), 4.30 (t, J = 6.9 Hz, 2 H, $C(=O)CH_2CH_2C\underline{H}_2N$), 3.80 (tt, J = 6.9, 3.6 Hz, 1 H, $NC\underline{H}(CH_2)_2$), 3.62 (br t, J = 5.2, 5.2 Hz, 4 H, $C(=O)N(C\underline{H}_2)C\underline{H}_2$), 3.38 (td, J = 11.4, 5.5 Hz, 1 H, $SC\underline{H}H$), 3.34 (br. s, 4 H, $C(=O)N(CH_2C\underline{H}_2)CH_2C\underline{H}_2$), 3.27 (ddd, J = 11.0, 6.9, 1.6 Hz, 1 H, $SC\underline{H}\underline{H}$), 2.64 (t, J = 7.6 Hz, 2 H, $CH=CC\underline{H}_2$), 2.44 (t, J = 7.5 Hz, 2 H, $C\underline{H}_2C(=O)O$), 2.40 (dddd, J = 12.3, 6.8, 5.4, 1.4 Hz, 1 H, $SCH_2C\underline{H}H$), 2.12 (t, J = 7.8 Hz, 1 H, $NHC(=O)C\underline{H}H$), 2.12 (t, J = 6.8 Hz, 1 H, $NHC(=O)C\underline{H}H$), 1.98 - 2.07 (m, 3 H, $SCH_2C\underline{H}H$ and $NHC(=O)CH_2C\underline{H}_2$), 1.86 (quin, J = 7.5 Hz, 2 H, $CH=CCH_2C\underline{H}_2$), 1.29 - 1.36 (m, 2 H, $NCH(C\underline{H}H)_2$), 1.14 - 1.21 (m, 2 H, $NCH(CH\underline{H})_2$)

¹³C NMR (101 MHz, DMSO d₆) δ / ppm = 205.5 (SC(=O)), 176.4 (C(=O)CC(=O)OH), 171.8 (C(=O)OCH₂O), 171.3 (NHC(=O)), 165.9 (C(=O)OH), 152.8 (d, J = 249.7 Hz, ipso to F), 152.9 (OC(=O)N), 148.1 (C=CC(=O)OH), 146.0 (CH=CCH₂), 144.9 (d, J = 9.6 Hz, ipso to piperazine), 139.1 (para to F), 122.0 (CH=CCH₂), 118.9 (d, J = 7.5 Hz, para to piperazine), 111.0 (d, J = 23.5 Hz, ortho to C=O and ortho to F), 106.8 (CC(=O)OH, and meta to C=O and meta to F), 80.3 (OCH₂O), 58.2 (CHNH), 49.1 (C(=O)N(CH₂CH₂)CH₂CH₂), 49.1 (C(=O)N(CH₂CH₂)CH₂CH₂), 48.6 (C(=O)CH₂CH₂CH₂N), 43.4 (N(CH₂)CH₂), 43.0 (N(CH₂)CH₂), 35.9 (NCH (CH₂)₂), 32.7 (CH=CCH₂CH₂CH₂C(=O)), 31.8 (NHC(=O)CH₂), 30.1 (SCH₂CH₂), 26.8 (SCH₂), 25.8 (C(=O)CH₂CH₂CH₂CH₂N), 24.2 (CH=CCH₂CH₂CH₂C(=O)), 24.0 (CH=CCH₂CH₂CH₂C(=O)), 7.6 (NCH(CH₂)₂)

¹⁹**F NMR** (376.45 MHz, DMSO d₆) δ / ppm = ??

no F

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

The compound has not been reported previously.

1.34 4-Bromo-N-(2-methoxyphenyl)butanamide 137

2-Methoxyaniline 177 (9.12 ml, 10.0 g, 81.2 mmol, 1 eq.) and NaHCO₃ (8.19 g, 97.4 mmol, 1.2 eq.) were dissolved in water (100 ml) and $\mathrm{CH_2Cl_2}$ (100 ml). The mixture was cooled to 0 °C and 4-bromobutyryl chloride 42 (9.40 ml, 15.1 g, 81.2 mmol, 1 eq.) was added dropwise over 15 min. The mixture was stirred at 0 °C for 1.5 h, then the aqueous layer was removed. The organic layer was dried with MgSO₄ and evaporated under reduced pressure. 137 was obtained as an initially colourless liquid which slowly turned blue then black if left out on the bench (11.0 g, 40.6 mmol, 50.0 %).

TLC $R_f = 0.16 \ (10 \% \ \text{EtOAc/P.E.})$

IR (neat)
$$\nu_{max} / \text{cm}^{-1} = ??$$

¹**H NMR** (400 MHz, CDCl₃ d₁) δ / ppm = 8.32 (dd, J = 8.0, 1.7 Hz, 1 H, ortho to NH), 7.85 (br s, 1 H, N<u>H</u>), 7.02 (td, J = 7.9, 1.7 Hz, 1 H, para to NH), 6.93 (td, J = 7.7, 1.4 Hz, 1 H, para to OCH₃), 6.85 (dd, J = 8.1, 1.5 Hz, 1 H, ortho to OCH₃), 3.85 (s, 3 H, C<u>H</u>₃), 3.50 (t, J = 6.4 Hz, 2 H, C<u>H</u>₂Br), 2.56 (t, J = 7.1 Hz, 2 H, C(=O)C<u>H</u>₂), 2.25 (quin, J = 6.7 Hz, 2 H, C(=O)CH₂C<u>H</u>₂)

¹³C NMR (101 MHz, CDCl₃ d₁) δ / ppm = 169.4 (\underline{C} (=O)), 147.6 (*ipso* to OCH₃), 127.2 (*ipso* to NH), 123.5 (*para* to NH), 120.7 (*para* to OCH₃), 119.6 (*ortho* to NH and *meta* to OCH₃), 109.8 (*ortho* to OCH₃ and *meta* to NH), 55.5 (CH₃), 35.4 (\underline{C} (=O)CH₂), 33.1 (CH₂Br), 27.9 (\underline{C} (=O)CH₂CH₂)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

The compound has not been reported previously.

1.35 4-Bromo-N-(3-methoxyphenyl)butanamide 138

3-Methoxyaniline 178 (3.04 ml, 3.33 g, 27.1 mmol, 1 eq.) and NaHCO $_3$ (2.73 g, 32.5 mmol, 1.2 eq.) were dissolved in water (30 ml) and CH $_2$ Cl $_2$ (30 ml). The mixture was cooled to 0 °C and 4-bromobutyryl chloride 42 (3.13 ml, 5.03 g, 27.1 mmol, 1 eq.) was added dropwise over 5 min. The mixture was stirred at 0 °C for 1 h, then the aqueous layer was removed. The organic layer was dry-loaded onto SiO $_2$ and purified by column chromatography using a Combiflash (SiO $_2$, 0-100 % EtOAc/P.E.). 138 was obtained as a pale pink solid (3.66 g, 13.5 mmol, 49.6 %).

how to report?

TLC $R_f = 0.18 \ (25 \% \ \text{EtOAc/P.E.})$

mp T / °C = ?? (??)

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹**H NMR** (400 MHz, CDCl₃ d₁) δ / ppm = 8.45 (s, 1 H, N<u>H</u>), 7.27 (t, J = 2.2 Hz, 1 H, ortho to OCH₃ and ortho to NH), 7.14 (t, J = 8.1 Hz, 1 H, meta to OCH₃ and meta to NH), 7.02 (d, J = 8.3 Hz, 1 H, para to OCH₃), 6.62 (dd, J = 8.2, 2.1 Hz, 1 H, para to NH), 3.71 (s, 3 H, C<u>H</u>₃), 3.42 (t, J = 6.5 Hz, 2 H, C<u>H</u>₂Br), 2.51 (t, J = 6.9 Hz, 2 H, C(=O)CH₂), 2.19 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂)

¹³C NMR (101 MHz, CDCl₃ d₁) δ / ppm = 170.3 ($\underline{\text{C}}$ (=O)), 159.9 (*ipso* to OCH₃), 139.0 (*ipso* to NH), 129.5 (*meta* to OCH₃ and *meta* to NH), 112.1 (*para* to OCH₃), 109.9 (*para* to NH), 105.7 (*ortho* to OCH₃ and *ortho* to NH), 55.2 ($\underline{\text{CH}}_3$), 35.3 ($\underline{\text{C}}$ (=O) $\underline{\text{C}}$ H₂), 33.2 ($\underline{\text{C}}$ H₂Br), 28.0 ($\underline{\text{C}}$ (=O)CH₂CH₂)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

The compound has not been reported previously.

1.36 4-Azido-N-(2-methoxyphenyl)butanamide 139

4-Bromo-N-(2-methoxyphenyl) butanamide ${\bf 137}$ (2.05 g, 7.51 mmol, 1 eq.) and NaN₃ (1.17 g, 18.0 mmol, 2.4 eq.) were refluxed in acetonitrile (100 ml) for 2 h. The mixture was cooled and filtered, and the fit rate was dry-loaded onto SiO₂ and purified by column chromatography using a Combiflash (SiO₂, 8-14 % then hold at 14 % EtOAc/P.E.). ${\bf 139}$ was obtained as an initially colour less liquid which slowly turned blue then black if left out on the bench (0.469 g, 2.00 mmol, 26.7 %).

how to report?

TLC $R_f = 0.20 \ (25 \% \ \text{EtOAc/P.E.})$

IR (neat)
$$\nu_{max} / \text{cm}^{-1} = ??$$

¹**H NMR** (400 MHz, CDCl₃ d₁) δ / ppm = 8.32 (dd, J = 7.9, 1.0 Hz, 1 H, ortho to NH), 7.86 (br s, 1 H, N<u>H</u>), 7.00 (td, J = 7.5, 1.5 Hz, 1 H, para to NH), 6.90 (td, J = 7.7, 1.1 Hz, 1 H, para to OCH₃), 6.83 (dd, J = 8.1, 1.4 Hz, 1 H, ortho to OCH₃), 3.81 (s, 3 H, C<u>H</u>₃), 3.33 (t, J = 6.7 Hz, 2 H, C<u>H</u>₂Br), 2.42 (t, J = 7.2 Hz, 2 H, C(=O)C<u>H</u>₂), 1.94 (quin, J = 6.9 Hz, 2 H, C(=O)CH₂C<u>H</u>₂)

¹³C NMR (101 MHz, CDCl₃ d₁) δ / ppm = 169.5 (<u>C</u>(=O)), 147.6 (*ipso* to OCH₃), 127.1 (*ipso* to NH), 123.4 (*para* to NH), 120.5 (*para* to OCH₃), 119.5 (*ortho* to NH and *meta* to OCH₃), 109.6 (*ortho* to OCH₃ and *meta* to NH), 55.2 (<u>C</u>H₃), 50.3 (<u>C</u>H₂N₃), 33.9 (C(=O)<u>C</u>H₂), 24.3 (C(=O)CH₂<u>C</u>H₂)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

The data are consistent with the literature.⁹

1.37 4-Azido-N-(3-methoxyphenyl)butanamide 140

$$\begin{array}{c|c}
 & O \\
 & N \\
 & H
\end{array}$$

4-Bromo-N-(3-methoxyphenyl) butanamide ${\bf 138}$ (2.05 g, 7.51 mmol, 1 eq.) and NaN₃ (1.17 g, 18.0 mmol, 2.4 eq.) were refluxed in acetonitrile (100 ml) for 7 h. The mixture was cooled and filtered, and the fit rate was dry-loaded onto SiO₂ and purified by column chromatography using a Combiflash (SiO₂, 0-100 % EtOAc/P.E.). ${\bf 140}$ was obtained as an straw-coloured liquid (0.294 g, 1.25 mmol, 16.7 %).

how to report?

TLC $R_f = 0.37 (50 \% \text{ EtOAc/P.E.})$

IR (neat)
$$\nu_{max} / \text{cm}^{-1} = ??$$

¹**H NMR** (400 MHz, MeOD) δ / ppm = 8.63 (br s, 1 H, N<u>H</u>), 7.26 (t, J = 2.3 Hz, 1 H, ortho to OCH₃ and ortho to NH), 7.15 (t, J = 8.1 Hz, 1 H, meta to OCH₃ and meta to NH), 7.01 (dd, J = 7.8, 1.6 Hz, 1 H, para to OCH₃), 6.63 (dd, J = 8.2, 1.9 Hz, 1 H, para to NH), 3.69 (s, 3 H, C<u>H</u>₃), 3.28 (t, J = 6.7 Hz, 2 H, C<u>H</u>₂N₃), 2.39 (t, J = 7.4 Hz, 2 H, C(=O)C<u>H</u>₂), 1.91 (quin, J = 7.0 Hz, 2 H, C(=O)CH₂C<u>H</u>₂)

¹³C NMR (101 MHz, MeOD) δ / ppm = 170.8 (<u>C</u>(=O)), 159.6 (*ipso* to OCH₃), 138.9 (*ipso* to NH), 129.2 (*meta* to OCH₃ and *meta* to NH), 112.3 (*para* to OCH₃), 109.5 (*para* to NH), 106.0 (*ortho* to OCH₃ and *ortho* to NH), 54.8 (<u>C</u>H₃), 50.4 (<u>C</u>H₂N₃), 33.6 (C(=O)<u>C</u>H₂), 24.4 (C(=O)CH₂<u>C</u>H₂)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

The compound has not been reported previously.

1.38 Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-((2-methoxyphenyl)amino)-4-oxobutyl)-piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 141

Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate **131** (500 mg, 1.45 mmol, 1 eq.), 4-bromo-N-(2-methoxyphenyl)butanamide **137** (788 mg, 2.90 mmol, 2 eq.), DIPEA (1.28 ml, 950 mg, 7.35 mmol, 5 eq.), NaI (275 mg, 1.83 mmol, 1.3 eq.) and acetonitrile (10 ml) were stirred in a microwave reactor at 100 °C for 4 h. The mixture was dry-loaded onto SiO₂ and purified by column chromatography (SiO₂, 4 % MeOH/CH₂Cl₂). **141** was obtained as a bright pink gum (79.7 mg, 0.149 mmol, 10.2 %).

how to report?

TLC $R_f = 0.40 \ (10 \% \text{ MeOH/CH}_2\text{Cl}_2)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹H NMR (400 MHz, CDCl₃ d₁) δ / ppm = 8.48 (s, 1 H, ortho to C(=O)OCH₃), 8.36 (d, J = 7.9 Hz, 1 H, ortho to NH), 7.87 - 7.99 (m, 2 H, ortho to F and NH), 7.19 (d, J = 6.5 Hz, 1 H, meta to F), 7.01 (t, J = 7.5 Hz, 1 H, para to NH), 6.93 (t, J = 7.7 Hz, 1 H, para to OCH₃), 6.85 (d, J = 7.9 Hz, 1 H, ortho to OCH₃), 3.88 (s, 3 H, C(=O)OCH₃), 3.85 (s, 3 H, aromatic OCH₃), 3.41 (tt, J = 6.9, 4.0 Hz, 1 H, NCH(CH₂)₂), 3.25 (br t, J = 5.0, 5.0 Hz, 4 H, C(=O)CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 2.67 (br t, J = 5.0, 5.0 Hz, 4 H, C(=O)CH₂CH₂CH₂N(CH₂CH₂CH₂N), 2.47 (t, J = 7.1 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.97 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.25 - 1.33 (m, 2 H, NCH(CHH)₂), 1.07 - 1.14 (m, 2 H, NCH(CHH)₂)

¹³C NMR (101 MHz, CDCl₃ d₁) δ / ppm = 172.9 (<u>C</u>(=O)CC(=O)OCH₃), 170.8 (NH<u>C</u>(=O)), 166.2 (<u>C</u>(=O)OCH₃), 153.3 (d, J = 248.0 Hz, ipso to F), 148.2 (<u>C</u>=CC(=O)OCH₃), 147.6 (ipso to OCH₃), 144.4 (d, J = 10.4

Hz, *ipso* to piperazine), 137.9 (*para* to F), 127.6 (*ipso* to NH), 123.4 (*para* to NH), 122.7 (d, J = 7.8 Hz, *para* to piperazine), 121.0 (*para* to OCH₃), 119.7 (*ortho* to NH and *meta* to OCH₃), 113.0 (d, J = 22.5 Hz, *ortho* to C=O and *ortho* to F), 109.8 (*ortho* to OCH₃ and *meta* to NH), 104.7 ($\underline{C}C(=O)OCH_3$, and *meta* to C=O and *meta* to F), 57.2 ($\underline{C}H_2N$), 55.6 (aromatic O $\underline{C}H_3$), 52.7 ($\underline{C}(=O)CH_2CH_2CH_2N(\underline{C}H_2)\underline{C}H_2$), 51.9 ($\underline{C}(=O)O\underline{C}H_3$), 49.8 ($\underline{C}(=O)CH_2CH_2CH_2N(\underline{C}H_2)CH_2CH_2CH_2$), 35.5 ($\underline{C}(=O)\underline{C}H_2CH_2N$), 34.5 ($\underline{N}\underline{C}H(CH_2)_2$), 22.3 ($\underline{C}(=O)CH_2\underline{C}H_2CH_2N$), 8.0 ($\underline{N}\underline{C}H(\underline{C}H_2)_2$)

¹⁹**F NMR** (376.45 MHz, CDCl₃ d₁) δ / ppm = ??

Check for F

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

The compound has not been reported previously.

1.39 Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-((3-methoxyphenyl)amino)-4-oxobutyl)-piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 142

Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate **131** (500 mg, 1.45 mmol, 1 eq.), 4-bromo-N-(3-methoxyphenyl)butanamide **138** (788 mg, 2.90 mmol, 2 eq.), DIPEA (1.28 ml, 950 mg, 7.35 mmol, 5 eq.), NaI (275 mg, 1.83 mmol, 1.3 eq.) and acetonitrile (10 ml) were stirred in a microwave reactor at 100 °C for 4 h. The mixture was evaporated under reduced pressure and partitioned between CH_2Cl_2 (50 ml) and water (50 ml). The organic layer was separated off and the aqueous layer was extracted again with CH_2Cl_2 (50 ml). The combined organic layers were dried with $MgSO_4$ and purified by column chromatography (SiO_2 , 0-4 % $MeOH/CH_2Cl_2$). **142** was obtained as an off-white powder (81.7 mg, 0.152 mmol, 10.5 %).

how to report?

TLC $R_f = 0.38 \ (10 \% \text{ MeOH/CH}_2\text{Cl}_2)$

mp $T / {}^{\circ}C = ?? (??)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹**H NMR** (400 MHz, MeOD) δ / ppm = 8.56 (s, 1 H, ortho to C(=O)OCH₃), 8.06 (d, J = 13.3 Hz, 1 H, ortho to F), 8.02 (br s, 1 H, NH), 7.34 (t, J = 1.7 Hz, 1 H, ortho to OCH₃ and ortho to NH), 7.25 (d, J = 7.0 Hz, 1 H, meta to F), 7.20 (t, J = 8.2 Hz, 1 H, meta to OCH₃ and meta to NH), 6.98 (dd, J = 7.8, 1.7 Hz, 1 H, para to OCH₃), 6.65 (dd, J = 8.2, 2.1 Hz, 1 H, para to NH), 3.93 (s, 3 H, C(=O)OCH₃), 3.80 (s, 3 H, aromatic OCH₃), 3.42 (tt, J = 6.8, 3.7 Hz, 1 H, NCH(CH₂)₂), 3.31 (br t, J = 4.3, 4.3 Hz, 4 H, C(=O)CH₂CH₂CH₂N(CH₂CH₂), 2.73 (br t, J = 4.5, 4.5 Hz, 4 H, C(=O)CH₂CH₂CH₂N(CH₂), 2.00 (quin, 2.58 (t, J = 6.5 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 2.48 (t, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 2.00 (quin, 3.56 (dx, 3 H, ortho to CH₃), 3.60 (dx, 3 H, ortho to OCH₃), 3.60 (dx, 3 H, ort

 $J = 6.8 \text{ Hz}, 2 \text{ H}, \text{C}(=0)\text{CH}_2\text{CH}_2\text{CH}_2\text{N}), 1.29 - 1.36 \text{ (m, 2 H, NCH(CHH)}_2), 1.11 - 1.17 \text{ (m, 2 H, NCH(CHH)}_2)$

¹³**C NMR** (101 MHz, MeOD) δ / ppm = ??

C is too dilute to use

¹⁹**F NMR** (376.45 MHz, MeOD) δ / ppm = -123.5 (S)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

The compound has not been reported previously.

1.40 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-((2-methoxyphenyl)amino)-4-oxobutyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 143

1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **173** (24.1 mg, 58.6 μ mol, 1 eq.) and 4-azido-N-(2-methoxyphenyl)butanamide **139** (13.7 mg, 58.5 μ mol, 1 eq.) were dissolved in water (3 ml), t-BuOH (9 ml) and CH₂Cl₂ (9 ml), and the mixture was degassed by bubbling through N₂. A solution of CuSO₄ and THPTA (117 μ l, 5.85 μ mol, 0.1 eq., 50 mM, aq.) was added, followed by a solution of sodium ascorbate (234 μ l, 11.7 μ mol, 0.2 eq., 50 mM, aq.). The mixture was stirred at room temperature under argon for 16 h. Water (25 ml), CH₂Cl₂ (25 ml) and MeOH (5 ml) were added and the organic layer was separated off, dry-loaded onto SiO₂ and purified by column chromatography using a Combiflash (SiO₂, 3-23 % MeOH/CH₂Cl₂). **143** was obtained as ?? (?? mg, ?? mmol, ?? %).

how to phrase this?

how to report??

TLC $R_f = 0.28 \ (10 \% \ \mathrm{MeOH/CH_2Cl_2})$

 $mp T / {}^{\circ}C = ?? (??)$

and weight

state

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹H NMR (400 MHz, CDCl₃) δ / ppm = 15.05 (br s, 1 H, C(=O)O<u>H</u>), 8.76 (s, 1 H, ortho to C(=O)OH), 8.31 (dd, J = 8.0, 1.7 Hz, 1 H, ortho to NH), 8.00 (d, J = 13.0 Hz, 1 H, ortho to F), 7.83 (br s, 1 H, N<u>H</u>), 7.37 (s, 1 H, C<u>H</u>=CCH₂), 7.35 (d, J = 7.2 Hz, 1 H, meta to F), 7.04 (td, J = 7.7, 1.7 Hz, 1 H, para to NH), 6.95 (td, J = 7.8, 1.5 Hz, 1 H, para to OCH₃), 6.88 (dd, J = 8.1, 1.4 Hz, 1 H, ortho to OCH₃), 4.47 (t, J = 6.7 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 3.88 (s, 3 H, C<u>H</u>₃), 3.54 (tt, J = 6.9, 4.0 Hz, 1 H, NC<u>H</u>(CH₂)₂), 3.35 (br t, J = 4.7 Hz, 4 H, CH=CCH₂CH₂CH₂CH₂N(CH₂C<u>H</u>₂)CH₂CH₂), 2.76 (t, J = 7.5 Hz, 2 H, CH=CCH₂CH₂CH₂CH₂N), 2.46 (t, J = 4.7 Hz, 4 H, CH=CCH₂CH₂CH₂CH₂N(C<u>H</u>₂)C<u>H</u>₂), 2.47 (t, J = 7.3 Hz, 2 H, CH=CCH₂CH₂CH₂CH₂N), 2.44 (t, J = 6.8 Hz, 2 H, C(=O)C<u>H</u>₂CH₂CH₂CH₂N), 2.32 (quin, J = 6.7 Hz, 2 H, C(=O)CH₂C<u>H</u>₂CH₂N), 1.75 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.75 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.75 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.75 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.75 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.75 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.75 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.75 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.75 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.75 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.75 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.75 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.75 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.75 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.75 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.75 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.75 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.75 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 1.75 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂CH₂N), 1.75 (quin, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂

7.6 Hz, 2 H, CH=CCH₂CH₂CH₂CH₂CH₂N), 1.61 (quin, J = 7.5 Hz, 2 H, CH=CCH₂CH₂CH₂CH₂N), 1.35 - 1.42 (m, 2 H, NCH(C<u>H</u>H)₂), 1.17 - 1.22 (m, 2 H, NCH(CH<u>H</u>)₂)

¹⁹**F NMR** (376.45 MHz, CDCl₃) δ / ppm = -120.7 (S)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

The compound has not been reported previously.

1.41 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-((3-methoxyphenyl)amino)-4-oxobutyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 144

$$\begin{array}{c|c} & & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ &$$

1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **173** (24.1 mg, 58.6 μ mol, 1 eq.) and 4-azido-N-(3-methoxyphenyl)butanamide **140** (13.7 mg, 58.5 μ mol, 1 eq.) were dissolved in water (1 ml), t-BuOH (9 ml) and CH₂Cl₂ (10 ml), and the mixture was degassed by bubbling through N₂. A solution of CuSO₄ and THPTA (58.5 μ l, 5.85 μ mol, 0.1 eq. 100 mM, aq.) was added, followed by a solution of sodium ascorbate (117 μ l, 11.7 μ mol, 0.2 eq., 100 mM, aq.). The mixture was stirred at room temperature under argon for 2 h, then the solvent was removed under reduced pressure. The resudue was partitioned between water (15 ml) and CH₂Cl₂ (15 ml), and the aqeous layer was extracted a further four times with CH₂Cl₂ (4 × 15 ml). The combined organic layers were dried with MgSO₄, dry-loaded onto SiO₂ and purified by column chromatography (SiO₂, 0-10 % MeOH/CH₂Cl₂). **144** was obtained as ?? (1.9 mg, 2.9 μ mol, 5.0 %).

state

TLC $R_f = 0.22 \ (10 \% \ \text{MeOH/CH}_2\text{Cl}_2)$

 $mp T / {}^{\circ}C = ?? (??)$

¹³C NMR (101 MHz, DMSO d₆) δ / ppm = 176.3 ($\underline{\mathbf{C}}$ (=O)CC(=O)OH), 170.1 (NH $\underline{\mathbf{C}}$ (=O)), 165.9 ($\underline{\mathbf{C}}$ (=O)OH), 159.4 (*ipso* to OCH₃), 153.0 (d, J = 248.6 Hz, *ipso* to F), 148.0 (CH= $\underline{\mathbf{C}}$ CH₂), 146.9 ($\underline{\mathbf{C}}$ =CC(=O)OH), 145.2 (d, J = 10.7 Hz, *ipso* to piperazine), 140.3 (*para* to F), 139.2 (*ipso* to NH), 129.4 (*meta* to OCH₃ and *meta* to NH), 121.7 ($\underline{\mathbf{C}}$ H=CCH₂), 118.5 (d, J = 7.5 Hz, *para* to piperazine), 111.3 (*para* to OCH₃), 110.9 (d, J = 22.4 Hz, *ortho* to C=O and *ortho* to F), 108.4 (*para* to NH), 106.7 ($\underline{\mathbf{C}}$ C(=O)OH), 106.3 (*meta* to C=O and *meta* to F), 104.8 (*ortho* to OCH₃ and *ortho* to NH), 57.3 (CH=CCH₂CH₂CH₂CH₂CH₂N), 54.9 ($\underline{\mathbf{C}}$ H₃), 52.4 (CH=CCH₂CH₂CH₂CH₂N($\underline{\mathbf{C}}$ H₂)CH₂), 49.5 (CH=CCH₂CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 49.4 (CH=CCH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 48.7 (C(=O)CH₂CH₂CH₂CH₂N), 35.8 (NCH(CH₂)₂), 32.9 (C(=O)CH₂CH₂CH₂CH₂N), 26.8 (CH=CCH₂CH₂CH₂CH₂N), 25.7 (CH=CCH₂CH₂CH₂CH₂N), 25.5 (C(=O)CH₂CH₂CH₂N), 26.9 (CH=CCH₂CH₂CH₂N), 7.6 (NCH($\underline{\mathbf{C}}$ H₂)₂)

¹⁹**F NMR** (376.45 MHz, DMSO d₆) δ / ppm = -121.5 (S)

HRMS (ESI⁺)
$$m/z$$
 / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

The compound has not been reported previously.

1.42 Methyl 7-(4-(4-(tert-butoxy)-4-oxobutyl)piperazin-1-yl)-1-cyclopropyl-6-flu-oro-4-oxo-1,4-dihydroquinoline-3-carboxylate 145

Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate **131** (200 mg, 0.579 mmol, 1 eq.), tert-butyl 4-bromobutanoate **179** (103 μ l, 130 mg, 0.581 mmol, 1 eq.), NaI (86.9 mg, 0.580 mmol, 1 eq.), TEA (316 μ l, 229 mg, 2.27 mmol, 4 eq.) and acetonitrile (10 ml) were stirred in a microwave reactor at 100 °C for 8 h. A second portion of tert-butyl 4-bromobutanoate **179** (103 μ l, 130 mg, 0.581 mmol, 1 eq.) was added, and the mixture was stirred in a microwave reactor at 100 °C for a further 8 h. The mixture was then

how to report?

how to report?

dry-loaded onto SiO_2 and purified by column chromatography (SiO_2 , 0-4 % MeOH/CH₂Cl₂). **145** was obtained as ?? (141 mg, 0.289 mmol, 49.9 %).

state

TLC $R_f = 0.12 \ (4 \% \text{ MeOH/CH}_2\text{Cl}_2)$

 $mp T / {}^{\circ}C = ?? (??)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹**H NMR** (400 MHz, CDCl₃) δ / ppm = 8.39 (s, 1 H, ortho to C(=O)OCH₃), 7.82 (d, J = 13.3 Hz, 1 H, ortho to F), 7.17 (d, J = 7.2 Hz, 1 H, meta to F), 3.83 (s, 3 H, C<u>H</u>₃), 3.40 (tt, J = 7.2, 3.6 Hz, 1 H, NC<u>H</u>(CH₂)₂), 3.22 (t, J = 4.3 Hz, 4 H, CH₂N(CH₂C<u>H</u>₂)CH₂C<u>H</u>₂), 2.63 (t, J = 4.4 Hz, 4 H, CH₂N(C<u>H</u>₂)C<u>H</u>₂), 2.41 (t, J = 7.3 Hz, 2 H, C<u>H</u>₂N(CH₂)CH₂), 2.25 (t, J = 7.4 Hz, 2 H, C<u>H</u>₂CH₂CH₂N(CH₂)CH₂), 1.78 (quin, J = 7.3 Hz, 2 H, C<u>H</u>₂CH₂CH₂N(CH₂)CH₂), 1.41 (s, 9 H, C(C<u>H</u>₃)₃), 1.24 (m, 2 H, NCH(C<u>H</u>H)₂), 1.09 (m, 2 H, NCH(CH<u>H</u>)₂)

 $^{13}\mathbf{C} \ \mathbf{NMR} \ (101 \ \mathrm{MHz}, \ \mathrm{CDCl_3}) \ \delta \ / \ \mathrm{ppm} = 172.7 \ (\underline{\mathrm{C}}(=\mathrm{O})\mathrm{CC}(=\mathrm{O})\mathrm{OCH_3}), \ 172.6 \ (\underline{\mathrm{C}}(=\mathrm{O})\mathrm{OC}(\mathrm{CH_3})_3), \ 165.9 \ (\underline{\mathrm{C}}(=\mathrm{O})\mathrm{OCH_3}), \ 153.1 \ (\mathrm{d}, \ J = 249.7 \ \mathrm{Hz}, \ ipso \ \mathrm{to} \ \mathrm{F}), \ 148.1 \ (\underline{\mathrm{C}}=\mathrm{CC}(=\mathrm{O})\mathrm{OCH_3}), \ 144.3 \ (\mathrm{d}, \ J = 10.4 \ \mathrm{Hz}, \ ipso \ \mathrm{to} \ \mathrm{piperazine}), \ 137.7 \ (para \ \mathrm{to} \ \mathrm{F}), \ 122.5 \ (\mathrm{d}, \ J = 6.9 \ \mathrm{Hz}, \ para \ \mathrm{to} \ \mathrm{piperazine}) \ 112.6 \ (\mathrm{d}, \ J = 22.5 \ \mathrm{Hz}, \ ortho \ \mathrm{to} \ \mathrm{C}=\mathrm{O} \ \mathrm{and} \ ortho \ \mathrm{to} \ \mathrm{F}), \ 109.5 \ (\underline{\mathrm{C}}(=\mathrm{O})\mathrm{OCH_3}) \ 104.7 \ (meta \ \mathrm{to} \ \mathrm{C}=\mathrm{O} \ \mathrm{and} \ meta \ \mathrm{to} \ \mathrm{F}), \ 80.0 \ (\underline{\mathrm{C}}(\mathrm{CH_3})_3), \ 57.4 \ (\mathrm{C}(=\mathrm{O})\mathrm{CH_2}\mathrm{CH_2}\mathrm{N}), \ 52.7 \ (\mathrm{C}(=\mathrm{O})\mathrm{CH_2}\mathrm{CH_2}\mathrm{N}(\mathrm{CH_2}\mathrm{CH_2}), \ 51.7 \ (\underline{\mathrm{CH_3}}), \ 49.7 \ (\mathrm{C}(=\mathrm{O})\mathrm{CH_2}\mathrm{CH_2}\mathrm{N}(\mathrm{CH_2}\mathrm{CH_2}), \ 28.0 \ (\mathrm{C}(\underline{\mathrm{C}}\mathrm{H_3})_3), \ 22.0 \ (\mathrm{C}(=\mathrm{O})\mathrm{CH_2}\mathrm{CH_2}\mathrm{CH_2}), \ 7.9 \ (\mathrm{NCH}(\underline{\mathrm{CH_2}}\mathrm{L_2}), \ 34.4 \ (\mathrm{N}\underline{\mathrm{C}}\mathrm{H}(\mathrm{CH_2}\mathrm{L_2}), \ 33.2 \ (\mathrm{C}(=\mathrm{O})\underline{\mathrm{C}}\mathrm{H_2}), \ 28.0 \ (\mathrm{C}(\underline{\mathrm{C}}\mathrm{H_3})_3), \ 22.0 \ (\mathrm{C}(=\mathrm{O})\mathrm{CH_2}\mathrm{CH_2}), \ 7.9 \ (\mathrm{NCH}(\underline{\mathrm{C}}\mathrm{H_2}\mathrm{L_2})$

¹⁹**F NMR** (376.45 MHz, CDCl₃) δ / ppm = ??__

missing

should be

ranges

ideally,

go back

if time

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

The compound has not been reported previously.

1.43 4-(4-(1-Cyclopropyl-6-fluoro-3-(methoxycarbonyl)-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-yl)butanoic acid, trifluoroacetic acid salt 146

$$\begin{array}{c|c} & & & & \\ & &$$

Methyl 7-(4-(4-(tert-butoxy)-4-oxobutyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-car-boxylate **145** (20 mg, 41.0 μ mol) and TFA (0.2 ml) were stirred in CH₂Cl₂ (1.8 ml) at r.t. for 16 h then evaporated under reduced pressure. **146** was obtained as a white solid (21.4 mg, 39.2 μ mol, 95.6 %).

TLC $R_f = ?? (??)$

sure
how to
draw/nar

not

mp $T / {}^{\circ}C = ?? (??)$

this?

¹**H NMR** (400 MHz, DMSO d₆) δ / ppm = 8.47 (s, 1 H, ortho to C(=O)OH), 7.80 (d, J = 13.2 Hz, 1 H, ortho to F), 7.47 (d, J = 7.4 Hz, 1 H, meta to F), 3.73 (s, 3 H, C $\underline{\text{H}}_3$), 3.66 (tt, J = 7.2, 3.7 Hz, 1 H, NC $\underline{\text{H}}$ (CH₂)2), 3.30 - 3.54 (br s, 8 H, CH₂N(C $\underline{\text{H}}_2$)C $\underline{\text{H}}_2$ and CH₂N(CH₂C $\underline{\text{H}}_2$)CH₂C $\underline{\text{H}}_2$) 3.13 - 3.22 (m, 2 H, C $\underline{\text{H}}_2$ N(CH₂)CH₂), 2.36 (t, J = 7.1 Hz, 2 H, C $\underline{\text{H}}_2$ CH₂CH₂N(CH₂)CH₂), 1.87 - 1.98 (m, 2 H, C $\underline{\text{H}}_2$ CH₂N(CH₂)CH₂), 1.22 - 1.30 (m, 2 H, NCH(C $\underline{\text{H}}$ H)₂), 1.06 - 1.15 (m, 2 H, NCH(CH $\underline{\text{H}}$)₂)

¹³C NMR (101 MHz, DMSO d₆) δ / ppm = 173.5 (CH₂C(=O)OH), 171.6 (C(=O)CC(=O)OCH₃), 164.9 (C(=O)OCH₃), 158.2 (q, J = 31.5 Hz, CF₃C(=O)OH), 152.5 (d, J = 247.6 Hz, ipso to F), 148.5 (C=CC(=O)OH), 142.3 (d, J = 10.7 Hz, ipso to piperazine), 138.0 (para to F), 122.6 (d, J = 6.4 Hz, para to piperazine), 117.2 (q, J = 299.8 Hz, CF₃), 111.9 (d, J = 22.4 Hz, ortho to C=O and ortho to F), 109.1 (CC(=O)OCH₃), 106.9 (meta to C=O and meta to F), 55.1 (C(=O)CH₂CH₂CH₂N), 51.4 (CH₃), 50.8 (C(=O)CH₂CH₂CH₂N(CH₂)CH₂), 46.7 (C(=O)CH₂CH₂CH₂N(CH₂CH₂), 46.7 (C(=O)CH₂CH₂CH₂N), 19.1 (C(=O)CH₂CH₂), 7.6 (NCH(CH₂)₂)

¹⁹**F NMR** (376.45 MHz, DMSO d_6) δ / ppm = -73.62 (s, CF₃), -124.61 (s, ciprofloxacin F)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

The compound has not been reported previously.

1.44 (1S,2S)-2-(((S)-1-Phenylethyl)amino)cyclopentan-1-ol 147 and (1R,2R)-2-(((S)-1-phenylethyl)amino)cyclopentan-1-ol 148

(S)-1-phenylethan-1-amine 180 (7.85 ml, 7.38 g, 60.9 mmol, 1 eq.) was dissolved in CH_2Cl_2 (50 ml) and stirred rapidly at 0 °C. A solution of AlMe₃ (31 ml, 2.0 M in heptane, 60.9 mmol) was added dropwise and the solution was stirred at 0 °C for 1 h. A solution of cyclohexene oxide 181 (5.71 ml, 5.50 g, 65.4 mmol, 1.1 eq.) in CH_2Cl_2 (50 ml) was then added dropwise, and the mixture was stirred at 0 °C for a further 3 h, followed by 48 h at r.t.. The mixture was cooled to 0 °C and NaF (11 g, 262 mmol, 4.3 eq.) was added portionwise, followed by water (7.00 ml, 7.00 g, 389 mmol, 6.4 eq.) and CH_2Cl_2 (50 ml). The suspension was allowed to warm to r.t. and stirred for 1 h, then filtered through Celite and washed with CH_2Cl_2 (500 ml). The filtrate was dried with K_2CO_3 , concentrated under reduced pressure and purified by column chromatography (SiO₂, 20:5:1 hexane:EtOAc:TEA). 147 was obtained as a pale yellow oil (4.08 g, 19.9 mmol, 32.6 %). 148 was obtained as pale yellow crystals (4.48 g, 21.8 mmol, 35.8 %).

(1S,2S)-2-(((S)-1-Phenylethyl)amino)cyclopentan-1-ol 147

TLC $R_f = 0.25$ (15:5:1 hexane:EtOAc:TEA)

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

spacings for
subtitles

fix im-

age

sizes

¹H NMR (400 MHz, CDCl₃) δ / ppm = 7.28 - 7.38 (m, 4 H, ortho and meta to CHCH₃), 7.21 - 7.28 (m, 1 H, para to CHCH₃), 3.83 (q, J = 6.6 Hz, 1 H, CHCH₃), 3.78 (q, J = 7.0 Hz, 1 H, CHOH), 2.62 (dt, J = 8.2, 7.2 Hz, 1 H, CHNH), 1.97 (quin, J = 6.7 Hz, 1 H, CH₂CHNH), 1.90 (quin, J = 6.9 Hz, 1 H, CH₂CHOH), 1.56 - 1.68 (m, CH₂CH₂CHOH), 1.43 (dq, J = 12.5, 8.0 Hz, 1 H, CH₂CHOH), 1.37 (d, J = 6.6 Hz, 3 H, CH₃), 1.25 - 1.36 (m, 1 H, CH₂CHNH)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 144.75 (*ipso* to CHCH₃), 128.26 (*meta* to CHCH₃), 126.72 (*para* to CHCH₃), 126.30 (*ortho* to CHCH₃), 77.65 (<u>C</u>HOH), 63.38 (<u>C</u>HNH), 56.20 (<u>C</u>HCH₃), 31.74 (<u>C</u>H₂CHOH), 29.22 (<u>C</u>H₂CHNH), 24.58 (<u>C</u>H₃), 19.57 (<u>C</u>H₂CHOH)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

(1R,2R)-2-(((S)-1-Phenylethyl)amino)cyclopentan-1-ol 148

TLC $R_f = 0.36$ (15:5:1 hexane:EtOAc:TEA)

mp $T / {}^{\circ}C = ??$ (hexane, EtOAc, TEA)

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹H NMR (400 MHz, CDCl₃) δ / ppm = 7.28 - 7.34 (m, 4 H, ortho and meta to CHCH₃), 7.20 - 7.26 (m, 1 H, para to CHCH₃), 3.86 (q, J = 6.6 Hz, 1 H, CHCH₃), 3.85 (q, J = 6.6 Hz, 1 H, CHOH), 2.83 (td, J = 7.6, 5.7 Hz, 1 H, CHNH), 1.85 - 1.97 (m, 1 H, CHHCHOH), 1.77 (dtd, J = 12.9, 7.9, 7.9, 4.9 Hz, 1 H, CHHCHNH), 1.55 - 1.68 (m, 2 H, CH₂CH₂CHOH), 1.47 - 1.55 (m, 1 H, CHHCHOH), 1.36 (d, J = 6.6 Hz, 3 H, CH₃), 1.12 (dq, J = 12.7, 8.1 Hz, 1 H, CHHCHNH)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 145.61 (*ipso* to CHCH₃), 128.08 (*meta* to CHCH₃), 126.61 (*para* to CHCH₃), 126.33 (*ortho* to CHCH₃), 77.43 (<u>C</u>HOH), 64.45 (<u>C</u>HNH), 56.62 (<u>C</u>HCH₃), 32.01 (<u>C</u>H₂CHOH), 30.56 (<u>C</u>H₂CHNH), 23.30 (<u>C</u>H₃), 20.06 (<u>C</u>H₂CHOH)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

The compounds have been synthesised previously, 10, 11 but NMR data were not published.

$1.45 \quad (1S,2S)$ -2-Aminocyclopentan-1-ol 149

OH NH₂

(1S,2S)-2-(((S)-1-Phenylethyl)amino)cyclopentan-1-ol **147** (3.90 g, 19.0 mmol, 1 eq.), $Pd(OH)_2$ (20 wt. % on C, moistened with 50 wt. % water, 1 g, 0.712 mmol, 0.04 eq.) and MeOH (50 ml) were stirred in a Paar hydrogenator at r.t. and 3 atm for 2 days. The mixture was then filtered through Celite and evaporated under reduced pressure. **149** was obtained as a yellow oil (1.92 g, 19.0 mmol, 100 %).

TLC $R_f = 0.10 \ (10 \% \ \text{MeOH/CH}_2\text{Cl}_2)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹**H NMR** (400 MHz, MeOD) δ / ppm = ??

NMR?

¹³**C NMR** (101 MHz, MeOD) δ / ppm = ??

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

The data are consistent with the literature. 12

check

1.46 (1R,2R)-2-Aminocyclopentan-1-ol 150

(1R,2R)-2-(((S)-1-Phenylethyl)amino)cyclopentan-1-ol **148** (3.00 g, 14.6 mmol, 1 eq.), $Pd(OH)_2$ (20 wt. % on C, moistened with 50 wt. % water, 0.5 g, 0.356 mmol, 0.025 eq.) and MeOH (50 ml) were stirred in a Paar hydrogenator at r.t. and 2.5 atm for 2 days. The mixture was then filtered through Celite and evaporated under reduced pressure. **150** was obtained as a yellow oil (1.48 g, 14.6 mmol, 100 %).

TLC $R_f = 0.10 \ (10 \% \ \text{MeOH/CH}_2\text{Cl}_2)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹**H NMR** (400 MHz, MeOD) δ / ppm = 3.77 (q, J = 6.2 Hz, 1 H, C $\underline{\text{H}}$ OH), 3.00 (td, J = 7.4, 5.6 Hz, 1 H, C $\underline{\text{H}}$ NH₂), 2.00 (dtd, J = 13.0, 7.7, 7.7, 5.6 Hz, 1 H, C $\underline{\text{H}}$ HCHNH₂), 1.97 (ddt, J = 13.0, 8.7, 6.4, 6.4 Hz, 1 H, C $\underline{\text{H}}$ HCHOH), 1.64 - 1.77 (m, 2 H, C $\underline{\text{H}}$ 2CH₂CHOH), 1.53 (ddt, J = 13.0, 9.5, 6.2, 6.2 Hz, 1 H, CH $\underline{\text{H}}$ CHOH), 1.37 (ddt, J = 12.8, 8.5, 7.7, 7.7 Hz, 1 H, CHHCHNH₂)

¹³C NMR (101 MHz, MeOD) δ / ppm = 80.61 (<u>C</u>HOH), 60.74 (<u>C</u>HNH₂), 33.18 (<u>C</u>H₂CHOH), 32.09 (<u>C</u>H₂CHNH₂), 21.19 (<u>C</u>H₂CH₂CHOH)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

The data are consistent with the literature. 12

$1.47 \quad (1R,2R)$ -2-((tert-butyldimethylsilyl)oxy)cyclopentan-1-amine 151

(1R,2R)-2-aminocyclopentan-1-ol **150** (0.480 g, 4.75 mmol) was stirred in dry CH_2Cl_2 (20 ml) under N_2 at 0 °C. TEA (3.14 ml, 2.28 g, 22.5 mmol, 5 eq.) was added dropwise, followed by TBSOTf (3 ml, 3.45 g, 13.1 mmol, 3 eq.) dropwise. The reaction was allowed to reach r.t. and stirred for 1 h. The reaction was quenched with NH_4Cl , diluted with CH_2Cl_2 (20 ml) and washed with water (20 ml). The organic phase was dried with Na_2SO_4 , concentrated under reduced pressure and purified by column chromatography (SiO₂, 4 % MeOH/CH₂Cl₂). **182**(RR) was obtained as a yellow oil(1.00 g, 4.64 mmol, 97.7 %).

TLC $R_f = 0.23 \ (10 \% \text{ MeOH/CH}_2\text{Cl}_2, \text{ ninhydrin stain})$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

check stains for oth-

check

¹**H NMR** (400 MHz, CDCl₃) δ / ppm = 4.13 (q, J = 5.8 Hz, 1 H, CHOSi), 3.31 (td, J = 7.1, 5.2 Hz, 1 H, CHNH₂), 2.09 - 2.19 (m, 1 H, CHHCHNH₂), 1.97 (ddq, J = 8.8, 7.0, 6.0, 6.0, 6.0 Hz, 1 H, CHHCHOSi), 1.74 - 1.86 (m, 2 H, CH₂CH₂CHOSi), 1.64 - 1.74 (m, 1 H, CHHCHOSi), 1.58 (ddt, J = 13.2, 9.1, 6.0, 6.0 Hz, 1 H, CHHCHNH₂), 0.88 (s, 9 H, C(CH₃)₃), 0.09 (s, 3 H, SiCH₃), 0.07 (s, 3 H, SiCH₃)

 $^{13}\mathbf{C}\ \mathbf{NMR}\ (101\ \mathrm{MHz},\mathrm{CDCl_3})\ \delta\ /\ \mathrm{ppm} = 76.29\ (\underline{\mathrm{C}}\mathrm{HOSi}), 59.69\ (\underline{\mathrm{C}}\mathrm{HNH}), 32.18\ (\underline{\mathrm{C}}\mathrm{H_2}\mathrm{CHOSi}), 26.78\ (\underline{\mathrm{C}}\mathrm{H_2}\mathrm{CHNH_2}), \\ 25.62\ (\mathrm{C}(\underline{\mathrm{C}}\mathrm{H_3})_3), \ 19.73\ (\underline{\mathrm{C}}\mathrm{H_2}\mathrm{CHOSi}), \ 17.74\ (\underline{\mathrm{C}}(\mathrm{CH_3})_3), \ -4.82\ (\mathrm{Si}\underline{\mathrm{C}}\mathrm{H_3}), \ -5.23\ (\mathrm{Si}\underline{\mathrm{C}}\mathrm{H_3})$

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

1.48 4-Chloro-N-((1S,2S)-2-hydroxycyclopentyl)butanamide 152

(1S,2S)-2-aminocyclopentan-1-ol **149** (500 mg, 4.94 mmol, 1 eq.), TEA (827 μ l, 600 mg, 5.93 mmol, 1.2 eq.) and CH₂Cl₂ (20 ml) were stirred at 0°C. 4-Chlorobutyryl chloride **183**(608 μ l, 766 mg, 5.43 mmol, 1.1 eq.) was added dropwise over 5 min. The mixture was stirred at 0°C for 30 min, then water (50 ml) was added. The organic layer was separated off, and the aqueous layer was extracted with CH₂Cl₂ (7×50 ml). The combined organic layers were dried with MgSO₄, concentrated under reduced pressure and purified by column chromatography (SiO₂, Et₂O). **184**(SS) was obtained as white needles (651 mg, 3.16 mmol, 64.1 %).

TLC $R_f = 0.39$ (EtOAc, ninhydrin stain)

check stains for other

¹H NMR (400 MHz, CDCl₃) δ / ppm = 6.12 (br. s., 1 H, N<u>H</u>), 4.42 (br. s., 1 H, O<u>H</u>), 3.94 (q, J = 6.6 Hz, 1 H, C<u>H</u>OH), 3.82 (tdd, J = 8.2, 8.2, 6.4, 4.5 Hz, 1 H, C<u>H</u>NH), 3.60 (t, J = 6.2 Hz, 2 H, C<u>H</u>₂Cl), 2.38 (t, J = 7.2 Hz, 2 H, C<u>H</u>₂C=O), 2.05 - 2.16 (m, 3 H, C<u>H</u>HCHNH and C<u>H</u>₂CH₂Cl), 1.96 - 2.04 (m, 1 H, C<u>H</u>HCHOH), 1.74 - 1.85 (m, 1 H, C<u>H</u>HCH₂CHOH), 1.58 - 1.73 (m, 2 H, CH<u>H</u>CH₂CHOH and CH<u>H</u>CHOH), 1.43 (dq, J = 12.7, 8.3 Hz, 1 H, CH<u>H</u>CHNH)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 173.82 (<u>C</u>=O), 79.39 (<u>C</u>HOH), 60.61 (<u>C</u>HNH), 44.37 (<u>C</u>H₂Cl), 32.79 (<u>C</u>H₂C=O), 32.40 (<u>C</u>H₂CHOH), 30.12 (<u>C</u>H₂CHNH), 28.01 (<u>C</u>H₂CH₂Cl), 21.10 (<u>C</u>H₂CH₂CHOH)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

1.49 4-Chloro-N-((1R,2R)-2-hydroxycyclopentyl)butanamide 153

to do

1.50 4-Azido-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclopentyl)butanamide 154(RR)

check
brackets outside for
all

(1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclopentan-1-amine **151** (50 mg, 0.232 mmol, 1 eq.) and NaHCO₃ (22.0 mg, 0.262 mmol, 1.1 eq.) were added to CH₂Cl₂ (3 ml) and water (3 ml). 4-Bromobutyryl chloride (25.3 ml, 40.5 mg, 0.219 mmol, 0.95 eq.) was added dropwise at 0 °C and the mixture was stirred for 3 h. The aqueous layer was removed and NaN₃ (100 mg, 1.54 mmol, 6.6 eq.) and DMF (3 ml) were added. The mixture was stirred at 40 °C for 6 h. The solvents were then evaporated using a N₂ stream and the residue was purified by column chromatography (SiO₂, 0.5 % MeOH/CH₂Cl₂). **154**(RR) was obtained as a white solid (71 mg, 0.217 mmol, 99.2 %).

cneck

TLC $R_f = 0.84 \ (1 \% \text{ MeOH/CH}_2\text{Cl}_2)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹**H NMR** (400 MHz, CDCl₃) δ / ppm = 5.35 (d, J = 5.1 Hz, 1 H, N<u>H</u>), 3.97 - 4.01 (m, 1 H, C<u>H</u>OSi), 3.93 - 3.98 (m, 1 H, C<u>H</u>NH), 3.35 (t, J = 6.6 Hz, 2 H, C<u>H</u>₂N₃), 2.24 (t, J = 7.0 Hz, 2 H, C<u>H</u>₂C=O), 2.09 - 2.19

(m, 1 H, C<u>H</u>HCHNH), 1.89 - 1.97 (quin, J = 6.8 Hz, 2 H, C<u>H</u>₂CH₂N₃), 1.74 - 1.84 (m, 2 H, C<u>H</u>HCHOSi and C<u>H</u>HCH₂CHOSi), 1.60 - 1.70 (m, 1 H, CH<u>H</u>CH₂CHOSi), 1.51 - 1.61 (m, 1 H, CH<u>H</u>CHOSi), 1.31 - 1.39 (m, 1 H, CH<u>H</u>CHNH), 0.87 (s, 9 H, C(C<u>H</u>₃)₃), 0.08 (s, 3 H, SiC<u>H</u>₃), 0.06 (s, 3 H, SiC<u>H</u>₃)

 $\begin{array}{l} ^{13}\textbf{C NMR} \ (101 \ \text{MHz}, \text{CDCl}_3) \ \delta \ / \ \text{ppm} = 171.17 \ (\underline{\text{C}} = \text{O}), \ 77.80 \ (\underline{\text{C}} \text{HOSi}), \ 58.36 \ (\underline{\text{C}} \text{HNH}), \ 50.77 \ (\underline{\text{C}} \text{H}_2 \text{N}_3), \ 33.29 \\ (\underline{\text{C}} \text{H}_2 \text{C} = \text{O}), \ 32.57 \ (\underline{\text{C}} \text{H}_2 \text{CHOSi}), \ 29.36 \ (\underline{\text{C}} \text{H}_2 \text{CHNH}), \ 25.72 \ (\underline{\text{C}} (\underline{\text{C}} \text{H}_3)_3), \ 24.77 \ (\underline{\text{C}} \text{H}_2 \text{CH}_2 \text{N}_3), \ 20.40 \ (\underline{\text{C}} \text{H}_2 \text{CHOSi}), \ 17.95 \ (\underline{\text{C}} (\text{CH}_3)_3), \ -4.75 \ (\text{Si}\underline{\text{C}} \text{H}_3) \end{array}$

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

1.51 4-Azido-N-((1S,2S)-2-hydroxycyclopentyl)butanamide 155

4-Chloro-N-((1S,2S)-2-hydroxycyclopentyl) butanamide **152** (200 mg, 0.972 mmol, 1 eq.) and NaN₃ (126 mg, 1.94 mmol, 2 eq.) were stirred in acetonitrile (4 ml) at 50 °C for 16 h. The solvent was then evaporated under reduced pressure and the residue was partitioned between water (20 ml) and 10 % i-PrOH/CHCl₃ (20 ml). The aqueous layer was extracted again with 10 % i-PrOH/CHCl₃ (3 × 20 ml) and the combined organic fractions were dried with MgSO₄ and evaporated under reduced pressure. **155** was obtained as a white solid (181 mg, 0.852 mmol, 87.6 %).

TLC $R_f = 0.39$ (EtOAc, ninhydrin stain)

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

stains for others

check

¹**H NMR** (400 MHz, CDCl₃) δ / ppm = 6.72 (d, J = 4.4 Hz, 1 H, N<u>H</u>), 4.82 (br. s., 1 H, O<u>H</u>), 3.88 (q, J = 6.6 Hz, 1 H, C<u>H</u>OH), 3.75 (tdd, J = 8.4, 8.4, 6.6, 4.4 Hz, 1 H, C<u>H</u>NH), 3.28 (t, J = 6.6 Hz, 2 H, C<u>H</u>₂N₃), 2.23 (t, J = 7.3 Hz, 2 H, C<u>H</u>₂C=O), 2.04 (dtd, J = 13.0, 8.0, 8.0, 4.9 Hz, 1 H, C<u>H</u>HCHNH), 1.92 (dtd, J = 13.0, 7.6, 7.6, 5.8 Hz, 1 H, C<u>H</u>HCHOH), 1.84 (quin, J = 7.0 Hz, 2 H, C<u>H</u>₂CH₂N₃), 1.59 - 1.77 (m, 2 H, C<u>H</u>₂CH₂CHOH), 1.54 (ddt, J = 12.7, 9.0, 6.7, 6.7 Hz, 1 H, CHHCHOH), 1.39 (dq, J = 12.9, 8.4 Hz, 1 H, CHHCHNH)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 173.77 (<u>C</u>=O), 78.80 (<u>C</u>HOH), 59.94 (<u>C</u>HNH), 50.50 (<u>C</u>H₂N₃), 32.52 (<u>C</u>H₂C=O), 32.03 (<u>C</u>H₂CHOH), 29.49 (<u>C</u>H₂CHNH), 24.58 (<u>C</u>H₂CH₂N₃), 20.74 (<u>C</u>H₂CH₂CHOH)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

1.52 4-Azido-N-((1R,2R)-2-hydroxycyclopentyl)butanamide 156

to do

1.53 Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-(((1S,2S)-2-hydroxycyclopentyl)amino)-4-oxobutyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 157

146 (200 mg, 0.367 mmol, 1 eq.), 149 (80 mg, 0.791 mmol, 2.1 eq.), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (112 mg, 0.584 mmol, 1.6 eq.), 1-hydroxybenzotriazole (96 mg, 0.710 mmol, 1.9 eq.) and DIPEA (192 μ l, 142 mg, 1.10 mmol, 3 eq.) were dissolved in DMF (5 ml) and stirred at r.t. for 16 h. The solvent was removed using a stream of N₂ and the residue was purified by preparatory HPLC (5-60 % acetonitrile/water over 12 min). The combined pure fractions were evaporated under reduced pressure and then partitioned between NaHCO₃ (aq., sat., 10 ml) and CH₂Cl₂ (10 ml). The organic layer was removed and the aqueous layer was extracted twice more with CH₂Cl₂ (2 × 10 ml). The combined organic fractions were dried with MgSO₄ and evaporated under reduced pressure. 157 was obtained as a clear gum (73.0 mg, 0.142 mmol, 38.7 %).

column?
equipment?

check??

TLC $R_f = 0.43 (30 \% \text{ MeOH/EtOAc})$

 $mp \ T \ / \ ^{\circ}C = ?? \ (??)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹H NMR (400 MHz, DMSO d₆) δ / ppm = 8.44 (s, 1 H, ortho to C(=O)OC \underline{H}_3), 7.75 (d, J = 13.5 Hz, 1 H, ortho to F), 7.70 (d, J = 7.2 Hz, 1 H, CHN \underline{H}), 7.43 (d, J = 7.5 Hz, 1 H, meta to F), 4.74 (d, J = 4.0 Hz, 1 H, CHO \underline{H}), 3.78 - 3.82 (m, 1 H, C \underline{H} OH), 3.74 - 3.78 (m, 1 H, C \underline{H} NH), 3.74 (s, 3 H, C \underline{H}_3), 3.65 (tt, J = 7.2, 3.9 Hz, 1 H, NC \underline{H} (CH₂)₂), 3.25 (t, J = 4.8 Hz, 4 H, CH₂N(CH₂C \underline{H}_2)CH₂CH₂CH₂D, 2.57 (br s, 4 H, CH₂N(C \underline{H}_2)C \underline{H}_2), 2.34 (t, J = 7.4 Hz, 2 H, C \underline{H}_2 N(CH₂)CH₂), 2.11 (t, J = 7.4 Hz, 2 H, C \underline{H}_2 CH₂CH₂N(CH₂)CH₂), 1.92 (dddd, J = 13.0, 8.7, 7.3, 6.0 Hz, 1 H, C \underline{H} HCHNH), 1.78 (dddd, J = 12.5, 8.9, 7.0, 6.0 Hz, 1 H, C \underline{H} HCHOH), 1.69 (quin, J = 7.3 Hz, 2 H, C \underline{H}_2 CH₂N(CH₂)CH₂), 1.54 - 1.65 (m, 2 H, C \underline{H}_2 CH₂CHOH), 1.42 (ddt, J = 13.1, 8.2, 5.3, 5.3 Hz, 1 H, CH \underline{H} CHOH), 1.32 (dddd, J = 13.4, 8.5, 6.8, 5.8 Hz, 1 H, CH \underline{H} CHNH), 1.21 - 1.29 (m, 2 H, NCH(C \underline{H} H)₂), 1.07 - 1.13 (m, 2 H, NCH(CH \underline{H})₂)

¹³C NMR (101 MHz, DMSO d₆) δ / ppm = 171.9 (CH₂C(=O)NH), 171.6 (C(=O)CC(=O)OCH₃), 165.0 (C(=O)OCH₃), 152.6 (d, J = 246.5 Hz, ipso to F), 148.3 (C=CC(=O)OCH₃), 143.9 (d, J = 10.7 Hz, ipso to piperazine), 138.1 (para to F), 121.8 (d, J = 6.4 Hz, para to piperazine), 111.5 (d, J = 22.4 Hz, ortho to C=O

and ortho to F), 109.0 ($\underline{C}C(=O)OCH_3$), 106.2 (meta to C=O and meta to F), 76.3 ($\underline{C}HOH$), 57.6 ($\underline{C}HNH$), 57.2 ($C(=O)CH_2CH_2\underline{C}H_2N$), 52.4 ($C(=O)CH_2CH_2CH_2N(\underline{C}H_2)\underline{C}H_2$), 51.3 ($\underline{C}H_3$), 49.6 ($C(=O)CH_2CH_2CH_2N(CH_2\underline{C}H_2)CH_2$) 34.8 ($N\underline{C}H(CH_2)_2$), 33.3 ($C(=O)\underline{C}H_2$), 32.2 ($\underline{C}H_2CHOH$), 29.5 ($\underline{C}H_2CHNH$), 22.5 ($C(=O)CH_2\underline{C}H_2$), 20.6 ($\underline{C}H_2CHOH$), 7.6 ($NCH(\underline{C}H_2)_2$)

 19 F NMR (376.45 MHz, DMSO d₆) δ / ppm = -124.3 (ciprofloxacin F)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

1.54 Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-(((1R,2R)-2-hydroxycyclopentyl)amino)-4-oxobutyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 158

146 (52.1 mg, 95.5 μ mol, 1 eq.), 150 (19.5 mg, 193 μ mol, 2 eq.), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (29.7 mg, 155 μ mol, 1.6 eq.), 1-hydroxybenzotriazole (25.8 mg, 191 μ mol, 2 eq.) and DIPEA (33.3 μ l, 24.7 mg, 191 μ mol, 2 eq.) were dissolved in DMF (2 ml) and stirred at r.t. for 16 h. The solvent was removed using a stream of N₂ and the residue was purified by preparatory HPLC (5-50 % acetonitrile/water over 15 min). The combined pure fractions were evaporated under reduced pressure and then partitioned between NaHCO₃ (aq., sat., 5 ml) and CH₂Cl₂ (5 ml). The organic layer was removed and the aqueous layer was extracted twice more with CH₂Cl₂ (2 × 5 ml). The combined organic fractions were dried with MgSO₄ and evaporated under reduced pressure. 157 was obtained as a clear gum ().

TLC $R_f = ?? (??)$

 $mp T / {}^{\circ}C = ?? (??)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹**H NMR** (400 MHz, MeOD) δ / ppm = ??

¹³**C NMR** (101 MHz, MeOD) δ / ppm = ??

¹⁹**F NMR** (376.45 MHz, MeOD) δ / ppm = ??

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

 column? equipment?

not
done
yet?

check??

This is the TFA salt!!!

Need to

desalt this

this and

then
put H
here!!

check

this is for the salt

and meta to F), 78.6 (<u>C</u>HOH), 59.6 (<u>C</u>HNH), 58.4 (C(=O)CH₂CH₂CH₂N), 53.1 (C(=O)CH₂CH₂CH₂N(<u>C</u>H₂)CH₂), 52.4 (<u>C</u>H₃), 48.3 (C(=O)CH₂CH₂CH₂N(CH₂<u>C</u>H₂)CH₂CH₂), 36.5 (N<u>C</u>H(CH₂)₂), 34.3 (C(=O)<u>C</u>H₂), 33.3 (<u>C</u>H₂CHOH), 30.5 (<u>C</u>H₂CHNH), 21.7 (<u>C</u>H₂CH₂CHOH), 21.0 (C(=O)CH₂<u>C</u>H₂), 8.7 (NCH(<u>C</u>H₂)₂)

F

-77.0 (C<u>F</u>₃), -125.4 (ciprofloxacin F)

1.55 Methyl (R)-1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxocyclopentyl)amino)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate 159

find??

1.56 7-(4-(4-(1-(4-(((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclopentyl)amino)-4-oxobutyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 160

1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **173** (42.9 mg, 104 μ mol, 1 eq.) and 4-azido-N-((1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclopentyl)butanamide **154**(RR) (33.9 mg, 104 μ mol, 1 eq.) were dissolved in 10 % water/t-BuOH (3 ml), and the mixture was degassed by bubbling N₂ through it. A solution of CuSO₄ and THPTA (104 μ l, 10.4 μ mol, 0.1 eq. 100 mM, aq.) was added, followed by a solution of sodium ascorbate (208 μ l, 20.8 μ mol, 0.2 eq., 100 mM, aq.). The mixture was stirred at room temperature under argon for 16 h, then solvent was removed under reduced pressure. The resudue was partitioned between water (10 ml) and CH₂Cl₂ (10 ml), the organic layer was separated and the aqeous layer was extracted again with CH₂Cl₂ (10 ml). The combined organic layers were dried with MgSO₄ and evaporated under reduced pressure. **160** was obtained as ?? (67.1 mg, 90.9 μ mol, 87.4 %).

state

TLC $R_f = ?? (??)$

 $mp T / {}^{\circ}C = ?? (??)$

¹H NMR (400 MHz, CDCl₃) δ / ppm = 8.67 (s, 1 H, ortho to C(=O)OH), 7.87 (d, J = 13.1 Hz, 1 H, ortho to F), 7.34 (s, 1 H, CH=CCH₂), 7.33 (d, J = 8.2 Hz, 1 H, meta to F), 5.92 (t, J = 6.6 Hz, 1 H, CHNH), 4.35 (t, J = 6.7 Hz, 2 H, CH₂NCH=C), 3.96 - 4.02 (m, 1 H, CHOSi), 3.90 - 3.96 (m, 1 H, CHNH), 3.55 (tt, J = 6.7, 4.0 Hz, 1 H, NCH(CH₂)₂), 3.34 (br t, J = 5.0 Hz, 4 H, CH₂N(CH₂CH₂)CH₂CH₂), 2.71 (t, J = 7.5 Hz, 2 H, CH=CCH₂), 2.66 (br s, 4 H, CH₂N(CH₂)CH₂), 2.46 (t, J = 7.3 Hz, 2 H, CH₂N(CH₂)CH₂), 2.03 - 2.22 (m, 5 H, CHHCHNH, C(=O)CH₂ and C(=O)CH₂CH₂), 1.65 - 1.83 (m, 4 H, CHHCHOSi, CHHCH₂CHOSi and NCH=CCH₂CH₂), 1.47 - 1.65 (m, 4 H, CHHCHOSi, CHHCH₂CHOSi and NCH=CCH₂CH₂), 1.33 - 1.41 (m, 3 H, CHHCHNH and NCH(CHH)₂), 1.14 - 1.20 (m, 2 H, NCH(CHH)₂), 0.82 (s, 9 H, C(CH₃)₃), 0.03 (s, 3 H, SiCH₃), 0.01 (s, 3 H, SiCH₃)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 176.9 (\underline{C} (=O)CC(=O)OH), 170.9 (CH₂ \underline{C} (=O)NH), 166.9 (\underline{C} (=O)OH), 153.5 (d, J = 251.4 Hz, ipso to F), 147.9 (CH= \underline{C} CH₂), 147.2 (\underline{C} =CC(=O)OH), 145.8 (d, J = 10.4 Hz, ipso to piperazine), 139.0 (para to F), 120.9 (N \underline{C} H=CCH₂), 119.4 (d, J = 7.8 Hz, para to piperazine), 112.0 (d, J = 23.4 Hz, ortho to C=O and ortho to F), 107.7 (\underline{C} C(=O)OH), 104.7 (d, J = 3.5 Hz, meta to C=O and meta to F), 77.7 (\underline{C} HOSi), 58.2 (\underline{C} HNH), 57.9 (CH=CCH₂CH₂CH₂CH₂N), 52.6 (CH=CCH₂CH₂CH₂CH₂CH₂N(\underline{C} H₂), 49.5 (d, J = 6.1 Hz, CH=CCH₂CH₂CH₂CH₂CH₂N(CH₂ \underline{C} H₂)CH₂CH₂D, 48.9 (d, J = 3.5 Hz, \underline{C} H₂NCH=CCH₂), 35.3 (N \underline{C} H(CH₂)₂), 32.6 (C(=O) \underline{C} H₂), 32.6 (\underline{C} H₂CHOSi), 29.3 (\underline{C} H₂CHNH), 27.2 (CH=CCH₂ \underline{C} H₂), 26.0 - 26.3 (C(=O)CH₂ \underline{C} H₂ and CH=CCH₂ \underline{C} H₂), 25.6 (C(\underline{C} H₃)₃), 25.4 (CH=C \underline{C} H₂), 20.4 (\underline{C} H₂CH₂CHOSi), 17.8 (\underline{C} (CH₃)₃), 8.1 (NCH(\underline{C} H₂)₂), -4.8 (Si \underline{C} H₃)

¹⁹**F NMR** (376.45 MHz, CDCl₃) δ / ppm = ??

F?'

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ?? CDCl₃

 $1.57 \quad 1- \text{Cyclopropyl-6-fluoro-7-} (4-(4-(1-(4-(((1S,2S)-2-\text{hydroxycyclopentyl})\text{amino})-4-\text{oxobutyl})-1\text{H}-1,2,3-\text{triazol-4-yl})\text{butyl})\text{piperazin-1-yl})-4-\text{oxo-1,4-dihydroquino-line-3-carboxylic acid 161}$

$$\begin{array}{c} O \\ O \\ O \\ O \\ N \end{array}$$

1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **173** (42.9 mg, 104 μ mol, 1 eq.) and 4-azido-N-((1S,2S)-2-hydroxycyclopentyl)butanamide **155** (22.0 mg, 104 μ mol, 1 eq.) were dissolved in 10 % water/t-BuOH (3 ml), and the mixture was degassed by bubbling N₂ through it. A solution of CuSO₄ and THPTA (104 μ l, 10.4 μ mol, 0.1 eq. 100 mM, aq.) was added, followed by a solution of sodium ascorbate (208 μ l, 20.8 μ mol, 0.2 eq., 100 mM, aq.). The mixture was stirred at room temperature under argon for 16 h. Water (30 ml) and CH₂Cl₂ (30 ml) were added, the organic layer was separated and the aqueous layer was extracted again with CH₂Cl₂ (4 × 30 ml). The combined organic layers were dried with MgSO₄ and

evaporated under reduced pressure. The residue was purified by preparatory HPLC (5-95 % acetonitrile/water over 20 min). The combined pure fractions were evaporated under reduced pressure and then partitioned between NaHCO₃ (aq., sat., 10 ml) and 10 % i-PrOH/CHCl₃ (10 ml). The organic layer was dried with MgSO₄ and evaporated under reduced pressure. **160** was obtained as ?? (17.6 mg, 28.2 μ mol, 27.1 %).

column?
equipment?

state

TLC $R_f = ?? (??)$

 $mp T / {}^{\circ}C = ?? (??)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹H NMR (700 MHz, DMSO d₆) δ / ppm = 8.64 (s, 1 H, ortho to C(=O)OH), 7.87 (d, J = 13.3 Hz, 1 H, ortho to F), 7.84 (s, 1 H, CH=CCH₂), 7.75 (d, J = 7.1 Hz, 1 H, CHNH), 7.54 (d, J = 7.5 Hz, 1 H, meta to F), 4.73 (d, J = 3.8 Hz, 1 H, CHOH), 4.29 (t, J = 6.9 Hz, 2 H, CH₂NCH=C), 3.78 - 3.83 (m, 1 H, NCH(CH₂)₂), 3.75 - 3.78 (m, 1 H, CHOH), 3.71 - 3.75 (m, 1 H, CHNH), 3.31 (br t, J = 4.3 Hz, 4 H, CH₂N(CH₂CH₂)CH₂CH₂CH₂), 2.63 (t, J = 7.5 Hz, 2 H, CH=CCH₂), 2.56 (br t, J = 4.2 Hz, 4 H, CH₂N(CH₂)CH₂), 2.37 (t, J = 7.3 Hz, 2 H, CH₂N(CH₂)CH₂), 2.03 - 2.06 (m, 2 H, C(=O)CH₂), 1.97 - 2.02 (m, 2 H, C(=O)CH₂CH₂), 1.89 (dddd, J = 13.1, 8.9, 7.4, 5.7 Hz, 1 H, CHHCHNH), 1.75 (ddt, J = 13.0, 8.9, 6.4, 6.4 Hz, 1 H, CHHCHOH), 1.61 - 1.66 (m, 2 H, CH=CCH₂CH₂), 1.57 - 1.61 (m, 1 H, CHHCH₂CHOH), 1.54 - 1.57 (m, 1 H, CHHCHOH), 1.49 - 1.53 (m, 2 H, CH=CCH₂CH₂CH₂), 1.40 (ddt, J = 13.0, 8.4, 5.3, 5.3 Hz, 1 H, CHHCHOH), 1.29 - 1.32 (m, 2 H, NCH(CHH)₂), 1.25 - 1.29 (m, 1 H, CHHCHNH), 1.13 - 1.20 (m, 2 H, NCH(CHH)₂)

¹³C NMR (175 MHz, DMSO d₆) δ / ppm = 176.3 ($\underline{\mathbf{C}}$ (=O)CC(=O)OH), 170.9 (CH₂ $\underline{\mathbf{C}}$ (=O)NH), 166.1 ($\underline{\mathbf{C}}$ (=O)OH), 153.0 (d, J = 251.4 Hz, ipso to F), 147.9 ($\underline{\mathbf{C}}$ =CC(=O)OH), 146.9 (CH= $\underline{\mathbf{C}}$ CH₂), 145.2 (d, J = 8.7 Hz, ipso to piperazine), 139.2 (para to F), 121.7 (NCH=CCH₂), 118.7 (d, J = 5.8 Hz, para to piperazine), 111.0 (d, J = 23.3 Hz, ortho to C=O and ortho to F), 106.3 (meta to C=O and meta to F and $\underline{\mathbf{C}}$ C(=O)OH), 76.2 ($\underline{\mathbf{C}}$ HOH), 57.6 ($\underline{\mathbf{C}}$ HNH), 57.4 (CH=CCH₂CH₂CH₂CH₂N), 52.5 (CH=CCH₂CH₂CH₂CH₂N($\underline{\mathbf{C}}$ H₂), 49.5 (d, J = 4.4 Hz, CH=CCH₂CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 48.8 ($\underline{\mathbf{C}}$ H₂NCH=CCH₂), 35.8 (NCH(CH₂)₂), 32.2 ($\underline{\mathbf{C}}$ H₂CHOH), 32.0 (C(=O) $\underline{\mathbf{C}}$ H₂), 29.5 ($\underline{\mathbf{C}}$ H₂CHNH), 26.9 (CH=CCH₂ $\underline{\mathbf{C}}$ H₂), 26.0 (C(=O)CH₂ $\underline{\mathbf{C}}$ H₂), 25.8 (CH=CCH₂CH₂CH₂), 25.0 (CH=CCH₂), 20.5 ($\underline{\mathbf{C}}$ H₂CHOH), 7.6 (NCH($\underline{\mathbf{C}}$ H₂)₂)

¹⁹**F NMR** (376.45 MHz, MeOD) δ / ppm = ??

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

F?? Change freqency to for 700 1H $1.58 \quad 1\text{-Cyclopropyl-6-fluoro-7-} (4\text{-}(4\text{-}(1\text{-}(4\text{-}(((1R,2R)\text{-}2\text{-hydroxycyclopentyl})\text{amino})\text{-}}\\ 4\text{-}oxobutyl)\text{-}1\text{H-}1,2,3\text{-triazol-}4\text{-yl})\text{butyl})\text{piperazin-}1\text{-yl})\text{-}4\text{-}oxo\text{-}1,4\text{-}dihydroquino-line-}3\text{-carboxylic acid }162$

 $1.59 \quad (S)\text{-1-cyclopropyl-6-fluoro-4-oxo-7-} (4\text{-}(4\text{-}(1\text{-}(4\text{-}oxo\text{-}4\text{-}((2\text{-}oxocyclopentyl)amino})\text{-}butyl)\text{-}1\text{H-}1,2,3\text{-}triazol\text{-}4\text{-}yl)\text{butyl}) piperazin-1\text{-}yl)\text{-}1,4\text{-}dihydroquinoline-3-carboxylic acid }163$

$$\bigcap_{N=N}^{\mathsf{F}}\bigcap_{N=N}^{\mathsf{O}}$$

 $1.60 \quad (R)\hbox{-1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(4-(4-(4-(4-oxo-4-((2-oxocyclopentyl)amino)-butyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 164$

1.61 (Trans)-2-aminocyclohexan-1-ol 165

this is racemic

Cyclohexene oxide **185** (10 ml, 9.70 g, 98.8 mmol, 1 eq.), NH₃ (90 ml, 35 % w/w aq., 27.7 g, 791 mmol, 8 eq.) and MeOH (100 ml) were stirred at r.t. for 72 h. The solvent was removed by blowing a stream of N₂ over it, followed by evaporation under high vacuum. **165** was obtained as white crystals (9.90 g, 85.2 mmol, 86.2 %)

phrasing

TLC $R_f = ?? (??)$

 $mp \ T / {}^{\circ}C = ?? (??)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹**H NMR** (400 MHz, CDCl₃) δ / ppm = 3.01 (td, J = 9.4, 4.8 Hz, 1 H, C<u>H</u>OH), 2.80 - 2.92 (m, 2 H, O<u>H</u> and N<u>H</u>₂), 2.35 (ddd, J = 11.1, 9.1, 4.1 Hz, 1 H, C<u>H</u>NH₂), 1.77 - 1.84 (m, 1 H, C<u>H</u>HCHOH), 1.69 - 1.76 (m, 1 H, C<u>H</u>HCHNH₂), 1.56 - 1.66 (m, 1 H, C<u>H</u>HCH₂CHOH), 1.45 - 1.56 (m, 1 H, C<u>H</u>HCH₂CHNH₂), 1.07 - 1.19 (m, 3 H, CH<u>H</u>CH₂CHOH, CH<u>H</u>CH₂CHNH₂ and CH<u>H</u>CHOH), 0.94 - 1.05 (m, 1 H, CH<u>H</u>CHNH₂)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 75.4 (<u>C</u>HOH), 56.6 (<u>C</u>HN₂), 33.8 (<u>C</u>H₂CHOH and <u>C</u>H₂CHN₂), 24.7 (<u>C</u>H₂CH₂CH₂CH₂), 24.6 (<u>C</u>H₂CH₂CHOH)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

1.62 4-Chloro-N-((trans)-2-hydroxycyclohexyl)butanamide 166

(Trans)-2-aminocyclohexan-1-ol **165** (1.04 g, 9.03 mmol, 1 eq.), TEA (1.65 ml, 1.20 g, 11.8 mmol, 1.3 eq.) and $\mathrm{CH_2Cl_2}$ (50 ml) were stirred at 0°C. 4-Chlorobutyryl chloride **183** (1.22 ml, 1.54 g, 10.9 mmol, 1.2 eq.) was added dropwise over 5 min. The mixture was stirred at 0°C for 30 min, then water (50 ml) was added. The organic layer was separated off, and the aqueous layer was extracted with 10 % *i*-PrOH/water (2 × 50 ml). The combined organic layers were dried with MgSO₄, concentrated under reduced pressure and purified by column chromatography (SiO₂, 0-100 % EtOAc/Et₂O). **166** was obtained as white crystals (1.51 g, 6.87 mmol, 76.1 %).

check

TLC $R_f = 0.19 \; (\text{Et}_2\text{O})$

 $mp T / {}^{\circ}C = ?? (??)$

¹**H NMR** (400 MHz, MeOD) δ / ppm = 3.60 (t, J = 6.6 Hz, 2 H, CH₂Cl), 3.51 - 3.60 (m, 1 H, CHNH), 3.28 - $3.39 \text{ (m, 1 H, C}_{\underline{\underline{H}OH})}, 2.37 \text{ (td, } J = 7.4, 2.3 \text{ Hz, 2 H, C}(=O)\text{C}_{\underline{\underline{H}_2}}), 2.06 \text{ (quin, } J = 7.0 \text{ Hz, 2 H, C}(=O)\text{C}_{\underline{\underline{H}_2}}),$ 1.97 - 2.01 (m, 1 H, CHHCHOH), 1.85 - 1.93 (m, 1 H, CHHCHNH), 1.70 - 1.77 (m, 1 H, CHHCH₂CHOH), 1.64 - 1.70 (m, 1 H, CHHCH2CHNH), 1.24 - 1.35 (m, 3 H, CHHCH2CHOH, CHHCH2CHNH and CHHCHOH), 1.13 - 1.25 (m, 1 H, CH<u>H</u>CHNH₂)

¹³C NMR (101 MHz, MeOD) δ / ppm = 175.0 (<u>C(=O)</u>), 74.1 (<u>CHOH</u>), 56.3 (<u>CHNH</u>), 45.3 (<u>CH</u>₂Cl), 35.6 (CH₂CHOH), 34.5 (C(=O)CH₂), 32.7 (CH₂CHNH), 30.1 (C(=O)CH₂CH₂), 25.8 (CH₂CH₂CHNH), 25.5 $(\underline{CH_2CH_2CHOH})$

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

1.63 4-Azido-N-((trans)-2-hydroxycyclohexyl)butanamide 167

4-Chloro-N-((trans)-2-hydroxycyclohexyl)butanamide 166 (300 mg, 1.37 mmol, 1 eq.) and NaN₃ (180 mg, 2.77 mmol, 2 eq.) were stirred in DMF (12 ml) at 50 °C for 16 h. Water (50 ml) and 10 % i-PrOH/CHCl₃ (50 ml) were added, and the organic layer was removed. The aqueous layer was extracted again with 10 % i-PrOH/CHCl₃ (50 ml) and the combined organic fractions were dried with MgSO₄. The solvent was evaporated under reduced pressure, and then by using a N_2 stream. 186 was obtained as a white solid (374 mg, 1.65 mmol, %).

TLC $R_f = 0.23$ (EtOAc)

mp $T / {}^{\circ}C = ?? (??)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹**H NMR** (400 MHz, MeOD) δ / ppm = 7.87 (d, J = 7.9 Hz, 1 H, N<u>H</u>), 5.27 (d, J = 4.3 Hz, 1 H, O<u>H</u>), 3.56 (td, J = 10.5, 4.4 Hz, 1 H, CHNH), 3.28 - 3.41 (m, 3 H, CHOH and CH_2N_3), 2.30 (td, J = 7.4, 2.7 Hz, $2~H,~C(=O)C\underline{H}_2),~1.95~-~2.03~(m,~1~H,~C\underline{H}HCHOH),~1.87~(m,~3~H,~C(=O)CH_2C\underline{H}_2~and~C\underline{H}HCHNH),~1.70~-~1.01~(m,~1~H,~C\underline{H}HCHOH),~1.10~(m,~1~H,~C\underline{H}HCHOH),~1.10~(m,~1~H,~C\underline{H}H$ 1.76 (m, 1 H, CHHCH₂CHOH), 1.63 - 1.70 (m, 1 H, CHHCH₂CHNH), 1.25 - 1.38 (m, 3 H, CHHCH₂CHOH, $CH\underline{H}CH_2CHNH$ and $CH\underline{H}CHOH$), 1.14 - 1.24 (m, 1 H, $CH\underline{H}CHNH_2$)

¹³C NMR (101 MHz, MeOD) δ / ppm = 175.1 (<u>C</u>(=O)), 74.0 (<u>C</u>HOH), 56.3 (<u>C</u>HNH), 52.0 (<u>C</u>H₂N₃), $35.5 \ (\underline{\text{CH}}_2\text{CHOH}), \ 34.3 \ (\text{C(=O)}\underline{\text{CH}}_2), \ 32.7 \ (\underline{\text{CH}}_2\text{CHNH}), \ 26.3 \ (\text{C(=O)}\underline{\text{CH}}_2\underline{\text{CH}}_2), \ 25.8 \ (\underline{\text{CH}}_2\text{CH}_2\text{CHNH}), \ 25.5 \ (\underline{\text{CH}}_2\text{CHOH}), \ 26.8 \ (\underline{\text{CH}}_2\text{CHOH}), \ 26.8 \ (\underline{\text{CH}}_2\text{CHOH})$ $(\underline{C}H_2CH_2CHOH)$

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

check??

this was

over 100.

check?

1.64 Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-oxobutyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 168

146 (200 mg, 0.367 mmol, 1 eq.), 165 (91.1 mg, 0.791 mmol, 2.1 eq.), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (112 mg, 0.584 mmol, 1.6 eq.), 1-hydroxybenzotriazole (96 mg, 0.710 mmol, 1.9 eq.) and DIPEA (192 μ l, 142 mg, 1.10 mmol, 3 eq.) were dissolved in DMF (5 ml) and stirred at r.t. for 16 h. The solvent was removed using a stream of N₂ and the residue was purified by preparatory HPLC (5-50 % acetonitrile/water over 10 min). The combined pure fractions were evaporated under reduced pressure and then partitioned between NaHCO₃ (aq., sat., 10 ml) and CH₂Cl₂ (10 ml). The organic layer was dried with MgSO₄ and evaporated under reduced pressure. 157 was obtained as a clear gum (73.0 mg, 0.142 mmol, 38.7 %).

column

equip-

ment? check??

TLC $R_f = ?? (??)$

 $mp T / {}^{\circ}C = ?? (??)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹H NMR (400 MHz, MeOD) δ / ppm = 8.60 (s, 1 H, ortho to C(=O)OC \underline{H}_3), 7.79 (d, J = 13.5 Hz, 1 H, ortho to F), 7.46 (d, J = 7.2 Hz, 1 H, meta to F), 3.84 (s, 3 H, C \underline{H}_3), 3.62 - 3.68 (m, 1 H, NC \underline{H} (CH₂)₂), 3.58 (td, J = 10.3, 4.2 Hz, 1 H, C \underline{H} NH), 3.38 (br s, 4 H, CH₂N(CH₂C \underline{H}_2)CH₂C \underline{H}_2), 3.32 - 3.36 (m, 1 H, C \underline{H} OH), 2.83 (br s, 4 H, CH₂N(C \underline{H}_2)C \underline{H}_2), 2.60 (t, J = 7.3 Hz, 2 H, C(=O)CH₂CH₂C \underline{H}_2 N), 2.32 (td, J = 7.1, 3.1 Hz, 2 H, C(=O)C \underline{H}_2), 1.96 - 2.04 (m, 1 H, C \underline{H} HCHOH), 1.87 - 1.96 (m, 3 H, C \underline{H} HCHNH and C(=O)CH₂C \underline{H}_2), 1.72 - 1.77 (m, 1 H, C \underline{H} HCH₂CHOH), 1.66 - 1.72 (m, 1 H, C \underline{H} HCH₂CHNH), 1.25 - 1.39 (m, 5 H, CH \underline{H} CHOH, CH \underline{H} CHOH, CH \underline{H} CHOH, CH \underline{H} CHNH and NCH(C \underline{H} H)₂), 1.15 - 1.25 (m, 3 H, CH \underline{H} CHOH and NCH(CH \underline{H})₂)

 $^{13}\mathbf{C} \ \mathbf{NMR} \ (101 \ \mathrm{MHz}, \mathrm{MeOD}) \ \delta \ / \ \mathrm{ppm} = 175.8 \ (\mathrm{CH_2\underline{C}}(=\mathrm{O})\mathrm{NH}), 175.3 \ (\underline{\mathrm{C}}(=\mathrm{O})\mathrm{CC}(=\mathrm{O})\mathrm{OCH_3}), 166.8 \ (\underline{\mathrm{C}}(=\mathrm{O})\mathrm{OCH_3}), \\ 154.9 \ (\mathrm{d}, \ J = 248.8 \ \mathrm{Hz}, \ ipso \ \mathrm{to} \ \mathrm{F}), 150.2 \ (\underline{\mathrm{C}}=\mathrm{CC}(=\mathrm{O})\mathrm{OCH_3}), 146.1 \ (\mathrm{d}, \ J = 10.8 \ \mathrm{Hz}, \ ipso \ \mathrm{to} \ \mathrm{piperazine}), 139.9 \\ (para \ \mathrm{to} \ \mathrm{F}), 123.5 \ (\mathrm{d}, \ J = 7.5 \ \mathrm{Hz}, \ para \ \mathrm{to} \ \mathrm{piperazine}), 113.2 \ (\mathrm{d}, \ J = 23.2 \ \mathrm{Hz}, \ ortho \ \mathrm{to} \ \mathrm{C=O} \ \mathrm{and} \ ortho \ \mathrm{to} \ \mathrm{F}), \\ 110.2 \ (\underline{\mathrm{CC}}(=\mathrm{O})\mathrm{OCH_3}), 107.2 \ (meta \ \mathrm{to} \ \mathrm{C=O} \ \mathrm{and} \ meta \ \mathrm{to} \ \mathrm{F}), 74.1 \ (\underline{\mathrm{CHOH}}), 58.9 \ (\mathrm{C}(=\mathrm{O})\mathrm{CH_2\mathrm{CH_2\underline{C}H_2\mathrm{N}}), 56.4 \\ (\underline{\mathrm{CHNH}}), 54.0 \ (\mathrm{C}(=\mathrm{O})\mathrm{CH_2\mathrm{CH_2\mathrm{CH_2N}}(\underline{\mathrm{CH_2}})\underline{\mathrm{CH_2}}), 52.3 \ (\underline{\mathrm{CH_3}}), 50.5 \ (\mathrm{d}, \ J = 5.0 \ \mathrm{Hz}, \mathrm{C}(=\mathrm{O})\mathrm{CH_2\mathrm{CH_2\mathrm{CH_2N}}(\mathrm{CH_2\underline{C}H_2})\mathrm{CH_2\underline{C}H_2}), \\ 36.4 \ (\mathrm{N\underline{CH}}(\mathrm{CH_2})_2), 35.7 \ (\underline{\mathrm{CH_2\mathrm{CHOH}}}), 35.1 \ (\mathrm{C}(=\mathrm{O})\underline{\mathrm{CH_2}}), 32.8 \ (\underline{\mathrm{CH_2\mathrm{CHNH}}}), 25.9 \ (\underline{\mathrm{CH_2\mathrm{CH_2\mathrm{CHNH}}}}), 25.5 \ (\underline{\mathrm{CH_2\mathrm{CH_2\mathrm{CHOH}}}), \\ 23.5 \ (\mathrm{C}(=\mathrm{O})\mathrm{CH_2\underline{CH_2}}), 8.7 \ (\mathrm{N\mathrm{CH}}(\underline{\mathrm{CH_2}})_2)$

 $^{19}\mathbf{F}$ NMR (376.45 MHz, MeOD) δ / ppm = -124.7 (ciprofloxacin $\underline{\mathbf{F}})$

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

1.65 Methyl 1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-oxo-4-((2-oxocyclohexyl)amino)-butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate 169

Methyl 1-cyclopropyl-6-fluoro-7-(4-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-oxobutyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate ${\bf 168}$ (5.2 mg, 9.84 mmol, 1 eq.) and Dess-Martin Periodane (16.4 mg, 38.7 mmol, 4 eq.) were stirred in ${\rm CH_2Cl_2}$ (3 ml) for 6 h. The solvent was removed under reduced pressure and the residue was purified by preparatory HPLC (5-95 % acetonitrile/water over ??min). The combined pure fractions were evaporated under reduced pressure to a volume of 20 ml, then NaHCO₃ (aq., sat., 30 ml) and 10 % i-PrOH/CHCl₃ (30 ml) were added. The organic layer was dried with MgSO₄ and evaporated under reduced pressure. ${\bf 187}$ was obtained as a clear gum (??mg, ? mmol, ?? %).

orig?

column'

equip-

ment?

weigh

TLC $R_f = 0.74 (30 \% \text{ MeOH/CH}_2\text{Cl}_2)$

mp $T / {}^{\circ}C = ?? (??)$

IR (neat) $\nu_{max} / \text{cm}^{-1} = ??$

¹**H NMR** (400 MHz, DMSO d₆) δ / ppm = 8.45 (s, 1 H, ortho to C(=O)OC \underline{H}_3), 7.87 (d, J = 6.2 Hz, 1 H, N \underline{H}), 7.76 (d, J = 13.4 Hz, 1 H, ortho to F), 7.44 (d, J = 7.5 Hz, 1 H, meta to F), 4.42 (dddd, J = 13.0, 7.6, 6.0, 1.0 Hz, 1 H, C \underline{H} NH), 3.73 (s, 3 H, C \underline{H}_3), 3.65 (tt, J = 7.1, 3.9 Hz, 1 H, NC \underline{H} (CH₂)₂), 3.25 (br s, 4 H, CH₂N(CH₂C \underline{H}_2)CH₂CH₂CH₂CH₂D), 2.58 (br s, 4 H, CH₂N(C \underline{H}_2)C \underline{H}_2), 2.45 - 2.53 (m, 1 H, C \underline{H} HC(=O)CHNH), 2.36 (br s, 2 H, C(=O)CH₂CH₂CH₂N), 2.26 (dtt, J = 13.4, 2.6, 2.6, 1.6, 1.6 Hz, 1 H, CH \underline{H} C(=O)CHNH), 2.16 - 2.22 (m, 2 H, C(=O)C \underline{H}_2 CH₂CH₂N), 2.12 (ddq, J = 12.7, 6.0, 2.8, 2.8, 2.8 Hz, 1 H, C \underline{H} HCHNH), 2.00 (ddquin, J = 13.2, 6.0, 2.9, 2.9, 2.9, 2.9 Hz, 1 H, C \underline{H} HCH₂C(=O)), 1.65 - 1.83 (m, 4 H, C \underline{H} 2CH₂CHNH), 1.41 - 1.56 (m, 2 H, CHHCHNH and CHHCH₂C(=O)), 1.20 - 1.30 (m, 2 H, NCH(CHH)₂), 1.05 - 1.13 (m, 2 H, NCH(CHH)₂)

¹³C NMR (101 MHz, DMSO d₆) δ / ppm = 207.5 ($\underline{\mathbf{C}}$ (=O)CHNH), 171.7 ($\underline{\mathbf{C}}$ (=O)CC(=O)OCH₃), 171.6 (CH₂ $\underline{\mathbf{C}}$ (=O)NH), 165.0 ($\underline{\mathbf{C}}$ (=O)OCH₃), 152.6 (d, J = 247.6 Hz, ipso to F), 148.3 ($\underline{\mathbf{C}}$ =CC(=O)OCH₃), 143.9 (br s, ipso to piperazine), 138.1 (para to F), 121.8 (d, J = 6.4 Hz, para to piperazine), 111.5 (d, J = 22.4 Hz, ortho to C=O and ortho to F), 109.0 ($\underline{\mathbf{C}}$ C(=O)OCH₃), 106.3 (meta to C=O and meta to F), 57.0 ($\underline{\mathbf{C}}$ HNH and C(=O)CH₂CH₂CH₂N), 52.3 (br s, C(=O)CH₂CH₂CH₂N($\underline{\mathbf{C}}$ H₂), 51.3 ($\underline{\mathbf{C}}$ H₃), 49.5 (br s, C(=O)CH₂CH₂CH₂CH₂N(CH₂CH₂), 40.6 ($\underline{\mathbf{C}}$ H₂C(=O)CHNH), 34.8 ($\underline{\mathbf{N}}$ CH(CH₂)₂), 33.9 ($\underline{\mathbf{C}}$ H₂CHNH), 32.9 (C(=O) $\underline{\mathbf{C}}$ H₂CH₂CH₂N), 27.2 ($\underline{\mathbf{C}}$ H₂CH₂C(=O)CHNH), 23.8 ($\underline{\mathbf{C}}$ H₂CH₂CHNH), 22.4 (br s, C(=O)CH₂CH₂CH₂N), 7.6 ($\underline{\mathbf{N}}$ CH($\underline{\mathbf{C}}$ H₂)₂)

¹⁹**F NMR** (376.45 MHz, DMSO d₆) δ / ppm = -124.3 (ciprofloxacin <u>F</u>)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

1.66 1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-oxobutyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquino-line-3-carboxylic acid 170

$$\begin{array}{c} O \\ O \\ O \\ O \\ N = N \end{array}$$

1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **173** (40 mg, 97.2 μ mol, 1 eq.) and 4-azido-N-((trans)-2-hydroxycyclohexyl)butanamide **167** (22.0 mg, 97.2 μ mol, 1 eq.) were dissolved in 10 % water/t-BuOH (3 ml), and the mixture was degassed by bubbling N₂ through it. A solution of CuSO₄ and THPTA (97.2 μ l, 9.72 μ mol, 0.1 eq. 100 mM, aq.) was added, followed by a solution of sodium ascorbate (194 μ l, 19.4 μ mol, 0.2 eq., 100 mM, aq.). The mixture was stirred at r.t. under argon for 16 h. Water (50 ml) and 10 % i-PrOH/CHCl₃ (50 ml) were added, then the organic layer was separated and dried with MgSO₄ and evaporated under reduced pressure. The residue was purified by preparatory HPLC (5-70 % acetonitrile/water over 15 min). The combined pure fractions were evaporated under reduced pressure and then partitioned between NaHCO₃ (aq., sat., 50 ml) and 10 % i-PrOH/CHCl₃ (50 ml). The organic layer was dried with MgSO₄ and evaporated under reduced pressure. **170** was obtained as a white powder (30.3 mg, 47.5 μ mol, 48.9 %).

column?
equipment?

TLC
$$R_f = ?? (??)$$

$$mp T / {}^{\circ}C = ?? (??)$$

IR (neat)
$$\nu_{max} / \text{cm}^{-1} = ??$$

¹H NMR (400 MHz, DMSO d₆) δ / ppm = 8.64 (s, 1 H, ortho to C(=O)OH), 7.86 (d, J = 13.9 Hz, 1 H, ortho to F), 7.84 (s, 1 H, CH=CCH₂), 7.64 (d, J = 8.1 Hz, 1 H, NH), 7.54 (d, J = 7.5 Hz, 1 H, meta to F), 4.54 (d, J = 4.7 Hz, 1 H, OH), 4.30 (t, J = 6.8 Hz, 2 H, C(=O)CH₂CH₂CH₂N), 3.77 - 3.86 (m 1 H, NCH(CH₂)₂), 3.33 - 3.40 (m, 1 H, CHNH), 3.31 (br t, J = 4.8, 4.8 Hz, 4 H, CH=CCH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂CH₂), 3.14 - 3.24 (m, 1 H, CHOH), 2.63 (t, J = 7.4 Hz, 2 H, CH=CCH₂), 2.56 (br t, J = 4.6, 4.6 Hz, 4 H, CH=CCH₂CH₂CH₂N(CH₂)CH₂), 2.38 (t, J = 6.9 Hz, 2 H, CH=CCH₂CH₂CH₂CH₂N), 2.04 - 2.08 (m, 2 H, C(=O)CH₂CH₂CH₂CH₂N), 1.96 - 2.04 (m, 2 H, C(=O)CH₂CH₂CH₂N), 1.78 - 1.87 (m, 1 H, CHHCHOH), 1.69 - 1.78 (m, 1 H, CHHCHNH), 1.63 (quin, J = 7.5 Hz, 2 H, CH=CCH₂CH₂CH₂CH₂N), 1.54 - 1.60 (m, 1 H, CHHCH₂OH), 1.51 (quin, J = 7.4 Hz, 2 H, CH=CCH₂CH₂CH₂CH₂N), 1.28 - 1.35 (m, 1 H, NCH(CHH)₂), 1.11 - 1.22 (m, 5 H, NCH(CHH)₂, CHHCHOH, CHHCH₂CHOH and CH₂CH₂CHNH), 1.04 - 1.13 (m, 1 H, CHHCHNH)

¹³C NMR (101 MHz, DMSO d₆) δ / ppm = 176.4 (<u>C</u>(=O)CC(=O)OH), 170.9 (CH₂<u>C</u>(=O)NH), 166.0 (<u>C</u>(=O)OH), 153.1 (d, J = 252.1 Hz, *ipso* to F), 148.0 (<u>C</u>=CC(=O)OH), 146.9 (CH=<u>C</u>CH₂), 145.3 (d, J = 10.0

Hz, ipso to piperazine), 139.2 (para to F), 121.8 (NCH=CCH₂), 118.5 (d, J = 8.3 Hz, para to piperazine), 110.9 $(d, J = 23.2 \text{ Hz}, or tho \text{ to C=O} \text{ and } or tho \text{ to F}), 106.7 (\underline{\text{C}}\text{C}(=\text{O})\text{OH}), 106.3 (d, J = 3.3 \text{ Hz}, meta \text{ to C=O} \text{ and } meta$ to F), 71.4 (CHOH), 57.4 (CH=CCH₂CH₂CH₂CH₂CH₂N), 54.2 (CHNH), 52.4 (CH=CCH₂CH₂CH₂CH₂CH₂N(CH₂)CH₂), $49.5 \text{ (d, } J = 5.0 \text{ Hz, CH} = \text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\underline{\text{CH}}_2)\text{CH}_2\underline{\text{CH}}_2), 48.8 \text{ (C(=O)CH}_2\text{CH}_2\underline{\text{CH}}_2\text{NCH} = C), 35.9$ $(NCH(CH_2)_2)$, 34.1 (CH_2CHOH) , 32.3 $(C(=O)CH_2CH_2CH_2NCH=C)$, 31.1 (CH_2CHNH) , 26.9 $(CH=CCH_2CH_2CH_2N)$, $26.1 \ (C(=O)CH_{2}CH_{2}CH_{2}NCH=C), \ 25.8 \ (CH=CCH_{2}CH_{2}CH_{2}CH_{2}N), \ 25.0 \ (CH=CCH_{2}CH_{2}CH_{2}CH_{2}N), \ 24.2 \ (CH=CCH_{2}CH_{2}CH_{2}N), \ 24.2 \ (CH=CCH_{2}CH_{2}N), \ 24.2 \ (CH=CCH_{2}CH_{2}N), \ 24.2 \ (CH=CCH_{2}N), \$ $(C\underline{H}_2CH_2CHNH)$, 23.8 $(C\underline{H}_2CH_2CHOH)$, 7.6 $(NCH(\underline{C}H_2)_2)$

¹⁹**F NMR** (376.45 MHz, DMSO d₆) δ / ppm = -121.4 (ciprofloxacin <u>F</u>)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(4-(1-(4-oxo-4-((2-oxocyclohexyl)amino)butyl)-1.67 1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 171

1-Cyclopropyl-6-fluoro-7-(4-(4-(1-(4-(((trans)-2-hydroxycyclohexyl)amino)-4-oxobutyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 170 (15.0 mg, 23.6 mmol, 1 eq.) and Dess-Martin Periodane (35.0 mg, 82.5 mmol, 3.5 eq.) were stirred in CH_2Cl_2 (3 ml) for 4 h. The solvent was removed under reduced pressure and the residue was purified by preparatory HPLC (5-70 % acetonitrile/water over 15 min). The combined pure fractions were evaporated under reduced pressure, then NaHCO₃ (aq., sat., 30 ml) and 10 % i-PrOH/CHCl $_3$ (30 ml) were added. The organic layer was dried with MgSO $_4$ and evaporated under reduced pressure. 171 was obtained as a clear gum (??mg, ? mmol, ?? %).

column' equipment?

This is the TFA salt, need to desalt!

check??

weigh

2 References

- [1] Y. Baker. Novel Affinity Based Probes for Use in Chemical Proteomic Studies. 2012.
- [2] J. D. Scribner, D. L. Smith and J. A. McCloskey. Meldrum's Acid in Organic Synthesis. 2. A General and Versatile Synthesis of β -Keto Esters. The Journal of Organic Chemistry, 43(10):2087–2088. 1978.
- [3] J. T. Hodgkinson. The synthesis of Pseudomonas Quinolone Signal analogues and their effects on quinolone signalling in *Pseudomonas aeruginosa*. PhD thesis, University of Cambridge. 2011.
- [4] D. M. Stacy, S. T. Le Quement, C. L. Hansen, J. W. Clausen, T. Tolker-Nielsen, J. W. Brummond, M. Givskov, T. E. Nielsen and H. E. Blackwell. Synthesis and biological evaluation of triazole-containing N-acyl homoserine lactones as quorum sensing modulators. Organic & Biomolecular Chemistry, 11(6):938–954. 2013.
- [5] L. S. Kocsis, E. Benedetti and K. M. Brummond. LETTERS A Thermal Dehydrogenative Diels À Alder Reaction of Styrenes for the Concise Synthesis of Functionalized Naphthalenes. *Organic Letters*, 14(17):4430– 4433. 2012.
- [6] K. Sachin, E.-M. Kim, S.-J. Cheong, H.-J. Jeong, S. T. Lim, M.-H. Sohn and D. W. Kim. Synthesis of N₄'-[¹⁸F]fluoroalkylated ciprofloxacin as a potential bacterial infection imaging agent for PET study. *Bioconjugate chemistry*, 21(12):2282–2288. 2010.
- [7] K. Ganguly, R. Wu, M. Ollivault-Shiflett, P. M. Goodwin, L. A. Silks and R. Iyer. Design, synthesis, and a novel application of quorum-sensing agonists as potential drug-delivery vehicles. *Journal of drug targeting*, 19(7):528–539. 2011.
- [8] R. Iyer, K. Ganguly and L. A. Silks. Synthetic analogs of bacterial quorum sensors. 2012.
- [9] R. Srinivasan, L. P. Tan, H. Wu, P.-Y. Yang, K. A. Kalesh and S. Q. Yao. High-throughput synthesis of azide libraries suitable for direct "click" chemistry and in situ screening. *Organic & Biomolecular Chemistry*, 7(9):1821. 2009.
- [10] J. Aubé, Michael S. Wolfe, R. K. Yantiss, S. M. Cook, F. Takusagawa, M. S. Wolfe, R. K. Yantiss, S. M. Cook and F. Takusagawa. Synthesis of Enantiopure N-tert-Butoxycarbonyl-2- aminocycloalkanones. *Synthetic Communications*, 22(20):3003–3012. 1992.
- [11] L. E. Overman, S. Sugai, L. E. Overman and S. Sugai. A Convenient Method for Obtaining trans -2-Aminocyclohexanol and trans -2-Aminocyclopentanol in Enantiomerically Pure Form. The Journal of Organic Chemistry, 50:4154-4155. 1985.
- [12] I. Schiffers, T. Rantanen, F. Schmidt, W. Bergmans, L. Zani and C. Bolm. Resolution of racemic 2-aminocyclohexanol derivatives and their application as ligands in asymmetric catalysis. The Journal of organic chemistry, 71(1):2320–2331. 2006.